# EDGAR Filing Document

**Accession Number:** 0001881570
**File Stem:** 0001670254-25-000647
**Filing Date:** 2025-6
**Character Count:** 291159
**Document Hash:** a7a9ee0ad083d8b5907d9ee6ae2934c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001670254-25-000647.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001670254-25-000647

**CONFORMED SUBMISSION TYPE**: C

**PUBLIC DOCUMENT COUNT**: 19

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ViiT Health Inc
- **CENTRAL INDEX KEY:** 0001881570

**ORGANIZATION NAME:**
- **EIN:** 871619332
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** C
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-36002
- **FILM NUMBER:** 251038590

**BUSINESS ADDRESS:**
- **STREET 1:** 3655 RESEARCH RD
- **CITY:** LAS CRUCES
- **STATE:** NM
- **ZIP:** 88003
- **BUSINESS PHONE:** 5106982462

**MAIL ADDRESS:**
- **STREET 1:** 1647 S SAGUARO
- **STREET 2:** MESA
- **CITY:** MESA
- **STATE:** AZ

## Ex-99

### Attached PDF Documents

**Attachment 1:** `document_1.pdf`

# Form C

---

## Cover Page

Name of issuer:
Viit Health Inc

Legal status of issuer:
Form: Corporation
Jurisdiction of Incorporation/Organization: DE
Date of organization: 6/15/2021

Physical address of issuer:
1647 S Saguaro
Mesa AZ 85202

Website of issuer:
https://www.viit.health

Name of intermediary through which the offering will be conducted:
Wefunder Portal LLC

CIK number of intermediary:
0001670254

SEC file number of intermediary:
007-00033

CRD number, if applicable, of intermediary:
283503

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering:

7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the issuer in connection with the offering.

Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest:
No

Type of security offered:
☐ Common Stock
☐ Preferred Stock
☐ Debt
☑ Other

If Other, describe the security offered:

Simple Agreement for Future Equity (SAFE)

Target number of securities to be offered:
50,000

Price:
$1.000000

Method for determining price:
Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.

Target offering amount:
$50,000.00

Oversubscriptions accepted:
☑ Yes
☐ No

If yes, disclose how oversubscriptions will be allocated:
☐ Pro-rata basis
☐ First-come, first-served basis
☑ Other

If other, describe how oversubscriptions will be allocated:
As determined by the issuer

Maximum offering amount (if different from target offering amount):
$111,308.00

Deadline to reach the target offering amount:
4/30/2026

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

Current number of employees:
15

|  | Most recent fiscal year-end: | Prior fiscal year-end: |
| --- | --- | --- |
| Total Assets: | $25,065.00 | $13,044.00 |
| Cash & Cash Equivalents: | $25,065.00 | $13,044.00 |
| Accounts Receivable: | $0.00 | $0.00 |
| Current Liabilities: | $0.00 | $0.00 |
| Non-Current Liabilities: | $1,688,898.00 | $1,330,283.00 |
| Revenues/Sales: | $0.00 | $0.00 |
| Cost of Goods Sold: | $0.00 | $0.00 |
| Taxes Paid: | $850.00 | $450.00 |
| Net Income: | ($346,594.00) | ($533,768.00) |

Select the jurisdictions in which the issuer intends to offer the securities:
AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, BS, GU, PR, VI, IV

# Offering Statement

Respond to each question in each paragraph of this part. Set forth each question and any notes, but not any instructions thereto, in their entirety. If disclosure in response to any question is responsive to one or more other questions, it is not necessary to repeat the disclosure. If a question or series of questions is inapplicable or the response is available elsewhere in the Form, either state that it is inapplicable, include a cross-reference to the responsive disclosure, or omit the question or series of questions.

Be very careful and precise in answering all questions. Give full and complete answers so that they are not misleading under the circumstances involved. Do not discuss any future performance or other anticipated event unless you have a reasonable basis to believe that it will actually occur within the foreseeable future. If any answer requiring significant information is materially inaccurate, incomplete or misleading, the Company, its management and principal shareholders may be liable to investors based on that information.

## THE COMPANY

1. Name of issuer:
Viit Health Inc

## COMPANY ELIGIBILITY

2. ☐ Check this box to certify that all of the following statements are true for the issuer.

- Organized under, and subject to, the laws of a State or territory of the United States or the District of Columbia.
- Not subject to the requirement to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.
- Not an investment company registered or required to be registered under the Investment Company Act of 1940.
- Not ineligible to rely on this exemption under Section 4(a)(6) of the Securities Act as a result of a disqualification specified in Rule 503(a) of Regulation Crowdfunding.
- Has filed with the Commission and provided to investors, to the extent required, the ongoing annual reports required by Regulation Crowdfunding during the two years immediately preceding the filing of this offering statement (or for such shorter period that the issuer was required to file such reports).
- Not a development stage company that (a) has no specific business plan or (b) has indicated that its business plan is to engage in a merger or acquisition with an unidentified company or companies.

INSTRUCTION TO QUESTION 2: If any of these statements are not true, then you are NOT eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

3. Has the issuer or any of its predecessors previously failed to comply with the ongoing reporting requirements of Rule 202 of Regulation Crowdfunding?

☐ Yes ☐ No

# DIRECTORS OF THE COMPANY

4. Provide the following information about each director (and any persons occupying a similar status or performing a similar function) of the issuer.

| Director | Principal Occupation | Main Employer | Year Joined as Director |
| --- | --- | --- | --- |
| Jorge Villegas | Regional Director | CONACYT | 2024 |
| Gerardo Rioseco Orihuela | Vice president | Grupo Posadas | 2024 |
| Roberto Jones Arakelian | Owner | Insurance Mass Solutions Group Sanford Heisler | 2024 |
| Shaun Rosenthal | Lawyer | Sharp McKnight, LLP | 2024 |
| Luis Gomez Sanchez | Corporate Affairs | Viit Health | 2021 |
| Lorena De La Maza Krzeptowsky | Medical Research | Viit Health | 2021 |
| Luis Fernando Gomez | CEO | Viit Health | 2021 |

For three years of business experience, refer to Appendix D: Director &amp; Officer Work History.

# OFFICERS OF THE COMPANY

5. Provide the following information about each officer (and any persons occupying a similar status or performing a similar function) of the issuer.

| Officer | Positions Held | Year Joined |
| --- | --- | --- |
| Gerardo Rioseco Rubio | Treasurer | 2021 |
| Luis Gomez Sanchez | President | 2021 |
| Lorena De La Maza Krzeptowsky | Vice President | 2021 |
| Luis Fernando Gomez | CEO | 2021 |
| Sofia Alvarez Cano | Secretary | 2021 |

For three years of business experience, refer to Appendix D: Director &amp; Officer Work History.

**INSTRUCTION TO QUESTION 5:** For purposes of this Question 5, the term officer means a president, vice president, secretary, treasurer or principal financial officer, comptroller or principal accounting officer, and any person that routinely performing similar functions.

# PRINCIPAL SECURITY HOLDERS

6. Provide the name and ownership level of each person, as of the most recent practicable date, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.

| Name of Holder | No. and Class of Securities Now Held | % of Voting Power Prior to Offering |
| --- | --- | --- |
| Luis Fernando Gomez | 4800000.0 Common Stock | 32.0 |
| Luis Gomez Sanchez | 4500000.0 Common Stock | 30.0 |
| Lorena De La Maza Krzeptowsky | 4500000.0 Common Stock | 30.0 |

**INSTRUCTION TO QUESTION 6:** The above information must be provided as of a date that is no more than 120 days prior to the date of filing of this offering statement.

To calculate total voting power, include all securities for which the person directly or indirectly has or shares the voting power, which includes the power to vote or to direct the voting of such securities. If the person has the right to acquire voting power of such securities within 60 days, including through the exercise of any option, warrant or right, the conversion of a security, or other arrangement, or if securities are held by a member of the family, through corporations or partnerships, or otherwise in a manner that would allow a person to direct or control the voting of the securities (or share in such direction or control - as, for example, a co-trustee) they should be included as being "beneficially owned." You should include an explanation of these circumstances in a footnote to the "Number of and Class of Securities Now Held." To calculate outstanding voting equity securities, assume all outstanding options are exercised and all outstanding convertible securities converted.

## BUSINESS AND ANTICIPATED BUSINESS PLAN

7. Describe in detail the business of the issuer and the anticipated business plan of the issuer.

For a description of our business and our business plan, please refer to the attached Appendix A, Business Description &amp; Plan

INSTRUCTION TO QUESTION 7: Wefunder will provide your company's Wefunder profile as an appendix (Appendix A) to the Form C in PDF format. The submission will include all Q&amp;A items and "read more" links in an un-collapsed format. All videos will be transcribed.

This means that any information provided in your Wefunder profile will be provided to the SEC in response to this question. As a result, your company will be potentially liable for misstatements and omissions in your profile under the Securities Act of 1933, which requires you to provide material information related to your business and anticipated business plan. Please review your Wefunder profile carefully to ensure it provides all material information, is not false or misleading, and does not omit any information that would cause the information included to be false or misleading.

## RISK FACTORS

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

8. Discuss the material factors that make an investment in the issuer speculative or risky:

Business Projections.

Viit Health's financial and business forecasts are forward-looking estimates based on internal models, market trends, and projected costs. These are intended to illustrate potential scenarios and do not guarantee future performance. Actual outcomes may vary significantly due to unforeseen economic, regulatory, or market changes. While we have validated our technology in clinical

changes. While we have validated our technology in clinical settings for a subset of the population, broader performance may vary. If our product does not perform as expected in wider real-world use, adoption and revenue may be affected. Additionally, our current valuation has not been independently verified and could change. Investors should not rely solely on these projections when evaluating this opportunity.

## Intellectual Property

Viit Health has filed patent applications in the U.S. and through the PCT system. However, the intellectual property landscape in our field is still evolving. While we believe our technology is novel and defensible, we cannot guarantee that our IP will not be challenged, invalidated, or circumvented. Competitors, including well-funded corporations, may pursue overlapping or conflicting IP claims. Enforcing our rights could involve lengthy and costly litigation, particularly in jurisdictions where enforcement is weak. These risks may affect our ability to protect and commercialize our innovations.

## Key Personnel

Our progress depends on the expertise and continued contributions of our core team and collaborators. The departure or unavailability of key personnel could disrupt operations and delay milestones. Recruiting and retaining top talent-especially in engineering, regulatory, and clinical roles-is competitive and challenging. Although we have confidentiality and retention strategies in place, we cannot guarantee long-term continuity of our team or success in attracting additional skilled collaborators as we scale.

## Competitors

Viit Health operates in a rapidly evolving healthtech space. We anticipate increased competition from established companies and new players who may develop similar or superior solutions, sometimes with greater financial and operational resources. Competitors may also attempt to replicate or bypass our technology. To remain competitive, we must continually improve the accuracy, reliability, and usability of our products. There is no assurance that our innovations will maintain a competitive edge or that the market will not shift toward alternative approaches.

## Additional Financing

Developing, validating, and commercializing medical technology is capital-intensive. While this campaign supports our next major milestone, we will likely need to raise additional capital. Future funding rounds may involve terms that are less favorable to current investors and could result in dilution. If we are unable to secure additional funding, we may need to delay, scale back, or revise our business plans, which could negatively affect our progress and valuation.

## Government Regulations

Our ability to scale depends on securing regulatory clearance in target markets. Currently, our technology is not approved for commercial sale. Regulatory requirements vary by region and are subject to change, potentially introducing delays or new hurdles. While we are committed to compliance and quality, we cannot predict how quickly-or if-our technology will be authorized for sale. These uncertainties can materially impact our go-to-market timelines and revenue projections.

## Security &amp; Confidentiality

We manage sensitive data, including proprietary information, customer health data, and employee records. While we implement standard cybersecurity measures, we are not immune to potential breaches, data loss, or unauthorized access. Such incidents could lead to reputation damage, legal consequences, and operational disruptions. As we scale, ensuring robust data protection will remain a critical challenge and priority.

## Natural &amp; Man-Made Disasters

Unexpected disruptions-ranging from natural disasters to cyberattacks-could affect our supply chain, operations, and financial health. As an early-stage company, we rely on continued investor support to sustain development. Any significant external shock affecting global markets or investor confidence could delay our progress or threaten business continuity.

## Company Growth

Rapid growth can place stress on management systems, infrastructure, and team dynamics. Our ability to manage scaling operations-while maintaining quality, compliance, and agility-is essential to our long-term success. If we cannot effectively onboard and manage talent or expand systems in step with our growth, operational inefficiencies may arise and impact performance.

## Reliability &amp; Press

Product reliability and brand reputation are critical. If users experience device malfunctions or inconsistent results, it could lead to loss of trust and lower adoption. Similarly, negative media coverage-whether accurate or not-can harm perception and investor confidence. While we strive to maintain high quality and transparent communications, we cannot fully control external narratives.

## Disruptive Technology

Our approach-combining multi-sensor inputs with AI for non-invasive biomarker monitoring-is innovative but unproven at scale. Although our technology has shown strong promise in controlled trials, we must still validate long-term reliability, industrial scalability, and regulatory performance. We do not yet have established manufacturing processes or a distribution network. Success depends on overcoming remaining technical, legal, and operational barriers.

## Outside Suppliers

We currently rely on third-party suppliers for all components of our device. Any disruption in supply, quality inconsistency, or incompatibility could delay production, increase costs, or affect product performance. Establishing reliable sourcing alternatives may take time and could require design adjustments. Our production roadmap depends heavily on timely, stable, and high-quality component procurement.

Future Equity Financing. The Company may never receive a future equity financing or elect to convert the Securities upon such future financing. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an IPO. If neither the conversion of the Securities nor a liquidity event occurs, the Purchasers could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. The Securities are not equity interests, have no ownership rights, have no rights to the Company's assets or profits and have no voting rights or ability to direct the Company or its actions.

Part time employees. Gerardo Rioseco Rubio is a part-time officer. As such, it is likely that the company will not make the same progress as it would if that were not the case.

The Company may never receive a future equity financing or elect to convert the Securities upon such future financing. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an IPO. If neither the conversion of the Securities nor a liquidity event occurs, the Purchasers could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. The Securities are not equity interests, have no ownership rights, have no rights to the Company's assets or profits and have no voting rights or ability to direct the Company or its actions.

INSTRUCTION TO QUESTION 1. Avoid secondhand statements and individuals

INSTRUCTION TO QUESTION 8: Avoid generalized statements and include only those factors that are unique to the issuer. Discussion should be tailored to the issuer's business and the offering and should not repeat the factors addressed in the legends set forth above. No specific number of risk factors is required to be identified.

# The Offering

## USE OF FUNDS

9. What is the purpose of this offering?

The Company intends to use the net proceeds of this offering for working capital and general corporate purposes, which includes the specific items listed in Item 10 below. While the Company expects to use the net proceeds from the Offering in the manner described above, it cannot specify with certainty the particular uses of the net proceeds that it will receive from this Offering. Accordingly, the Company will have broad discretion in using these proceeds.

10. How does the issuer intend to use the proceeds of this offering?

| If we raise: | $50,000 |
| --- | --- |
| Use of Proceeds: | 30% towards Clinical Studies and Regulatory approval, 26% towards Operations and Legal activities, 20% towards Artificial Intelligence (model training and validation), 16.1% towards Hardware Development for the third and final iteration, and 7.9% towards Wefunder fees. |
| If we raise: | $111,308 |
| Use of Proceeds: | 30% towards Hardware Development for the third and final iteration, 22.1% towards Operations and Legal activities, 20% towards Artificial Intelligence (model training and validation), 20% towards Clinical Studies and Regulatory approval, and 7.9% towards Wefunder fees. Raising our maximum target will better position us to finish our current clinical trials and begin the development phase of our last product iteration. |

INSTRUCTION TO QUESTION 10: An issuer must provide a reasonably detailed description of any intended use of proceeds, such that investors are provided with an adequate amount of information to understand how the offering proceeds will be used. If an issuer has identified a range of possible uses, the issuer should identify and describe each probable use and the factors the issuer may consider in allocating proceeds among the potential uses. If the issuer will accept proceeds in excess of the target offering amount, the issuer must describe the purpose, method for allocating oversubscriptions, and intended use of the excess proceeds with similar specificity. Please include all potential uses of the proceeds of the offering, including any that may apply only in the case of oversubscriptions. If you do not do so, you may later be required to amend your Form C. Wefunder is not responsible for any failure by you to describe a potential use of offering proceeds.

## DELIVERY &amp; CANCELLATIONS

11. How will the issuer complete the transaction and deliver securities to the investors?

Book Entry and Investment in the Co-Issuer. Investors will make their investments by investing in interests issued by one or more co-issuers, each of which is a special purpose vehicle ("SPV"). The SPV will invest all amounts it receives from investors in securities issued by the Company. Interests issued to investors by the SPV will be in book entry form. This means that the investor will not receive a certificate representing his or her investment. Each

receive a certificate representing his or her investment. Each investment will be recorded in the books and records of the SPV. In addition, investors' interests in the investments will be recorded in each investor's "Portfolio" page on the Wefunder platform. All references in this Form C to an Investor's investment in the Company (or similar phrases) should be interpreted to include investments in a SPV.

12. How can an investor cancel an investment commitment?

NOTE: Investors may cancel an investment commitment until 48 hours prior to the deadline identified in these offering materials.

The intermediary will notify investors when the target offering amount has been met. If the issuer reaches the target offering amount prior to the deadline identified in the offering materials, it may close the offering early if it provides notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment).

If an investor does not cancel an investment commitment before the 48-hour period prior to the offering deadline, the funds will be released to the issuer upon closing of the offering and the investor will receive securities in exchange for his or her investment.

If an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.

An Investor's right to cancel. An Investor may cancel his or her investment commitment at any time until 48 hours prior to the offering deadline.

If there is a material change to the terms of the offering or the information provided to the Investor about the offering and/or the Company, the Investor will be provided notice of the change and must re-confirm his or her investment commitment within five business days of receipt of the notice. If the Investor does not reconfirm, he or she will receive notifications disclosing that the commitment was cancelled, the reason for the cancellation, and the refund amount that the investor is required to receive. If a material change occurs within five business days of the maximum number of days the offering is to remain open, the offering will be extended to allow for a period of five business days for the investor to reconfirm.

If the Investor cancels his or her investment commitment during the period when cancellation is permissible, or does not reconfirm a commitment in the case of a material change to the investment, or the offering does not close, all of the Investor's funds will be returned within five business days.

Within five business days of cancellation of an offering by the Company, the Company will give each investor notification of the cancellation, disclose the reason for the cancellation, identify the refund amount the Investor will receive, and refund the Investor's funds.

The Company's right to cancel. The Investment Agreement you will execute with us provides the Company the right to cancel for any reason before the offering deadline.

If the sum of the investment commitments from all investors does not equal or exceed the target offering amount at the time of the

offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

# Ownership and Capital Structure

## THE OFFERING

13. Describe the terms of the securities being offered.

To view a copy of the SAFE you will purchase, please see Appendix B, Investor Contracts. The main terms of the SAFEs are provided below.

The SAFEs. We are offering securities in the form of a Simple Agreement for Future Equity ("SAFE"), which provides Investors the right to Preferred Stock in the Company ("Preferred Stock"), when and if the Company sponsors an equity offering that involves Preferred Stock, on the standard terms offered to other Investors.

Conversion to Preferred Equity. Based on our SAFEs, when we engage in an offering of equity interests involving Preferred Stock, Investors will receive a number of shares of Preferred Stock calculated using the method that results in the greater number of Preferred Stock:

i. the total value of the Investor's investment, divided by
a. the price of Preferred Stock issued to new Investors multiplied by
b. the discount rate (80%), or
ii. if the valuation for the company is more than $20,000,000.00 (the "Valuation Cap"), the amount invested by the Investor divided by the quotient of
a. the Valuation Cap divided by
b. the total amount of the Company's capitalization at that time.
iii. For investors up to the first $75,000.00 of the securities, investors will receive a valuation cap of $15,000,000.00 and a discount rate of 80.0%. Wefunder VIP investors will be entitled to these terms for the entire duration of the offering, even if the threshold limit noted above is met.

Additional Terms of the Valuation Cap. For purposes of option (ii) above, the Company's capitalization calculated as of immediately prior to the Equity Financing and (without double-counting, in each case calculated on an as-converted to Common Stock basis):

- Includes all shares of Capital Stock issued and outstanding;
- Includes all Converting Securities;
- Includes all (i) issued and outstanding Options and (ii) Promised Options; and
- Includes the Unissued Option Pool, except that any increase to the Unissued Option Pool in connection with the Equity Financing shall only be included to the extent that the number of Promised Options exceeds the Unissued Option Pool prior to such increase.

Liquidity Events. If the Company has an initial public offering or is acquired by, merged with, or otherwise taken over by another company or new owners prior to Investors in the SAFEs receiving Preferred Stock, Investors will receive

- proceeds equal to the greater of (i) the Purchase Amount (the "Cash-Out Amount") or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the "Conversion Amount")

Liquidity Priority. In a Liquidity Event or Dissolution Event, this Safe is intended to operate like standard nonparticipating Preferred Stock. The Investor's right to receive its Cash-Out Amount is:

i. Junior to payment of outstanding indebtedness and creditor claims, including contractual claims for payment and convertible promissory notes (to the extent such convertible promissory notes are not actually or notionally converted into Capital Stock);

ii. On par with payments for other Safes and/or Preferred Stock, and if the applicable Proceeds are insufficient to permit full payments to the Investor and such other Safes and/or Preferred Stock, the applicable Proceeds will be distributed pro rata to the Investor and such other Safes and/or Preferred Stock in proportion to the full payments that would otherwise be due; and

iii. Senior to payments for Common Stock.

## VIP Bonus

Viit Health will offer a discount to the normal terms listed in this Form C for all investments that are committed by investors who are part of Wefunder, Inc's VIP program. This means eligible Wefunder investors will receive a discount for any securities they purchased in this offering. For more specific details on the company's discount, please review the description of the terms above.

The discount is only valid until the offering closes. Investors eligible for the bonus will also receive priority if they are on a waitlist to invest and the company exceeds its maximum funding goal. They will be given the first opportunity to invest if space in the offering becomes available due to the cancellation or failure of previous investments.

## Securities Issued by the SPV

Instead of issuing its securities directly to investors, the Company has decided to issue its securities to the SPV, which will then issue interests in the SPV to investors. The SPV is formed concurrently with the filing of the Form C. Given this, the SPV does not have any financials to report. The SPV is managed by Wefunder Admin, LLC and is a co-issuer with the Company of the securities being offered in this offering. The Company's use of the SPV is intended to allow investors in the SPV to achieve the same economic exposure, voting power, and ability to assert State and Federal law rights, and receive the same disclosures, as if they had invested directly in the Company. While the Issuer may be required to pay an annual administrative fee for the maintenance of the SPV, investors should note the Company's use of the SPV will not result in any additional fees being charged to investors.

The SPV has been organized and will be operated for the sole purpose of directly acquiring, holding and disposing of the Company's securities, will not borrow money and will use all of the proceeds from the sale of its securities solely to purchase a single class of securities of the Company. As a result, an investor investing in the Company through the SPV will have the same relationship to the Company's securities, in terms of number, denomination, type and rights, as if the investor invested directly in the Company.

## Voting Rights

If the securities offered by the Company and those offered by the SPV have voting rights, those voting rights may be exercised by

the investor or his or her proxy. The applicable proxy is the Lead Investor, if the Proxy (described below) is in effect.

## Proxy to the Lead Investor

The SPV securities have voting rights. With respect to those voting rights, the investor and his, her, or its transferees or assignees (collectively, the "Investor"), through a power of attorney granted by Investor in the Investor Agreement, has appointed or will appoint the Lead Investor as the Investor's true and lawful proxy and attorney (the "Proxy") with the power to act alone and with full power of substitution, on behalf of the Investor to: (i) vote all securities related to the Company purchased in an offering hosted by Wefunder Portal, and (ii) execute, in connection with such voting power, any instrument or document that the Lead Investor determines is necessary and appropriate in the exercise of his or her authority. Such Proxy will be irrevocable by the Investor unless and until a successor lead investor ("Replacement Lead Investor") takes the place of the Lead Investor. Upon notice that a Replacement Lead Investor has taken the place of the Lead Investor, the Investor will have five (5) calendar days to revoke the Proxy. If the Proxy is not revoked within the 5-day time period, it shall remain in effect.

## Restriction on Transferability

The SPV securities are subject to restrictions on transfer, as set forth in the Subscription Agreement and the Limited Liability Company Agreement of Wefunder SPV, LLC, and may not be transferred without the prior approval of the Company, on behalf of the SPV.

14. Do the securities offered have voting rights?
☐ Yes
☑ No

15. Are there any limitations on any voting or other rights identified above?

See the above description of the Proxy to the Lead Investor.

16. How may the terms of the securities being offered be modified?

Any provision of this Safe may be amended, waived or modified by written consent of the Company and either:
i. the Investor or
ii. the majority-in-interest of all then-outstanding Safes with the same "Post-Money Valuation Cap" and "Discount Rate" as this Safe (and Safes lacking one or both of such terms will be considered to be the same with respect to such term(s)), provided that with respect to clause (ii):
A. the Purchase Amount may not be amended, waived or modified in this manner,
B. the consent of the Investor and each holder of such Safes must be solicited (even if not obtained), and
C. such amendment, waiver or modification treats all such holders in the same manner. "Majority-in-interest" refers to the holders of the applicable group of Safes whose Safes have a total Purchase Amount greater than 50% of the total Purchase Amount of all of such applicable group of Safes.

Pursuant to authorization in the Investor Agreement between each Investor and Wefunder Portal, Wefunder Portal is authorized to take the following actions with respect to the investment contract between the Company and an investor:
A. Wefunder Portal may amend the terms of an investment contract, provided that the amended terms are more favorable to the investor than the original terms; and
B. Wefunder Portal may reduce the amount of an investor's investment if the reason for the reduction is that the Company's offering is oversubscribed.

# RESTRICTIONS ON TRANSFER OF THE SECURITIES BEING OFFERED:

The securities being offered may not be transferred by any purchaser of such securities during the one year period beginning when the securities were issued, unless such securities are transferred:

1. to the issuer;
2. to an accredited investor;
3. as part of an offering registered with the U.S. Securities and Exchange Commission; or
4. to a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

NOTE: The term "accredited investor" means any person who comes within any of the categories set forth in Rule 501(a) of Regulation D, or who the seller reasonably believes comes within any of such categories, at the time of the sale of the securities to that person.

The term "member of the family of the purchaser or the equivalent" includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the purchaser, and includes adoptive relationships. The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.

# DESCRIPTION OF ISSUER'S SECURITIES

17. What other securities or classes of securities of the issuer are outstanding? Describe the material terms of any other outstanding securities or classes of securities of the issuer.

| Class of Security | Securities (or Amount) Authorized | Securities (or Amount) Outstanding | Voting Rights |
| --- | --- | --- | --- |
| Preferred | 2,000,000 | 0 | No |
| Common | 15,000,000 | 15,000,000 | Yes |

# Securities Reserved for Class of Security Issuance upon Exercise or Conversion Warrants:

Options:
Total Pool:
Issued:

Describe any other rights:

Investors in this offering would receive preferred stock if the SAFE converts as part of an equity financing event. Preferred stock has a liquidation preference over common stock.

18. How may the rights of the securities being offered be materially limited, diluted or qualified by the rights of any other class of security identified above?

The holders of a majority-in-interest of voting rights in the Company could limit the Investor's rights in a material way. For example, those interest holders could vote to change the terms of the agreements governing the Company's operations or cause the Company to engage in additional offerings (including potentially a public offering).

These changes could result in further limitations on the voting rights the Investor will have as an owner of equity in the Company, for example by diluting those rights or limiting them to certain types of events or consents.

To the extent applicable, in cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also diminish the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional equity, an Investor's interest will typically also be diluted.

Based on the risk that an Investor's rights could be limited, diluted or otherwise qualified, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

Additional risks related to the rights of other security holders are discussed below, in Question 20.

19. Are there any differences not reflected above between the securities being offered and each other class of security of the issuer?

No.

20. How could the exercise of rights held by the principal shareholders identified in Question 6 above affect the purchasers of the securities being offered?

As holders of a majority-in-interest of voting rights in the Company, the shareholders may make decisions with which the Investor disagrees, or that negatively affect the value of the Investor's securities in the Company, and the Investor will have no recourse to change these decisions. The Investor's interests may conflict with those of other investors, and there is no guarantee that the Company will develop in a way that is optimal for or advantageous to the Investor.

For example, the shareholders may change the terms of the articles of incorporation for the company, change the terms of securities issued by the Company, change the management of the Company, and even force out minority holders of securities. The shareholders may make changes that affect the tax treatment of the Company in ways that are unfavorable to you but favorable to them. They may also vote to engage in new offerings and/or to register certain of the Company's securities in a way that negatively affects the value of the securities the Investor owns. Other holders of securities of the Company may also have access to more information than the Investor, leaving the Investor at a disadvantage with respect to any decisions regarding the securities he or she owns.

The shareholders have the right to redeem their securities at any time. Shareholders could decide to force the Company to redeem their securities at a time that is not favorable to the Investor and is damaging to the Company. Investors' exit may affect the value of the Company and/or its viability.

In cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also diminish the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional stock, an Investor's

interest will typically also be diluted.

21. How are the securities being offered being valued? Include examples of methods for how such securities may be valued by the issuer in the future, including during subsequent corporate actions.

The offering price for the securities offered pursuant to this Form C has been determined arbitrarily by the Company, and does not necessarily bear any relationship to the Company's book value, assets, earnings or other generally accepted valuation criteria. In determining the offering price, the Company did not employ investment banking firms or other outside organizations to make an independent appraisal or evaluation. Accordingly, the offering price should not be considered to be indicative of the actual value of the securities offered hereby.

The initial amount invested in a SAFE is determined by the investor, and we do not guarantee that the SAFE will be converted into any particular number of shares of Preferred Stock. As discussed in Question 13, when we engage in an offering of equity interests involving Preferred Stock, Investors may receive a number of shares of Preferred Stock calculated as either (i) the total value of the Investor's investment, divided by the price of the Preferred Stock being issued to new Investors, or (ii) if the valuation for the company is more than the Valuation Cap, the amount invested divided by the quotient of (a) the Valuation Cap divided by (b) the total amount of the Company's capitalization at that time.

Because there will likely be no public market for our securities prior to an initial public offering or similar liquidity event, the price of the Preferred Stock that Investors will receive, and/or the total value of the Company's capitalization, will be determined by our board of directors. Among the factors we may consider in determining the price of Preferred Stock are prevailing market conditions, our financial information, market valuations of other companies that we believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.

In the future, we will perform valuations of our stock (including both common stock and Preferred Stock) that take into account, as applicable, factors such as the following:

- unrelated third party valuations;
- the price at which we sell other securities in light of the relative rights, preferences and privileges of those securities;
- our results of operations, financial position and capital resources;
- current business conditions and projections;
- the marketability or lack thereof of the securities;
- the hiring of key personnel and the experience of our management;
- the introduction of new products;
- the risk inherent in the development and expansion of our products;
- our stage of development and material risks related to our business;
- the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given the prevailing market conditions and the nature and history of our business;
- industry trends and competitive environment;
- trends in consumer spending, including consumer confidence;
- overall economic indicators, including gross domestic product, employment, inflation and interest rates; and
- the general economic outlook.

We will analyze factors such as those described above using a combination of financial and market-based methodologies to determine our business enterprise value. For example, we may use methodologies that assume that businesses operating in the same industry will share similar characteristics and that the Company's value will correlate to those characteristics, and/or methodologies that compare transactions in similar securities issued by us that were conducted in the market.

22. What are the risks to purchasers of the securities relating to minority ownership in the issuer?

An Investor in the Company will likely hold a minority position in the Company, and thus be limited as to its ability to control or influence the governance and operations of the Company.

The marketability and value of the Investor's interest in the Company will depend upon many factors outside the control of the Investor. The Company will be managed by its officers and be governed in accordance with the strategic direction and decision-making of its Board Of Directors, and the Investor will have no independent right to name or remove an officer or member of the Board Of Directors of the Company.

Following the Investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the Investor in the Company. The Investor may have the opportunity to increase its investment in the Company in such a transaction, but such opportunity cannot be assured.

The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the Investor to make a follow-on investment, or the lack of an opportunity to make such a follow-on investment, may result in substantial dilution of the Investor's interest in the Company.

23. What are the risks to purchasers associated with corporate actions, including additional issuances of securities, issuer repurchases of securities, a sale of the issuer or of assets of the issuer or transactions with related parties?

Additional issuances of securities. Following the Investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the Investor in the Company. The Investor may have the opportunity to increase its investment in the Company in such a transaction, but such opportunity cannot be assured. The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the Investor to make a follow-on investment, or the lack of an opportunity to make such a follow-on investment, may result in substantial dilution of the Investor's interest in the Company.

Issuer repurchases of securities. The Company may have authority to repurchase its securities from shareholders, which may serve to decrease any liquidity in the market for such securities, decrease the percentage interests held by other similarly situated investors to the Investor, and create pressure on the Investor to sell its securities to the Company concurrently.

A sale of the issuer or of assets of the issuer. As a minority owner of the Company, the Investor will have limited or no ability to influence a potential sale of the Company or a substantial portion of its assets. Thus, the Investor will rely upon the executive management of the Company and the Board of Directors of the

Company to manage the Company so as to maximize value for shareholders. Accordingly, the success of the Investor's investment in the Company will depend in large part upon the skill and expertise of the executive management of the Company and the Board of Directors of the Company. If the Board Of Directors of the Company authorizes a sale of all or a part of the Company, or a disposition of a substantial portion of the Company's assets, there can be no guarantee that the value received by the Investor, together with the fair market estimate of the value remaining in the Company, will be equal to or exceed the value of the Investor's initial investment in the Company.

Transactions with related parties. The Investor should be aware that there will be occasions when the Company may encounter potential conflicts of interest in its operations. On any issue involving conflicts of interest, the executive management and Board of Directors of the Company will be guided by their good faith judgement as to the Company's best interests. The Company may engage in transactions with affiliates, subsidiaries or other related parties, which may be on terms which are not arm's-length, but will be in all cases consistent with the duties of the management of the Company to its shareholders. By acquiring an interest in the Company, the Investor will be deemed to have acknowledged the existence of any such actual or potential conflicts of interest and to have waived any claim with respect to any liability arising from the existence of any such conflict of interest.

24. Describe the material terms of any indebtedness of the issuer:

| Loan |  |
| --- | --- |
| Lender | Fresh Consulting Inc |
| Issue date | 07/28/24 |
| Amount | $22,324.00 |
| Outstanding principal plus interest | $22,324.00 as of 05/27/25 |
| Interest rate | 0.0% per annum |
| Current with payments | Yes |

No interest, repayment contingent on funding availability. May be converted into equity on the same terms as latest SAFE agreements.

| Loan |  |
| --- | --- |
| Lender | Softeq Development Corp |
| Issue date | 08/07/24 |
| Amount | $110,522.00 |
| Outstanding principal plus interest | $110,522.00 as of 05/27/25 |
| Interest rate | 0.0% per annum |
| Current with payments | Yes |

No interest, repayment contingent on funding availability. May be converted into equity on the same terms as latest SAFE agreements.

| Loan |  |
| --- | --- |
| Lender | Shaun Rosenthal |
| Issue date | 08/26/24 |
| Amount | $14,000.00 |
| Outstanding principal plus interest | $14,000.00 as of 05/27/25 |
| Current with payments | Yes |

No interest, repayment contingent on funding availability. May be

converted into equity on the same terms as latest SAFE agreements.

## Loan

| Lender | Lorena De La Maza Krzeptowsky |
| --- | --- |
| Issue date | 09/29/24 |
| Amount | $42,000.00 |
| Outstanding principal plus interest | $32,000.00 as of 05/27/25 |
| Current with payments | Yes |

No interest, repayment contingent on funding availability. May be converted into equity on the same terms as latest SAFE agreements.

INSTRUCTION TO QUESTION 24: name the creditor, amount owed, interest rate, maturity date, and any other material terms.

25. What other exempt offerings has the issuer conducted within the past three years?

| Offering Date | Exemption | Security Type | Amount Sold | Use of Proceeds |
| --- | --- | --- | --- | --- |
| 7/2022 | Regulation D, Rule 506(b) | SAFE | $300,000 | General operations |
| 2/2023 | Regulation D, Rule 506(b) | SAFE | $25,000 | General operations |
| 4/2023 | Regulation D, Rule 506(b) | SAFE | $10,000 | General operations |
| 4/2023 | Regulation D, Rule 506(b) | SAFE | $25,000 | General operations |
| 4/2023 | Regulation D, Rule 506(b) | SAFE | $25,000 | General operations |
| 6/2023 | Regulation D, Rule 506(b) | SAFE | $20,000 | General operations |
| 6/2023 | Regulation D, Rule 506(b) | SAFE | $8,500 | General operations |
| 4/2024 | Regulation D, Rule 506(b) | SAFE | $20,000 | General operations |
| 5/2024 | Regulation D, Rule 506(b) | SAFE | $2,035 | General operations |
| 7/2024 | Regulation Crowdfunding | SAFE | $292,345 | General operations |
| 7/2024 | Regulation Crowdfunding | SAFE | $292,345 | General operations |
| 10/2024 | Regulation D, Rule 506(b) | SAFE | $65,000 | General operations |
| 2/2025 | Regulation D, Rule 506(b) | SAFE | $215,000 | General operations |
| 7/2025 | Regulation D, Rule 506(b) | SAFE | $250,000 | General operations |

26. Was or is the issuer or any entities controlled by or under common control with the issuer a party to any transaction since the beginning of the issuer's last fiscal year, or any currently proposed transaction, where the amount involved exceeds five percent of the aggregate amount of capital raised by the issuer in reliance on Section 4(a)(6) of the Securities Act during the preceding 12-month period, including the amount the issuer seeks to raise in the current offering, in which any of the following persons had or is to have a direct or indirect material interest:

1. any director or officer of the issuer;

2. any person who is, as of the most recent practicable date, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
3. if the issuer was incorporated or organized within the past three years, any promoter of the issuer;
4. or any immediate family member of any of the foregoing persons.

☑ Yes
☐ No

For each transaction specify the person, relationship to issuer, nature of interest in transaction, and amount of interest.

| Name | Gerardo Rioseco Rubio |
| --- | --- |
| Amount Invested | $20,000.00 |
| Transaction type | Safe |
| Issue date | 06/29/23 |
| Valuation cap | $20,000,000.00 |
| Relationship | Treasurer |

| Name | Luis Gomez Sanchez |
| --- | --- |
| Amount Invested | $8,500.00 |
| Transaction type | Safe |
| Issue date | 06/30/23 |
| Valuation cap | $20,000,000.00 |
| Relationship | Co-Founder & Director |

| Name | Luis Gomez Sánchez |
| --- | --- |
| Amount Invested | $2,035.00 |
| Transaction type | Safe |
| Issue date | 05/30/24 |
| Valuation cap | $20,000,000.00 |
| Relationship | Co-Founder & Director |

| Name | Shaun Rosenthal |
| --- | --- |
| Amount Invested | $14,000.00 |
| Transaction type | Loan |
| Issue date | 08/26/24 |
| Outstanding principal plus interest | $14,000.00 as of 05/27/25 |
| Current with payments | Yes |
| Relationship | Director |

| Name | Lorena De La Maza Krzeptowsky |
| --- | --- |
| Amount Invested | $42,000.00 |
| Transaction type | Loan |
| Issue date | 09/29/24 |
| Outstanding principal plus interest | $32,000.00 as of 05/27/25 |
| Current with payments | Yes |
| Relationship | Co-founder & Director |

INSTRUCTIONS TO QUESTION 26: The term transaction includes, but is not limited to, any financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) or any series of similar transactions, arrangements or relationships.

Beneficial ownership for purposes of paragraph (2) shall be determined as of a date that is no more than 120 days prior to the date of filing of this offering statement and using the same calculation described in Question 6 of this Question and Answer format.

The term "member of the family" includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the person, and includes adoptive relationships. The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.

Compute the amount of a related party's interest in any transaction without regard to the amount of the profit or loss involved in the transaction. Where it is not practicable to state the approximate amount of the interest, disclose the approximate amount involved in the transaction.

# FINANCIAL CONDITION OF THE ISSUER

27. Does the issuer have an operating history?
☑ Yes
☐ No

28. Describe the financial condition of the issuer, including, to the extent material, liquidity, capital resources and historical results of operations.

## Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

## Overview

Viit Health Inc. ("the Company") was incorporated in the State of Delaware on June 15, 2021. The Company develops non-invasive health monitoring technology based on light-based spectroscopy and AI-powered analytics. Its flagship product is designed to estimate biomarkers such as blood glucose, oxygen saturation, heart rate, and other physiological metrics. As of December 31, 2024, the Company remains in the research and development stage and has not generated revenue from product sales.

## Milestones

Viit Health Inc was incorporated in the State of Delaware in June 2021.

Since then, we have:

- Measures 10 biomarkers 97% faster and 95% cheaper than traditional measurement tools
- Proprietary patent-pending tech measures Glucose, Blood

Pressure, SpO2, Heart Rate, and more

- Validated in 3,700+ patients through 4 Clinical Trials; aiming to measure 100,000 more in 18 months
- Potential to predict 27+ diseases and 19+ complications, such as diabetes, hypertension and more
- 99.5% SpO2 accuracy, 97% Heart Rate, 95.9-93.9% Blood Pressure, and 92.2% regular Blood Glucose
- $1.8M raised from leading private investors. $3M in R&amp;D grants awarded to background dev company
- Partners include Fresh Consulting, InBody, Pharmatics, Softeq Engineering, and Hamamatsu

The Company is subject to risks and uncertainties common to early-stage companies. Given the Company's limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future.

## Historical Results of Operations

Our company was incorporated in June 2021 and has limited operations upon which prospective investors may base an evaluation of its performance.

- Revenues &amp; Gross Margin. For the period ended December 31, 2024, the Company had revenues of $0 compared to the year ended December 31, 2023, when the Company had revenues of $0.
- Assets. As of December 31, 2024, the Company had total assets of $25,065, including $25,065 in cash. As of December 31, 2023, the Company had $13,044 in total assets, including $13,044 in cash.
- Net Loss. The Company has had net losses of $346,594 and net losses of $533,768 for the fiscal years ended December 31, 2024 and December 31, 2023, respectively.
- Liabilities. The Company's liabilities totaled $1,688,898 for the fiscal year ended December 31, 2024 and $1,330,283 for the fiscal year ended December 31, 2023.

## Related Party Transaction

Refer to Question 26 of this Form C for disclosure of all related party transactions.

## Liquidity &amp; Capital Resources

To-date, the company has been financed with $188,846 in debt and $1,888,916 in SAFEs.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 3 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don't have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 3 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity

and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

## Runway &amp; Short/Mid Term Expenses

Viit Health Inc cash in hand is $49,009.35, as of June 2025. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $30,078/month, for an average burn rate of $30,078 per month. Our intent is to be profitable in 18 months.

Since the date of our financials, we received a $215,000 investment via SAFE agreement with the same terms as the current offering. We signed an additional SAFE agreement for $250,000 to be invested in July 2025. We hired two key employees (CTO &amp; CRO). We contracted a new Machine Learning team with whom we've been able to significantly improve the accuracy of our measurements. We submitted a proposal to the SBIR - NIH program for $2.4M. We started a new clinical trial at Hospital Juárez de México. We finalized out last prototype for product validation and activated new institutional partnerships in the US and Mexico.

We expect to generate revenue by July of 2026. We will need at least $1M to become revenue generating, which would be when we successfully place the first 200 devices in the market aimed towards disease prevention under a B2B subscription model.

In six months, we expect to incur approximately $400k in expenses.

We expect to become profitable by January of 2027 assuming we raise $2M in capital, after our initial customers have moved past the 6 month BETA mark using our devices for disease prevention at an organizational level. Such subscriptions will be extended through 2027, at which point our monthly burn rate will be lower than our monthly revenue.

Aside from Wefunder, we closed a $250,000 from a NY based VC for July 2025. There is also intent from a North American VC to invest $500,000 in October, and intent from an Angel Investment Group based out Chicago to invest up to $2.3M in 2025. We intend to cover the short-term burn with the $250,000 we have secured for July 2025.

All projections in the above narrative are forward-looking and not guaranteed.

**INSTRUCTIONS TO QUESTION 28:** The discussion must cover each year for which financial statements are provided. For issuers with no prior operating history, the discussion should focus on financial milestones and operational, liquidity and other challenges. For issuers with an operating history, the discussion should focus on whether historical results and cash flows are representative of what investors should expect in the future. Take into account the proceeds of the offering and any other known or pending sources of capital. Discuss how the proceeds from the offering will affect liquidity, whether receiving these funds and any other additional funds is necessary to the viability of the business, and how quickly the issuer anticipates using its available cash. Describe the other available sources of capital to the business, such as lines of credit or required contributions by shareholders. References to the issuer in this Question 28 and these instructions refer to the issuer and its predecessors, if any.

# FINANCIAL INFORMATION

29. Include financial statements covering the two most recently completed fiscal years or the period(s) since inception, if shorter:

Refer to Appendix C, Financial Statements

I, Luis Fernando Gomez, certify that:

(1) the financial statements of Viit Health Inc included in this Form are true and complete in all material respects; and
(2) the financial information of Viit Health Inc included in this Form reflects accurately the information reported on the tax return for Viit Health Inc filed for the most recently completed fiscal year.

Luis Fernando Gomez
CEO

# STAKEHOLDER ELIGIBILITY

30. With respect to the issuer, any predecessor of the issuer, any affiliated issuer, any director, officer, general partner or managing member of the issuer, any beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, any promoter connected with the issuer in any capacity at the time of such sale, any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with such sale of securities, or any general partner, director, officer or managing member of any such solicitor, prior to May 16, 2016:

(1) Has any such person been convicted, within 10 years (or five years, in the case of issuers, their predecessors and affiliated issuers) before the filing of this offering statement, of any felony or misdemeanor:

i. In connection with the purchase or sale of any security? ☐ Yes ☑ No
ii. Involving the making of any false filing with the Commission? ☐ Yes ☑ No
iii. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? ☐ Yes ☑ No

(2) Is any such person subject to any order, judgment or decree of any court of competent jurisdiction, entered within five years before the filing of the information required by Section 4A(b) of the Securities Act that, at the time of filing of this offering statement, restrains or enjoins such person from engaging or continuing to engage in any conduct or practice:

i. In connection with the purchase or sale of any security? ☐ Yes ☑ No
ii. involving the making of any false filing with the Commission? ☐ Yes ☑ No
iii. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? ☐ Yes ☑ No

(3) Is any such person subject to a final order of a state securities commission (or an agency or officer of a state performing like functions); a state authority that supervises or examines banks, savings associations or credit unions; a state insurance commission (or an agency or officer of a state performing like functions); an appropriate federal banking agency; the U.S. Commodity Futures Trading Commission; or the National Credit Union Administration that:

i. at the time of the filing of this offering statement bars the person

from:

A. association with an entity regulated by such commission, authority, agency or officer? ☐ Yes ☑ No
B. engaging in the business of securities, insurance or banking? ☐ Yes ☑ No
C. engaging in savings association or credit union activities? ☐ Yes ☑ No

ii. constitutes a final order based on a violation of any law or regulation that prohibits fraudulent, manipulative or deceptive conduct and for which the order was entered within the 10-year period ending on the date of the filing of this offering statement? ☐ Yes ☑ No

(4) Is any such person subject to an order of the Commission entered pursuant to Section 15(b) or 15B(c) of the Exchange Act or Section 203(e) or (f) of the Investment Advisers Act of 1940 that, at the time of the filing of this offering statement:

i. suspends or revokes such person's registration as a broker, dealer, municipal securities dealer, investment adviser or funding portal? ☐ Yes ☑ No
ii. places limitations on the activities, functions or operations of such person? ☐ Yes ☑ No
iii. bars such person from being associated with any entity or from participating in the offering of any penny stock? ☐ Yes ☑ No

(5) Is any such person subject to any order of the Commission entered within five years before the filing of this offering statement that, at the time of the filing of this offering statement, orders the person to cease and desist from committing or causing a violation or future violation of:

i. any scienter-based anti-fraud provision of the federal securities laws, including without limitation Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange Act, Section 15(c)(1) of the Exchange Act and Section 206(1) of the Investment Advisers Act of 1940 or any other rule or regulation thereunder? ☐ Yes ☑ No
ii. Section 5 of the Securities Act? ☐ Yes ☑ No

(6) Is any such person suspended or expelled from membership in, or suspended or barred from association with a member of, a registered national securities exchange or a registered national or affiliated securities association for any act or omission to act constituting conduct inconsistent with just and equitable principles of trade?

☐ Yes ☑ No

(7) Has any such person filed (as a registrant or issuer), or was any such person or was any such person named as an underwriter in, any registration statement or Regulation A offering statement filed with the Commission that, within five years before the filing of this offering statement, was the subject of a refusal order, stop order, or order suspending the Regulation A exemption, or is any such person, at the time of such filing, the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued?

☐ Yes ☑ No

(8) Is any such person subject to a United States Postal Service false representation order entered within five years before the filing of the information required by Section 4A(b) of the Securities Act, or is any such person, at the time of filing of this offering statement, subject to a temporary restraining order or preliminary injunction with respect to conduct alleged by the United States Postal Service to constitute a scheme or device for obtaining money or property through the mail by means of false representations?

☐ Yes ☑ No

If you would have answered "Yes" to any of these questions had the conviction, order, judgment, decree, suspension, expulsion or bar occurred or been issued after May 16, 2016, then you are NOT eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

INSTRUCTIONS TO QUESTION 30: Final order means a written directive or declaratory statement issued by a federal or state agency, described in Rule 503(a)(3)

of Regulation Crowdfunding, under applicable statutory authority that provides for notice and an opportunity for hearing, which constitutes a final disposition or action by that federal or state agency.

No matters are required to be disclosed with respect to events relating to any affiliated issuer that occurred before the affiliation arose if the affiliated entity is not (i) in control of the issuer or (ii) under common control with the issuer by a third party that was in control of the affiliated entity at the time of such events.

# OTHER MATERIAL INFORMATION

31. In addition to the information expressly required to be included in this Form, include:

- (1) any other material information presented to investors; and
- (2) such further material information, if any, as may be necessary to make the required statements, in the light of the circumstances under which they are made, not misleading.

The Lead Investor. As described above, each Investor that has entered into the Investor Agreement will grant a power of attorney to make voting decisions on behalf of that Investor to the Lead Investor (the "Proxy"). The Proxy is irrevocable unless and until a Successor Lead Investor takes the place of the Lead Investor, in which case, the Investor has a five (5) calendar day period to revoke the Proxy. Pursuant to the Proxy, the Lead Investor or his or her successor will make voting decisions and take any other actions in connection with the voting on Investors' behalf.

The Lead Investor is an experienced investor that is chosen to act in the role of Lead Investor on behalf of Investors that have a Proxy in effect. The Lead Investor will be chosen by the Company and approved by Wefunder Inc. and the identity of the initial Lead Investor will be disclosed to Investors before Investors make a final investment decision to purchase the securities related to the Company.

The Lead Investor can quit at any time or can be removed by Wefunder Inc. for cause or pursuant to a vote of investors as detailed in the Lead Investor Agreement. In the event the Lead Investor quits or is removed, the Company will choose a Successor Lead Investor who must be approved by Wefunder Inc. The identity of the Successor Lead Investor will be disclosed to Investors, and those that have a Proxy in effect can choose to either leave such Proxy in place or revoke such Proxy during a 5-day period beginning with notice of the replacement of the Lead Investor.

The Lead Investor will not receive any compensation for his or her services to the SPV. The Lead Investor may receive compensation if, in the future, Wefunder Advisors LLC forms a fund ("Fund") for accredited investors for the purpose of investing in a non-Regulation Crowdfunding offering of the Company. In such a circumstance, the Lead Investor may act as a portfolio manager for that Fund (and as a supervised person of Wefunder Advisors) and may be compensated through that role.

Although the Lead Investor may act in multiple roles with respect to the Company's offerings and may potentially be compensated for some of its services, the Lead Investor's goal is to maximize the value of the Company and therefore maximize the value of securities issued by or related to the Company. As a result, the Lead Investor's interests should always be aligned with those of

Lead Investor's interests should always be aligned with those of Investors. It is, however, possible that in some limited circumstances the Lead Investor's interests could diverge from the interests of Investors, as discussed in section 8 above.

Investors that wish to purchase securities related to the Company through Wefunder Portal must agree to give the Proxy described above to the Lead Investor, provided that if the Lead Investor is replaced, the Investor will have a 5-day period during which he or she may revoke the Proxy. If the Proxy is not revoked during this 5-day period, it will remain in effect.

Tax Filings. In order to complete necessary tax filings, the SPV is required to include information about each investor who holds an interest in the SPV, including each investor's taxpayer identification number ("TIN") (e.g., social security number or employer identification number). To the extent they have not already done so, each investor will be required to provide their TIN within the earlier of (i) two (2) years of making their investment or (ii) twenty (20) days prior to the date of any distribution from the SPV. If an investor does not provide their TIN within this time, the SPV reserves the right to withhold from any proceeds otherwise payable to the Investor an amount necessary for the SPV to satisfy its tax withholding obligations as well as the SPV's reasonable estimation of any penalties that may be charged by the IRS or other relevant authority as a result of the investor's failure to provide their TIN. If applicable, the Company may also be required to pay Wefunder certain fees for the preparation of tax filings. Such fees and the Company's obligation to deliver required tax documents are further specified in the related Tax Services Agreement ("TSA").

Investors should carefully review the terms of the SPV Subscription Agreement for additional information about tax filings.

Potential Dissolution of the SPV. The Company has agreed that it will pay an administrative fee and / or certain tax fees to Wefunder, in addition to delivering required tax information in the manner prescribed by the TSA, where applicable. Failure to pay such fees or provide Wefunder with required tax information could result in the dissolution of the SPV (an "SPV Dissolution Event"). Subsequent to an SPV Dissolution Event, the securities held by the SPV would be distributed directly and proportionally to the individual investors. This could create administrative complexities, as investors would need to manage the securities themselves rather than having them held and administered by the SPV. Additionally, the unplanned distribution of securities may not align with investors' intended investment strategy or asset allocation.

Upon an SPV Dissolution Event, the Investor hereby consents to and agrees to accept direct assignment of the SPV's rights and obligations under any investment agreements between the SPV and the Company that is located in the Form C or C/A offering materials. The Investor acknowledges they will be bound by all terms and conditions of such agreements as if they were an original party thereto.

INSTRUCTIONS TO QUESTION 30: If information is presented to investors in a format, media or other means not able to be reflected in text or portable document format, the issuer should include:

(a) a description of the material content of such information;
(b) a description of the format in which such disclosure is presented; and
(c) in the case of disclosure in video, audio or other dynamic media or format, a transcript or description of such disclosure.

# ONGOING REPORTING

32. The issuer will file a report electronically with the Securities &amp; Exchange Commission annually and post the report on its website, no later than:

120 days after the end of each fiscal year covered by the report.

33. Once posted, the annual report may be found on the issuer's website at:

https://www.viit.health/invest

The issuer must continue to comply with the ongoing reporting requirements until:

1. the issuer is required to file reports under Exchange Act Sections 13(a) or 15(d);
2. the issuer has filed at least one annual report and has fewer than 300 holders of record;
3. the issuer has filed at least three annual reports and has total assets that do not exceed $10 million;
4. the issuer or another party purchases or repurchases all of the securities issued pursuant to Section 4(a)(6), including any payment in full of debt securities or any complete redemption of redeemable securities; or the issuer liquidates or dissolves in accordance with state law.

# APPENDICES

Appendix A: Business Description &amp; Plan

Appendix B: Investor Contracts

- SPV Subscription Agreement - Early Bird
- Early Bird SAFE (Simple Agreement for Future Equity)
- SPV Subscription Agreement
- SAFE (Simple Agreement for Future Equity)

Appendix C: Financial Statements

Financials 1

Appendix D: Director &amp; Officer Work History

- Gerardo Rioseco Orihuela
- Gerardo Rioseco Rubio
- Jorge Villegas
- Lorena De La Maza Krzeptowsky
- Luis Fernando Gomez
- Luis Gomez Sanchez
- Roberto Jones Arakelian
- Shaun Rosenthal
- Sofia Alvarez Cano

Appendix E: Supporting Documents

# Signatures

Intentional misstatements or omissions of facts constitute federal criminal violations. See 18 U.S.C. 1001.

The issuer certifies that it has established means to keep accurate records of the holders of the securities it would offer and sell through the intermediary's platform.

The following documents will be filed with the SEC:

Cover Page XML

Offering Statement (this page)

Appendix A: Business Description &amp; Plan

Appendix B: Investor Contracts

- SPV Subscription Agreement - Early Bird
- Early Bird SAFE (Simple Agreement for Future Equity)
- SPV Subscription Agreement
- SAFE (Simple Agreement for Future Equity)

Appendix C: Financial Statements

Financials 1

Appendix D: Director &amp; Officer Work History

- Gerardo Rioseco Orihuela
- Gerardo Rioseco Rubio
- Jorge Villegas
- Lorena De La Maza Krzeptowsky
- Luis Fernando Gomez
- Luis Gomez Sanchez
- Roberto Jones Arakelian
- Shaun Rosenthal
- Sofia Alvarez Cano

Appendix E: Supporting Documents

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

Viit Health Inc

By

Luis Fernando Gomez

CEO

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C and Transfer Agent Agreement has been signed by the following persons in the capacities and on the dates indicated.

| Luis Fernando CEO 6/9/2025 |
| --- |
| Gerardo Rioseco Rubio Treasurer 6/9/2025 |
| Shaun Rosenthal Director 6/9/2025 |
| Luis Gomez Sanchez President 6/9/2025 |
| Lorena de la Maza Krzeptowsky Vice President 6/9/2025 |
| Luis Fernando Gomez CEO 6/9/2025 |

The Form C must be signed by the issuer, its principal executive officer or officers, its principal financial officer, its controller or principal accounting officer and at least a majority of the board of directors or persons performing similar functions.

I authorize Wefunder Portal to submit a Form C to the SEC based on the information I provided through this online form and my company's Wefunder profile.

As an authorized representative of the company, I appoint Wefunder Portal as the company's true and lawful representative and attorney-in-fact, in the company's name, place and stead to make, execute, sign, acknowledge, swear to and file a Form C on the company's behalf. This power of attorney is coupled with an interest and is irrevocable. The company hereby waives any and all defenses that may be available to contest, negate

or disaffirm the actions of Wefunder Portal taken in good faith under or in reliance upon this power of attorney.

**Attachment 2:** `document_2.pdf`

INVEST IN VIIT HEALTH

# Extending Lives through Light and Intelligence

![img-0.jpeg](img-0.jpeg)

viit.health Mesa, United States in f @ Technology Female Founder Healthcare B2C AI

# Highlights

## VC-Backed

Raised $250K or more from a venture firm

1. Measures 10 biomarkers 97% faster and 95% cheaper than traditional measurement tools
2. Proprietary patent-pending tech measures Glucose, Blood Pressure, SpO2, Heart Rate, and more
3. Validated in 3,700+ patients through 4 Clinical Trials; aiming to measure 100,000 more in 18 months

4. Potential to predict 27+ diseases and 19+ complications, such as diabetes, hypertension and more

5. 99.5% SpO2 accuracy, 97% Heart Rate, 95.9-93.9% Blood Pressure, and 92.2% regular Blood Glucose

6. $1.8M raised from leading private investors. $3M in R&amp;D grants awarded to background dev company

7. Partners include Fresh Consulting, InBody, Pharmatics, Softeq Engineering, and Hamamatsu

8. Supported by Mexico City’s Gov, top medical institutions, a leading US Family Office, and other VCs

# Featured Investors

| Softeq Venture Fund | Follow | Invested $300,000 |
| --- | --- | --- |

The Softeq Venture Fund invests in early-stage technology companies and de-risks them with a unique model of Fund + Venture Studio + Engineering Services.<br/>
softeq.com

## Bret Siarkowski, General Partner

“As General Partner at Softeq Venture Fund and MedScience Ventures, I am committed to supporting ventures that drive impact through innovation. Viit Health’s mission is fully aligned with this vision, offering scalable and effective solutions in personalized healthcare.”

SABA RICA
Sabacica Capital
Follow
Invested $250,000

We are a women-led fund with a focus on increasing transgenerational wealth, backed by research. We do this by deploying capital to women and POC-led start-ups at the seed and series A stage.
sabacicacapital.com

## Winnie Sabbat, Managing Partner

"Viit Health is tackling a key challenge in modern medicine -leveraging data to improve patient outcomes. Their approach aligns with my belief in supporting companies that combine strong technology with a clear path to market impact."

Robert C Campbell
Syndicate Lead

Follow

Invested $50,000 😊

Investor and Founder. Entrepreneur-In-Residence at the Softeq Venture Studio.

"Hello! I have known the team at VIIT Health for years. I am investing for three basic reasons: (1) the technology and product are a much-needed solution to help with the global diabetes epidemic as well as with broader lifestyle improvements for everyone; (2) the team is fantastic, from a technical perspective as well as from a business-acumen perspective; and (3) the scaling plan is viable: there is product-market fit with known customers and a path to scale. I could not be more excited about this opportunity and look forward to great things! - Robert"

Other investors include Cienega Investments LLC Notable &amp; 850 more

## Our Team

Luis Fernando CEO

Serial entrepreneur and social activist. Founded a Venture Builder at 20, launching 7 startups with 2 exits.

Recognized at the 73rd UN General Assembly, winner of Santander Challenge 2020, Startup World Cup finalist 2022, 2019 Paris Peace Forum awardee.

Sedentary lifestyles and unhealthy diets have made Type II Diabetes one the highest rising mortality causes in the world (second largest in Mexico). It has affected many people around us. We realize that the only way to change this and save lives is by raising awareness and promoting prevention through effective and regular monitoring.

![img-1.jpeg](img-1.jpeg)

## Mayra Mora CTO

MSc in Biomedical Engineering from Arts et Métiers, Paris. Led R&amp;D for medical devices across Europe and Latin America. Experience in digital health, preoperative simulation, and non-invasive monitoring in early-stage and international collaborations.

![img-2.jpeg](img-2.jpeg)

## Antonio Garcia CSO

Ph.D. in Chemical Engineering from UC Berkeley. Endowed Chair in Bioengineering at ASU. Leads research on bionanotech and diagnostics for low-resource settings. With 147+ publications and NIH/NSF funding, his work has been widely recognized and featured.

![img-3.jpeg](img-3.jpeg)

## Victoria Merino CRO

MSc in Biomedical Engineering from the University of Pennsylvania. Background in chemistry, cognitive science, and neurotechnology across the U.S., Japan, and Mexico. Focused on translational medicine and digital tools for preventive healthcare.

![img-4.jpeg](img-4.jpeg)

## Felix Agakov Artificial Intelligence

MSc and PhD in AI from the University of Edinburgh. Founder of multiple research-based organizations. Expert in transforming biomedical data into deployable AI for precision medicine. Holds 50+ publications and several patents in applied machine learning.

A

Adriano Morrey Guzman Clinical Research

![img-5.jpeg](img-5.jpeg)

# Adriana Monroy Guzman Clinical Research

MD and PhD from UNAM with postdocs at UT Health and UNAM. 30+ years studying chronic diseases like diabetes and cancer. Coordinator of Research at General Hospital of Mexico's Oncology Service, focused on translational science and public health equity.

![img-6.jpeg](img-6.jpeg)

# Luis Gomez Government Relations

JD in International Law and AMP from Harvard. Corporate lawyer and AI entrepreneur. Co-founded SolexVintel (exit to Grupo Bimbo). Former executive at Citibank, AT&amp;T, Alestra, Chrysler, and Walmart. Expert in legal, tech, and business strategy leadership.

![img-7.jpeg](img-7.jpeg)

# Lorena De La Maza Medical Relations

MD from UNAM, MSc in Microbiology from Harvard/MGH. Two-time founder and social impact entrepreneur. Co-founded AI vision tech company for health and agroindustries with an exit to Grupo Bimbo. Combines clinical expertise with scalable innovation.

![img-8.jpeg](img-8.jpeg)

# Gerardo Rioseco Finance

BS in International Business from Ibero-American University. Serial entrepreneur with 8 startups and 2 exits. Co-founded Sampa Explore in Baja California. Award-winning founder and former professional tennis player with global experience.

![img-9.jpeg](img-9.jpeg)

# Sofia Alvarez Administration

BS in Business Administration from ITAM. Serial entrepreneur with 8 startups and 2 exits. Over 10 years of experience in human resources, operations, and business management, building and scaling ventures across diverse industries and teams.

AI-Assisted Health Monitoring For Chronic Disease Prevention

Viit Health is back for one last community round before our launch! Our mission is to deliver the future of personalized disease prevention, aiming to extend 1 million lives by 10 healthy life-years over the next 5 years.

We have developed a unique, pocket-size device that uses light and artificial intelligence-not needles or consumables-to accurately measure blood glucose, blood pressure, oxygen saturation, heart rate, and other biomarkers in less than 30 seconds.

Through simple, painless monitoring and real-time personalized insights, our technology can detect early signs of health risks and help people stay healthy for longer.

![img-10.jpeg](img-10.jpeg)

![img-11.jpeg](img-11.jpeg)

Non-communicable diseases (NCDs) like hypertension, heart disease, diabetes, and other metabolic disorders, now account

for over 70% of deaths globally-claiming more than 40 million lives each year. Often symptomless in early stages, conditions like high blood pressure-affecting more than 1.2 billion people worldwide-or glucose-related dysfunction-estimated to impact half the world’s population-progress silently until disease becomes unavoidable.

These threats, driven by sedentary lifestyles, poor nutrition, chronic stress, and inequitable access to healthcare, can lead to heart attacks, strokes, kidney failure, and neurodegenerative conditions. The crisis isn’t just medical-it’s a failure of early detection and accessible prevention.

![img-12.jpeg](img-12.jpeg)

Monitoring vital health markers like blood glucose, blood pressure, and oxygen saturation remains a slow, fragmented, and costly process-especially for those at risk of chronic disease. Individuals often need multiple separate devices, each requiring setup, calibration, and manual interpretation.

Blood glucose tracking, for example, still relies on painful

finger pricks or expensive continuous monitors that involve frequent sensor insertions-costing users up to $3,600 annually. For many, especially those already managing complications like neuropathy, these tools are not just uncomfortable-they're unsustainable. At the clinic level, conducting a full assessment of basic vitals can take up to 17 minutes and cost nearly $7 per patient. These inefficiencies not only drive up costs but discourage consistent monitoring, delay diagnosis, and ultimately make prevention inaccessible for millions.

# Prevention Can Only Truly be Achieved
## Whithout Pain, At Low-Cost, &amp; With Fast Results

### Current Basic Clinical Analysis Is Costly, Painful, &amp; Inefficient

- $7 per patient
- 17 minutes
- No Interpretation

- 45% of adults have undiagnosed diabetes
- 46% of adults have undiagnosed hypertension
- 60% of diabetics abandon treatment due to pain

![img-13.jpeg](img-13.jpeg)

![img-14.jpeg](img-14.jpeg)

![img-15.jpeg](img-15.jpeg)

![img-16.jpeg](img-16.jpeg)

![img-17.jpeg](img-17.jpeg)

World Health Organization / International Diabetes Federation / Mexican Diabetes Federation

# There's A Smarter, Simpler Way To Monitor Your Health Reliably

Viit Health combines Near Infrared Transmittance Spectroscopy (NIRS-TA), Photoplethysmography (PPG), Light Rotation (LR), and AI to deliver fast, painless, and non-invasive readings of key health biomarkers-such as blood glucose, blood pressure, oxygen saturation, heart rate, and more-without the need for multiple devices, finger pricks, or consumables. What traditionally takes up to 17 minutes and costs over $7 per patient in clinical settings, can now be done in under 30 seconds for as little as $0.10-$0.35 per scan. This

in under 30 seconds for as little as $0.10-$0.35 per scan. This represents up to 97% in time savings and 95% in cost reduction, making real-time health monitoring vastly more accessible across personal, clinical, and public health settings.

As global attention turns toward prevention and health optimization, our proprietary, patent-pending technology offers a distinct technical edge by combining multiple optical methodologies into a single, compact system capable of acquiring strong, high-resolution signals for diverse biomarkers. Viit Health’s multi-sensor technique allows for more robust, accurate, and personalizable health monitoring compared to single-modality or algorithm-first solutions. Unlike approaches that overwhelm users with excessive or unreliable data, we focus on precision over quantity-delivering only the insights that matter, when they matter. And by prioritizing signal quality, cross-wavelength optimization, and efficient hardware design, we’re able to offer a scalable, cost-effective solution without compromising performance or usability.

# Game-Changing Approach

Spectral &amp; Multi-Sensor Powered by AI

Patent Pending

US No. 19/088,717

PCT/US2025/021174

![img-18.jpeg](img-18.jpeg)

Light Rotation

Optically active molecules rotate the plane of polarized light

![img-19.jpeg](img-19.jpeg)

Near Infrared Spectroscopy

Specific molecular bonds absorb light at characteristic wavelengths

![img-20.jpeg](img-20.jpeg)

Photoplethysmography

Blood flow alters the amount of light absorbed

![img-21.jpeg](img-21.jpeg)

Artificial Intelligence

Ensemble ML models trained on millions of data points can identify correlations

![img-22.jpeg](img-22.jpeg)

![img-23.jpeg](img-23.jpeg)

Backed by Thorough Clinical Testing And Finalizing Validation

Over six years of R&amp;D and multiple generations of device innovation, Viit Health has fine-tuned its proprietary technology through extensive calibration and clinical validation protocols. Since 2018, we’ve collaborated with leading healthcare institutions in the U.S. and Mexico, conducting 4 clinical studies and validating our technology in over 3,700 individuals to date.

With current results showing 2.4 BPM MAE for heart rate, 0.5% MAE for SpO2, 4.87 mmHg MAE for blood pressure, and 20.8 mg/dL MAE for regular blood glucose levels, we have mostly closed the gap between non-invasive wellness monitoring and clinical-grade performance. Over the next 18 months, we plan to launch three additional clinical trials to strengthen our evidence base across diverse populations and use cases. These trials will also support our regulatory strategy in both the U.S. and Latin America, laying the groundwork for broader deployment and FDA market entry through the wellness and digital health pathways.

![img-24.jpeg](img-24.jpeg)

![img-25.jpeg](img-25.jpeg)

![img-26.jpeg](img-26.jpeg)

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

![img-3.jpeg](img-3.jpeg)

Our active Clinical Studies in two of the largest hospitals in Mexico (Hospital General de México and Hospital Juárez de México).

![img-4.jpeg](img-4.jpeg)

Prevention is the only sustainable way to fight chronic diseases-but today, it's blocked by screening tools that are too complicated, expensive, and fragmented. Viit Health changes that. For just $350, anyone can access real-time, painless monitoring of key health biomarkers that traditionally required multiple devices, appointments, and consumables.

Our business model is designed for both access and long-term impact. We're launching a dual path: a reimbursable subscription model for clinics, healthcare providers, and public health programs (starting at $250/month per device), and an affordable wellness subscription for individuals focused on prevention and metabolic health (starting at $10/month). With fast, scalable deployment and a focus on early detection, Viit Health makes prevention practical-for people, professionals, and entire communities.

![img-5.jpeg](img-5.jpeg)

![img-6.jpeg](img-6.jpeg)

Viit Health is directly addressing a $780B+ market opportunity driven by the global shift toward personalized, preventive healthcare. The broader public health and personalized medicine market is projected to surpass $1 trillion by 2028, while non-communicable diseases like diabetes and hypertension are expected to cost the global economy over $47 trillion by 2030. More than 2 billion people are living with or at high risk of metabolic and cardiovascular conditions-often without a diagnosis or access to preventive care. As existing tools remain inefficient and hard to scale, Viit Health offers a timely alternative: accessible, non-invasive, real-time monitoring designed for everyday use and population-level impact.

![img-7.jpeg](img-7.jpeg)

541 623 730 Worldwide

International Diabetes Federation (IDF) / McKinsey &amp; Co / Research &amp; Markets

# Backed By Leading Scientific And Medical Institutions

Leading health experts, scientists, and investors recognize the urgent need for better tools to detect and manage chronic disease risk. That’s why Viit Health has gained support from a growing network of partners-including top research institutions in Mexico and the U.S., global health investors, engineering firms, and entrepreneurship organizations. Together, we’re building one of the most promising breakthroughs in consumer health: a scalable, science-backed platform for prevention that’s ready for the real world.

# Acomplishments &amp; Support

![img-8.jpeg](img-8.jpeg)

Expertise That Builds With Purpose That Leads

Viit Health is led by a rare combination of scientific expertise, financial acumen, and mission-driven entrepreneurship. Our team brings decades of experience across biotech, engineering, clinical research, and venture building-paired with a deep commitment to advancing public health through innovation. We’ve built and scaled startups, secured global partnerships, led cutting-edge research, and executed in both corporate and clinical environments. With a clear vision and a strong operational foundation, we’re committed to delivering measurable value for both our users and investors-while creating lasting impact in the fight against chronic disease.

![img-9.jpeg](img-9.jpeg)

![img-10.jpeg](img-10.jpeg)

Viit Health is on the verge of commercial activation after more than seven years of research and development. By the end of 2025, we expect to finalize the commercial-ready iteration of our monitoring device, with market entry planned for 2026 following additional clinical studies and regulatory

submissions already underway. Commercial clearance as a prevention tool is anticipated by mid-2026.

With several early clients already confirmed-including public health institutions, specialized clinics, and healthcare-oriented companies in both Mexico and the U.S.-we plan to deploy 200 units by summer 2026 as part of our initial market activation. From there, we will scale manufacturing to deliver over 15,000 units by 2028 across North and Latin America, supported by robust production partnerships that ensure quality and affordability. We’re excited to bring this breakthrough technology to market-ready for scale and built for impact.

![img-11.jpeg](img-11.jpeg)

![img-12.jpeg](img-12.jpeg)

The world faces a growing health and economic crisis: non-communicable diseases account for the vast majority of deaths, despite being largely preventable. What’s missing isn’t treatment-it’s access to early detection and practical prevention. Viit Health’s mission is to change that. After years of research, validation, and strategic partnerships,

we're ready to scale a breakthrough solution that delivers real-time, non-invasive health monitoring to individuals, healthcare providers, and public systems alike-with a model built for meaningful impact and strong, sustainable profitability.

![img-13.jpeg](img-13.jpeg)

This is a chance to be part of a global shift-toward smarter tools, healthier lives, and a more sustainable future. Invest in prevention.

Invest in

vii

health

# Downloads

Deck Viit May 2025 (1).pdf

**Attachment 3:** `document_3.pdf`

ViiT Health III EB (THE "SPV"), a series of Wefunder SPV, LLC, a Delaware limited liability company (the "LLC")

# Subscription Agreement

## [INVESTMENT AMOUNT]

## [INVESTMENT DATE]

ViiT Health III EB (the "SPV"), a series of Wefunder SPV, LLC (the "LLC"), is a special purpose vehicle that will invest all of its assets in securities issued by ViiT Health Inc (the "Company"). By making an investment in the SPV through the Wefunder website, I understand and agree to the representations set forth below.

I have reviewed the following information and documents in connection with this Subscription Agreement:

1. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that none of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC, nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

2. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

3. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

4. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

5. The LLC Agreement, which sets forth other terms applicable to each SPV;

6. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

7. The Wefunder Investor Agreement; and

8. The Wefunder Terms of Service.

By making an investment in the SPV through the Wefunder website, I agree to be bound by this Subscription Agreement and the terms of the other agreements listed above with respect to my investment in the SPV.

# Subscription Agreement

## SCOPE OF AGREEMENT AND INVESTOR ELIGIBILITY REPRESENTATIONS

A. This agreement ("Agreement") applies to each investment in a series ("SPV") of Wefunder SPV, LLC (the "LLC"). Each series is a separate pool of assets from every other series. Each SPV will invest all of its assets in securities issued by a single company ("Company") as set forth in the applicable series appendix ("Series Appendix") to the Wefunder SPV, LLC limited liability company agreement ("LLC Agreement"). The terms of the Company securities to be purchased by the SPV are summarized in an appendix ("Terms Appendix") attached to this Agreement.

B. Each SPV is formed by and operated by Wefunder Admin, LLC on behalf of the Company in whose securities that SPV invests.

C. Important information about the Company, about the related SPV, and more generally about investments through the Wefunder website, is available through the Wefunder website. The Investor should review that information, and all relevant Company Information (as defined below), carefully before making an investment in any SPV.

D. Each SPV will offer membership interests ("Interests") in that SPV pursuant to Regulation Crowdfunding under the U.S. Securities Act of 1933, as amended (the "Securities Act").

E. You hereby agree that each time you make an investment in any SPV, you will be deemed to have entered into this Agreement, and will be deemed to have made each representation and covenant contained in this Agreement.

F. Except as the context otherwise requires, any reference in this Subscription Agreement to:

1. a "SPV" shall mean "The LLC acting solely on behalf of and for the account of the SPV";

2. "Investor" and "you" shall mean a person (whether individually, jointly with another person, or through his or her individual retirement account) who has agreed to invest, or has invested, in any SPV; and

3. "Company Information" means:

a. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC (together, the "Wefunder entities," nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

b. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

c. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

d. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

e. The LLC Agreement, which sets forth other terms applicable to each SPV;

f. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

g. The Wefunder Investor Agreement; and

h. The Wefunder Terms of Service.

INVESTOR'S REPRESENTATIONS AND COVENANTS

## 1. Investor's Review of Information and Investment Decision

1.1. The Investor has carefully read and understands the Company Information. The Investor acknowledges that it has made an independent decision to invest indirectly in the Company through the SPV and that, in making its decision to invest in a SPV, the Investor has relied solely upon the Company Information, any other relevant information on the Wefunder website, and independent investigations made by the Investor. The Investor understands that no representations or warranties have been made to the Investor by the LLC, the relevant SPV, any administrator appointed from time to time with respect to the SPV (the "Administrator"), any lead investor appointed from time to time with respect to the SPV (the "Lead Investor"), or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them regarding the Company.

1.2. The Investor has been provided an opportunity to request additional information concerning the Company and the offering through the Ask A Question feature on wefunder.com.

1.3. The Investor understands and agrees that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC, any of their affiliates, nor any director, manager, officer, shareholder, member, employee or agent of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or any of their affiliates (each, a "Wefunder Party," and collectively, "Wefunder Parties") shall be liable in connection with any information or omission of information contained in materials prepared or supplied by the Company. Such materials may include, but are not limited to, information provided by the Company in the Form C related to the offering, information available through the Wefunder website, and materials distributed to the Investor by the SPV on behalf of a Company.

1.4. The Investor represents and agrees that no Wefunder Party has recommended or suggested any investment in a SPV, or any investment related to a Company, to the Investor.

1.5. Investor understands that no Wefunder Party is an adviser to Investor, and that Investor is not an advisory or other client of any Wefunder Party.

1.6. The Investor is not relying on any Wefunder Party or any other person or entity with respect to the legal, accounting, business, investment, pension, tax or other economic considerations involved in this investment other than the Investor's own advisers that are not affiliated with any of the foregoing persons.

1.7. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor's investment in the SPV and is able to bear such risks. The Investor has obtained, in the Investor's judgment, sufficient information to evaluate the merits and risks of such investment. The Investor has evaluated the risks of investing in the SPV, understands there are substantial risks of loss incidental to the purchase of an Interest and has determined that the Interest is a suitable investment for the Investor and consistent with the general investment objectives of the Investor.

## 2. Investor's Representations Related To Investment in a SPV.

2.1. The Investor is acquiring the Interest for its own account, for investment purposes only and not with an intent to resell or distribute the Interest (or any distributions received from the SPV in whole or in part), and the Investor agrees that it will not sell or otherwise transfer the Interest unless in compliance with Regulation Crowdfunding and other applicable securities laws, and with the terms and conditions of this Agreement.

2.2. The Investor's investment in the Interest is consistent with the investment purposes, objectives and cash flow requirements of the Investor and will not adversely affect the Investor's overall need for diversification and liquidity.

2.3. The Investor has all requisite power, authority and capacity to acquire and hold the Interest and to execute, deliver and comply with the terms of each of the instruments required to be executed and delivered by the Investor in connection with the Investor's subscription for the Interest, including without limitation this Subscription Agreement, and such execution, delivery and compliance does not conflict with, or constitute a default under, any instruments governing the Investor, any law, regulation or order, or any agreement or other undertaking to which the Investor is a party or by which the Investor may be bound. If the Investor is an entity, the person executing and delivering

each of such instruments on behalf of the Investor has all requisite power, authority and capacity to execute and deliver such instruments, and, upon request by the SPV, will furnish to the SPV a true and correct copy of any instruments governing the Investor, including all amendments thereto. The signature on each of such instruments is genuine and each of such instruments constitutes a legal, valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms.

2.4. The Wefunder Parties are each hereby authorized and instructed to accept and execute any instructions in respect of the Interest given by the Investor in written or electronic form. The Wefunder Parties may rely conclusively upon and shall incur no liability in respect of any action taken upon any notice, consent, request, instructions or other instrument believed in good faith to be genuine or to be signed by properly authorized persons of the Investor.

2.5. Pursuant to the requirements of Treas. Reg. § 301.6109-1(c), the Investor has provided, or agrees to provide upon the earlier of (i) two years of an acquisition of an Interest or (ii) twenty (20) days before any distribution is to be made from the SPV, his, her or its taxpayer identification number (e.g., social security number or employer identification number) under penalties of perjury and has or will attest that the Internal Revenue Service has not notified the Investor that he, she or it is subject to backup withholding.

# 3. The Manager Has The Right To Reject Any Subscription, In Whole Or In Part.

3.1. The Investor understands that the SPV will not register as an investment company under the U.S. Investment Company Act of 1940, as amended (the "Investment Company Act"), nor will it make a public offering of its securities within the United States.

3.2. The Investor understands that the value of all investments in any SPV made through individual retirement accounts ("IRAs") must be less than 25% of the value of the SPV's assets.

3.3. If the Investor is investing in a SPV through an employee benefit plan of any kind, including an individual retirement account (the "Plan"), and an individual or entity (the "Fiduciary") has entered into this Agreement on behalf of the Plan, the Fiduciary hereby makes the following representations, warranties, and covenants:

i. The Fiduciary is a fiduciary of the Plan who is authorized to invest Plan assets or is acting at the direction of a Plan fiduciary authorized to invest Plan assets. The Fiduciary has determined that an investment in the Fund is consistent with the Fiduciary's responsibilities to the Plan under Employee Retirement Income Security Act of 1974, as amended ("ERISA") or other applicable law, and is qualified to make such investment decision. The Fiduciary is authorized to make all representations, covenants and agreements set forth in this Agreement about and on behalf of the Investor, and the Fiduciary hereby agrees that, except for the representations, covenants and agreements contained in this section 3.3. all representations, covenants and agreements contained in this Agreement are made on behalf of the Investor who is investing through the Plan.

ii. The execution and delivery of this Subscription Agreement, and the investment contemplated hereby has been duly authorized by all appropriate and necessary parties pursuant to the provisions of the instrument or instruments governing the Plan and any related trust; and (B) will not violate, and is not otherwise inconsistent with, the terms of such instrument or instruments.

iii. The Fiduciary acknowledges that the assets of the Fund will be invested in accordance with the Company Information related to that Fund.

iv. The Plan's purchase and holding of an Interest will not constitute a non-exempt transaction prohibited under ERISA, Section 4975 of the Internal Revenue Code (the "Code"), or any similar laws or other federal, state, local, foreign or other laws or regulations applicable to the Plan and its investments. None of the Wefunder entities nor any of their affiliates, agents, or employees: (A) exercises any authority or control with respect to the management or disposition of assets of the Plan used to purchase an Interest, (B) renders investment advice for a fee (pursuant to an agreement or understanding that such advice will serve as a primary basis for investment decisions and that such advice will be based on the particular investment needs of the Plan), with respect to such assets of the Plan, or has the authority to do so, or (C) is an employer maintaining or contributing to, or any of whose employees are covered by, the Plan.

v. The Fiduciary understands and agrees to the fee arrangements described in the Company Information.

vi. The Fiduciary understands and agrees that, to prevent the assets of the SPV from being treated as "plan assets" for purposes of ERISA and Section 4975 of the Code, the Investor may be prohibited from purchasing or acquiring an Interest or may be required to redeem its Interest or a portion thereof.

3.4. The Investor acknowledges that the SPV and any Administrator, on the SPV's behalf, may not accept any investment from an Investor if the Investor cannot truthfully make the representations contained herein.

# 4. The Correctness And Accuracy Of All Information Provided By Investor To The LLC Or The SPV.

4.1. The Investor confirms that all information and documentation provided to the LLC, the SPV, and any Administrator, including, but not limited to, all information regarding the Investor's identity, taxpayer identification number, the source of the funds to be invested in the SPV, and the Investor's eligibility to invest in offerings under Regulation Crowdfunding, is true, correct and complete. Should any such information change or no longer be accurate, the Investor agrees and covenants that they will promptly notify the Wefunder Parties of such changes via the wefunder.com platform. The Investor agrees and covenants that he, she or it will maintain accurate and up-to-date contact information (including email and mailing address) on the wefunder.com platform and will promptly update such information in the event it changes or is no longer accurate.

4.2. The representations, warranties, agreements, undertakings and acknowledgments made by the Investor in this Subscription Agreement will be relied upon by the LLC, the SPV, and any Administrator in determining the Fund's compliance with federal and state securities laws, and shall survive the Investor's admission as a Member of the SPV.

4.3. All information that the Investor has provided to the LLC, the SPV, and any Administrator concerning the knowledge and experience of financial, tax and business matters of the Investor is correct and complete.

# 5. The Wefunder Parties' Right To Use Investor Information.

5.1. The Investor agrees and consents to the Wefunder Parties, their delegates and their duly authorized agents and any of their respective related, associated or affiliated companies obtaining, holding, using, disclosing and processing the Investor's data:

a. to facilitate the acceptance, management and administration of the Investor's subscription for an Interest on an on-going basis;

b. for any other specific purposes where the Investor has given specific consent to do so;

c. to carry out statistical analysis, market research, and tracking of investment performance over time;

d. to comply with legal or regulatory requirements applicable to the SPV and any Administrator or the Investor, including, but not limited to, in connection with anti-money laundering and similar laws;

e. for disclosure or transfer to third parties including the Investor's financial adviser (where appropriate), regulatory bodies, auditors, technology providers or to the SPV, any Administrator, any Lead Investor, and their delegates or their duly appointed agents and any of their respective related, associated or affiliated companies for the purposes specified above;

f. if the contents thereof are relevant to any issue in any action, suit or proceeding to which the LLC, the SPV, any Administrator, any Lead Investor, or their affiliates are a party or by which they are or may be bound;

g. for other legitimate business of the LLC, the SPV, any Administrator, or any Lead Investor.

5.2. The Investor acknowledges and agrees that it will provide additional information or take such other actions as may be necessary or advisable for the SPV or any Administrator (in the sole judgment of the SPV and/or any Administrator) to comply with any disclosure and compliance policies, related legal process or appropriate requests (whether formal or informal) or otherwise.

5.3. The Investor agrees and consents to disclosure by the LLC, the SPV and any of their agents, including any Administrator or any Lead Investor, to relevant third parties of information pertaining to the Investor in respect of disclosure and compliance policies or information requests related thereto. Without limiting the generality of the foregoing, the Investor agrees that information about the Investor may be provided to the Company in whose securities a SPV will or proposes to invest.

5.4. The Investor authorizes the LLC, the SPV, any Administrator, and each SPV service provider to disclose the Investor's nonpublic personal information to comply with regulatory and contractual requirements applicable to the SPV and its investments. Any such disclosure shall be permitted notwithstanding any privacy policy or similar restrictions regarding the disclosure of the Investor's nonpublic personal information.

## 6. Key Risk Factors

6.1. The Investor understands that investment in a SPV may involve a complete loss of the Investor's investment. In this regard, the Investor understands that such venture investments involve a high degree of risk, and that many or most venture company investments lose money. An Investor may ultimately receive cash, securities, or a combination of cash and securities (and in many cases nothing at all). If the Investor receives securities, the securities may not be publicly traded, and may not have any significant value.

6.2. The Investor understands and agrees that the Interests are subject to restrictions on transfer and cannot be redeemed. Instead, an Investor typically must hold his or her Interest in a SPV until the SPV has sold or otherwise disposed of its investments and the SPV distributes its investments to the investors in the SPV (a "Liquidation Event"). An Investor typically will not receive any distributions until such a Liquidation Event (and may not receive anything even upon a Liquidation Event), which may not occur for many years. The Investor must therefore bear the economic risk of holding their investment for an indefinite period of time.

6.3. The Investor understands and agrees that the Interests: (a) have not been registered under the Securities Act or any other law of the United States, or under the securities laws of any state or other jurisdiction, and therefore an Interest cannot be resold, pledged, assigned or otherwise disposed of unless it is so registered or an exemption from registration is available; and (b) can only be transferred as permitted under Regulation Crowdfunding and subject to the terms and conditions of this Agreement.

6.4. The Investor understands that no guarantees have been made to the Investor about future performance or financial results of the SPV, and an investment in the SPV may result in a gain or loss upon termination or liquidation of the SPV. It is possible that the investors in a SPV will have "phantom income," which could require them to pay taxes on their investment in a SPV even though the SPV does not distribute any income (or does not distribute sufficient income to pay the taxes).

6.5. The Investor understands and agrees that the SPV was formed by and is operated by Wefunder Admin, LLC on behalf of the Company. Investors will have no right to manage or influence the management of any SPV or of the LLC.

6.6. The Investor understands the Issuer may be required to pay an administrative fee for maintenance and operation of the SPV. Failure of the Issuer to pay such a fee could result in the dissolution of the SPV (an "SPV Dissolution Event"). Subsequent to an SPV Dissolution Event, the securities held by the SPV would be distributed directly and proportionally to the individual investors. The Investor understands that dissolution of the SPV pursuant to an SPV Dissolution Event could create administrative complexities, as investors would need to manage the securities themselves rather than having them held and administered by the SPV. Additionally, the unplanned distribution of securities may not align with investors' intended investment strategy or asset allocation. Upon an SPV Dissolution Event, the Investor hereby consents to and agrees to accept direct assignment of the SPV's rights and obligations under any investment agreements between the SPV and the Issuer that is located in the Form C or C/A offering materials. The Investor acknowledges they will be bound by all terms and conditions of such agreements as if they were an original party thereto.

6.7. The Investor understands and agrees that the Company may appoint a Lead Investor and that, if appointed, pursuant to a power of attorney granted by the Investor in the Investor Agreement, the Lead Investor will exercise voting authority on behalf of the Investor with respect to the SPV securities the Investor owns.

6.8. The Investor represents that he or she has read and understands the risk factors contained in the Company Information. The Investor understands and agrees that each Company is solely responsible for providing risk factors, conflicts of interest, and other disclosures that investors should consider when investing in securities issued by that Company (including through a SPV), and that the Wefunder Parties have no ability to assure, and have not in any way assured, that any or all such risk factors, conflicts of interest and other disclosures have been presented fully and fairly, or have been presented at all.

6.9. The Investor understands that any privacy statements, reports or other communications regarding the SPV and the Investor's investment in the SPV (including annual and other updates, and tax documents) will be delivered via electronic means, including through wefunder.com. The Investor hereby consents to electronic delivery as described in the preceding sentence. In so consenting, the Investor acknowledges that email messages are not secure and may contain computer viruses or other defects, may not be accurately replicated on other systems, or may be intercepted, deleted or interfered with, with or without the knowledge of the sender or the intended recipient. The Investor also acknowledges that an email from the Wefunder Parties may be accessed by recipients other than the Investor and may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. No Wefunder Party gives any warranties in relation to these matters.

6.10. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number under penalties of perjury, and attest that the Investor has not been notified by the Internal Revenue Service that he, she or it is subject to backup withholding, the SPV will be required to withhold from any proceeds otherwise payable to the Investor an amount necessary to satisfy the SPV's backup withholding obligations.

6.11. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number to the SPV, the SPV will withhold from any proceeds otherwise payable to the Investor an amount necessary for the SPV to satisfy its tax withholding obligations with respect to such amount. The SPV may also withhold any other amounts representing the SPV's reasonable estimation of penalties that may be charged by the Internal Revenue Service or any other taxing authority as a result of the Investor's failure to provide a valid taxpayer identification number.

6.12. The Investor understands that the Issuer may be required to pay to Wefunder certain fees for the rendering of tax services and may be required to furnish Wefunder with certain tax documents in connection with these services. These obligations are specified in the Tax Services Agreement ("TSA"), where applicable. The Investor further understands and agrees that failure by the Issuer to pay such fees or failure to deliver required tax documents in the manner prescribed in the TSA, may each constitute an SPV Dissolution Event, the consequences of which are detailed in Section 6.6.

7. Compliance With Anti-Money Laundering Laws.

7.1. The Investor represents and warrants that the Investor's investment was not directly or indirectly derived from illegal activities, including any activities that would violate U.S. Federal or State laws or any laws and regulations of other countries.

7.2. The Investor acknowledges that U.S. Federal law, regulations and Executive Orders administered by the U.S. Treasury Department's Office of Foreign Assets Control ("OFAC") may prohibit the SPV, any Administrator, or any Lead Investor from, among other things, engaging in transactions with, and the provision of services to, persons on the list of Specially Designated Nationals and Blocked Persons and persons, foreign countries and territories that are the subject of U.S. sanctions administered by OFAC (collectively, the "OFAC Maintained Sanctions").

7.3. The Investor acknowledges that the SPV prohibits the investment of funds by any persons or entities that are (i) the subject of OFAC Maintained Sanctions, (ii) acting, directly or indirectly, in contravention of any applicable laws and regulations, including anti-money laundering regulations or conventions, or on behalf of persons or entities subject to an OFAC Maintained Sanction, (iii) acting, directly or indirectly, for a senior foreign political figure, any member of a senior foreign political figure's immediate family or any close associate of a senior foreign political figure, unless the SPV, after being specifically notified by the Investor in writing that it is such a person, conducts further due diligence, and determines that such investment shall be permitted, or (iv) acting, directly or indirectly, for a foreign shell bank (such persons or entities in (i) - (iv) are collectively referred to as "Prohibited Persons"). The Investor represents and warrants that it is not, and is not acting directly or indirectly on behalf of, a Prohibited Person.

7.4. To the extent the Investor has any beneficial owners, (i) it has carried out thorough

due diligence to establish the identities of such beneficial owners, (ii) based on such due diligence, the Investor reasonably believes that no such beneficial owners are Prohibited Persons, (iii) it holds the evidence of such identities and status and will maintain all such evidence for at least five years from the date of the liquidation or termination of the SPV, and (iv) it will make available such information and any additional information requested by the SPV that is required under applicable regulations.

7.5. The Investor acknowledges and agrees that the SPV or any Administrator may "freeze the account" of the Investor, including, but not limited to, by suspending distributions from the SPV to which the Investor would otherwise be entitled, if necessary to comply with anti-money laundering statutes or regulations.

7.6. The Investor acknowledges and agrees that the SPV and/or any Administrator, in complying with anti-money laundering statutes, regulations and goals, may file voluntarily and/or as required by law suspicious activity reports ("SARs") or any other information with governmental and law enforcement agencies that identify transactions and activities that the SPV or any Administrator or their agents reasonably determine to be suspicious, or is otherwise required by law. The Investor acknowledges that the LLC, the SPV, and any Administrator are prohibited by law from disclosing to third parties, including the Investor, any filing or the substance of any SARs.

7.7. The Investor agrees that, upon the request of the LLC, the SPV, or any Administrator, it will provide such information as the LLC, the SPV, or any Administrator requires to satisfy applicable anti-money laundering laws and regulations, including, without limitation, background documentation about the Investor

## 8. Regulatory Provisions

8.1. The Investor understands that no federal or state agency has passed upon the Interests or made any findings or determination as to the fairness of this investment.

8.2. The Investor certifies that the information contained in the executed copy of Form W-9 submitted to the SPV (if any) and/or the taxpayer identification provided to the SPV is correct. The Investor agrees to provide such other documentation as the SPV determines may be necessary for the SPV to fulfill any tax reporting and/or withholding requirements.

8.3. The Investor understands and agrees that the Company may cause the SPV to make an election under Section 754 of the Internal Revenue Code (the "Code") or an election to be treated as an "electing investment partnership" for purposes of Section 743 of the Code. If the SPV elects to be treated as an electing investment partnership, the Investor shall cooperate with the SPV to maintain that status and shall not take any action that would be inconsistent with such election. Upon request, the Investor shall provide the SPV with any information necessary to allow the SPV to comply with (a) its obligations to make tax basis adjustments under Section 734 or 743 of the Code and (b) its obligations as an electing investment partnership.

8.4. The Investor consents to receive any Schedule K-1 (Partner's Share of Income, Deductions, Credits, etc.) from the SPV electronically via email, the Internet and/or another electronic reporting medium in lieu of paper copies. The Investor agrees that it will confirm this consent electronically at a future date in a manner set forth by the Company at such time and as required by the electronic receipt consent rules set forth by the Internal Revenue Service. The Investor may request a paper copy of the Investor's Schedule K-1 by contacting Wefunder Inc. at support@wefunder.com or such other email address as specified on the wefunder.com platform. Requesting a paper copy will not constitute a withdrawal of the Investor's consent to receive reports or other communications, including Schedule K-1, electronically. The Investor may withdraw its consent for electronic delivery or change its contact preferences for such delivery at any time by writing to support@wefunder.com or such other email address as specified on the wefunder.com platform. Such withdrawal will take effect promptly after receipt, unless otherwise agreed upon. Upon receipt of a withdrawal request, the SPV will confirm the withdrawal and the date on which it takes effect in writing (either electronically or on paper). A withdrawal of consent does not apply to a statement that was furnished electronically before the date on which the withdrawal of consent takes effect. The SPV will cease providing information electronically upon termination of the SPV. Notwithstanding the Investor's consent to receive materials electronically, the Investor still may be required to print and attach its Schedule K-1 to a federal, state or local tax return.

## 9. Miscellaneous Provisions

### 9.1. Indemnification

9.1.1. The Investor agrees to indemnify and hold harmless the LLC, the SPV, any Administrator, any Lead Investor, or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them, and each other person, if any, who controls, is controlled by, or is under common control with, any of the foregoing, within the meaning of Section 15 of the Securities Act, and their respective officers, directors, partners, members, shareholders, owners, employees and agents (collectively, the "Indemnified Parties") against any and all loss, liability, claim, damage and expense whatsoever (including all expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) arising out of or based upon (i) any false representation or warranty made by the Investor, or breach or failure by the Investor to comply with any covenant or agreement made by the Investor, in this Subscription Agreement or in any other document furnished by the Investor to any of the foregoing in connection with this transaction, or (ii) any action for securities law violations instituted by the Investor that is finally resolved by judgment against the Investor.

9.1.2. The Investor also agrees to indemnify each Indemnified Party for any and all costs, fees and expenses (including legal fees and disbursements) in connection with any damages resulting from the Investor's misrepresentation or misstatement contained herein, or the assertion of the Investor's lack of proper authorization from the beneficial owner to enter into this Subscription Agreement or perform the obligations thereof.

9.1.3. The Investor agrees to indemnify and hold harmless each Indemnified Party from and against any tax, interest, additions to tax, penalties, reasonable attorneys' and accountants' fees and disbursements, together with interest on the foregoing amounts at a rate determined by the SPV or any Administrator computed from the date of payment through the date of reimbursement, arising from the failure to withhold and pay over to the U.S. Internal Revenue Service or the taxing authority of any other jurisdiction any amounts computed, as required by applicable law, with respect to the income or gains allocated to or amounts distributed to the Investor with respect to its Interest during the period from the Investor's acquisition of the Interest until the Investor's transfer of the Interest in accordance with this Agreement, the LLC Agreement, and Regulation Crowdfunding.

9.1.4. If for any reason (other than the willful misfeasance or gross negligence of the entity that would otherwise be indemnified) the foregoing indemnification is unavailable to, or is insufficient to hold such Indemnified Party harmless, then the Investor shall contribute to the amount paid or payable by the Indemnified Party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the Investor on the one hand and the Indemnified Parties on the other but also the relative fault of the Investor and the Indemnified Parties, as well as any relevant equitable considerations.

9.1.5. The reimbursement, indemnity and contribution obligations of the Investor under this section shall be in addition to any liability that the Investor may otherwise have, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Indemnified Parties.

9.2. **Limitation of Liability.** The LLC is a Delaware "multi-series" limited liability company. As a multi-series limited liability company, the LLC may operate multiple series with the benefit of segregation of assets and liabilities among each of its series pursuant to the Delaware Limited Liability Company Act, as amended (the "Delaware Act"). Accordingly, the Investor hereby agrees that the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to a series (including the SPV) shall be enforceable against the assets of that series only and not against the LLC generally or the assets of any other series. In addition, none of the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to the LLC generally, or any particular series, shall be enforceable against the assets of any other series.

9.3. **Counsel.** The Investor understands that Morrison &amp; Foerster LLP serves as legal counsel on certain matters to Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC and Wefunder Advisors, LLC and not to the SPV or any Investor by virtue of its investment in the SPV, and that no independent counsel has been retained to represent the SPV or Investors in the SPV. The Investor also understands that Morrison &amp; Foerster LLP has not independently verified any factual assertions made in the Company Information or on the Wefunder website and is not responsible for the SPV's compliance with its investment program or applicable law.

9.4. **Power of Attorney.** The Investor hereby appoints each of the Company and Wefunder Admin, LLC as its true and lawful representative and attorney-in-fact, in its name,

place and stead to make, execute, sign, acknowledge, swear to and file:

9.4.1. a Certificate of Formation of the LLC and any amendments required under the Delaware Act

9.4.2. the LLC Agreement and any duly adopted amendments;

9.4.3. any and all instruments, certificates and other documents that may be deemed necessary or desirable to effect the winding-up and termination of the LLC or the SPV (including a Certificate of Cancellation of the Certificate of Formation); and

9.4.4. any business certificate, fictitious name certificate, related amendment or other instrument or document of any kind necessary or desirable to accomplish the LLC's or the SPV's business, purpose and objectives or required by any applicable U.S., state, local or other law.

This power of attorney is coupled with an interest, is irrevocable, and shall survive and shall not be affected by the subsequent death, disability, incompetence, termination, bankruptcy, insolvency or dissolution of the Investor; provided, however, that this power of attorney will terminate upon the substitution of another SPV member for all of the Investor's investment in the LLC or the SPV or upon the liquidation or termination of the LLC or the SPV. The Investor hereby waives any and all defenses that may be available to contest, negate or disaffirm the actions of the LLC, the SPV, and any Administrator taken in good faith under this power of attorney.

## 9.5. Confidentiality.

9.5.1. The Investor agrees that the Company Information and all financial statements (if any), tax reports (if any), portfolio valuations (if any), private placement memoranda (if any), reviews or analyses of potential or actual investments (if any), reports or other materials prepared or produced by the SPV and/or any Administrator and all other documents and information concerning the affairs of the SPV and/or the Fund's investments, including, without limitation, information about the Company, and/or the persons directly or indirectly investing in the SPV (collectively, the "Confidential Information") that the Investor may receive pursuant to or in accordance with the use of the Wefunder website, an investment in one or more SPVs, or otherwise as a result of its ownership of an Interest in the SPV, constitute proprietary and confidential information about the SPV, any Administrator, and/or any Lead Investor (the "Affected Parties").

9.5.2. The Investor acknowledges that the Affected Parties derive independent economic value from the Confidential Information not being generally known and that the Confidential Information is the subject of reasonable efforts to maintain its secrecy. The Investor further acknowledges that the Confidential Information is a trade secret, the disclosure of which is likely to cause substantial and irreparable competitive harm to the Affected Companies or their respective businesses. The Investor shall not reproduce any of the Confidential Information or portion thereof or make the contents thereof available to any third party other than a disclosure on a need-to-know basis to the Investor's legal, accounting or investment advisers, auditors and representatives (collectively, "Advisers"), except to the extent compelled to do so in accordance with applicable law (in which case the Investor shall promptly notify the SPV of the Investor's obligation to disclose any Confidential Information) or with respect to Confidential Information that otherwise becomes publicly available other than through breach of this provision by the Investor.

9.5.3. To the fullest extent permitted by law, the Investor agrees not to request disclosure or inspection of any such information after the Investor is notified (whether in response to the Investor's request for information or otherwise) that the SPV has determined not to disclose such information.

9.5.4. The Investor agrees that the LLC, the SPV, and the SPV service providers would be subject to potentially irreparable injury as a result of any breach by the Investor of the covenants and agreements set forth in this Item 9.5, and that monetary damages would not be sufficient to compensate or make whole the LLC, the SPV, and the SPV services providers for any such breach. Accordingly the Investor agrees that the LLC, the SPV, and the SPV service providers shall be entitled to equitable and injunctive relief, on an emergency, temporary, preliminary and/or permanent basis, to prevent any such breach or the continuation thereof.

9.6. Amendments. Neither this Subscription Agreement nor any term hereof may be

supplemented, changed, waived, discharged or terminated except with the written consent of the Investor and the Company on behalf of the relevant SPV. For the sake of clarity, the restriction on the Company in the preceding sentence applies solely to the form of this Subscription Agreement applicable to SPVs that have had a closing, and does not prevent the Company from changing the form and content of this Subscription Agreement for use in offerings of SPVs that have not had a closing.

9.7. **Assignability and Transferability.** This Subscription Agreement is not transferable or assignable by the Investor without the prior written consent of the Company on behalf of the SPV, and any transfer or assignment in violation of this provision shall be null and void. The Interests in the SPV being acquired by Investor herein may only be transferred by Investor in compliance with Regulation Crowdfunding and the terms and conditions of this Agreement. If Investor seeks to transfer the Interests, Investor shall first give written notice to the Company and Wefunder Admin, LLC, including the number of Interests that Investor desires to transfer, the proposed price, the name and contact information of the proposed buyer, and any other information that the Company or Wefunder Admin, LLC may reasonably request. To the extent possible, such notice shall be provided through the Wefunder.com website. Any transfer of Interests shall be subject to execution by Investor and the proposed transferee of appropriate documentation, as may be required by the Company or Wefunder Admin, LLC, in their discretion. Investor further acknowledges that pursuant to the LLC Agreement, Wefunder Admin, LLC (as Series Manager of the SPV), may impose additional restrictions on or prohibit the Transfer of Interests for any reason or no reason, in its sole discretion.

9.8. **Repurchase.** In the event that the SPV or any Administrator determines that it is likely that within twelve (12) months the securities of the SPV or the Company will be held of record by a number of persons that would require the SPV or the Company to register a class of its equity securities under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as required by Section 12(g) or 15(d) thereof, the SPV shall have the option to repurchase the Interests from each Investor to the extent necessary to avoid the requirement to register a class of its securities under the Exchange Act. Such repurchase of Interests shall be for the greater of (i) the purchase price of the Interests, or (ii) the fair market value of the Interests, as determined by an independent appraiser of securities chosen by the Administrator. Any such repurchase may only occur with the consent of Wefunder Admin, LLC, as Series Manager of the SPV.

9.9. **Governing Law:** Consent to Jurisdiction. Notwithstanding the place where this Subscription Agreement may be executed by any of the parties hereto, the parties expressly agree that all the terms and provisions hereof shall be construed under the laws of the State of Delaware. Any action or proceeding brought by the SPV or any SPV service provider against one or more investors in the SPV relating in any way to this Subscription Agreement or the LLC Agreement may, and any action or proceeding brought by any other party against the SPV or any SPV service provider relating in any way to this Subscription Agreement or the Company Information shall, be brought and enforced in the state courts of the State of Delaware located in Wilmington or (to the extent subject matter jurisdiction exists therefore) in the courts of the United States located in the District of Delaware; and the Investor and the SPV irrevocably submit to the jurisdiction of both such state and federal courts in respect of any such action or proceeding. The Investor and the SPV irrevocably waive, to the fullest extent permitted by law, any objection that they may now or hereafter have to laying the venue of any such action or proceeding in the courts of the State of Delaware located in Wilmington or in the courts of the United States located in the District of Delaware and any claim that any such action or proceeding brought in any such court has been brought in an inconvenient forum.

9.10. **Severability.** If any provision of this Subscription Agreement is invalid or unenforceable under any applicable law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such applicable law. Any provision hereof that may be held invalid or unenforceable under any applicable law shall not affect the validity or enforceability of any other provisions hereof, and to this extent the provisions hereof shall be severable.

9.11. **Headings.** The headings in this Subscription Agreement are for convenience of reference only, and shall not limit or otherwise affect the meaning hereof.

9.12. **General.** This Subscription Agreement shall be binding upon the Investor and the legal representatives, successors and assigns of the Investor, shall survive the admission of the Investor as a member of a SPV, and shall, if the Investor consists of more than one person, be the joint and several obligation of all such persons.

[Remainder of page intentionally left blank. Signature page follows.]

The undersigned have executed this instrument as of the date first above written.

SPV

ViiT Health III EB, as series of Wefunder SPV, LLC
By: Wefunder Admin, LLC, its Manager

By: Wefunder Signature
Date:

Name: Nicholas Tommarello
Title: Chief Executive Officer

Investor

[INVESTOR NAME]

By: Investor Signature
Date:

CONTACT INFORMATION:

Name: [INVESTOR NAME]

Mailing Address:

City:

Country:

E-mail:

# TERMS APPENDIX FOR THE PURCHASE OF Viit Health Inc SECURITIES BY ViIT Health III EB. A SERIES OF WEFUNDER SPV. LLC. A DELAWARE LIMITED LIABILITY COMPANY

Type of Security: Future Equity

Terms $15M valuation cap and 20% discount

{ To view a copy of the contract, please see <b>Appendix B, Investor Contracts</b> of the Form C. The latest Form C or C/A filing be found here:<br/>
<a target='blank' href="https://www.sec.gov/cgi-bin/srch-edgar?text=%28FORM-TYPE%3DC%2FA+or+FORM-TYPE%3DC%29+and+CIK%3D0001881570&amp;first=2016">https://www.sec.gov/cgi-bin/srch-edgar?text=%28FORM-TYPE%3DC%2FA+or+FORM-TYPE%3DC%29+and+CIK%3D0001881570&amp;first=2016</a> }

**Attachment 4:** `document_4.pdf`

THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS SAFE AND UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

## Viit Health Inc

## SAFE (Simple Agreement for Future Equity)

THIS CERTIFIES THAT in exchange for the payment by [INVESTOR NAME] (the "Investor") of $[INVESTMENT AMOUNT] (the "Purchase Amount") on or about [EFFECTIVE DATE], Viit Health Inc, a Delaware corporation (the "Company"), issues to the Investor the right to certain shares of the Company's Capital Stock, subject to the terms described below.

This Safe is one of the forms available at http://ycombinator.com/documents and the Company and the Investor agree that neither one has modified the form, except to fill in blanks and bracketed terms, and remove the requirement to be an accredited investor.

The "Post-Money Valuation Cap" is $15,000,000.00

The "Discount Rate" is 80.000%

See Section 2 for certain additional defined terms.

## 1. Events

(a) **Equity Financing.** If there is an Equity Financing before the termination of this Safe, on the initial closing of such Equity Financing, this Safe will automatically convert into the number of shares of Safe Preferred Stock equal to the Purchase Amount divided by the Conversion Price.

In connection with the automatic conversion of this Safe into shares of Safe Preferred Stock, the Investor will execute and deliver to the Company all of the transaction documents related to the Equity Financing; provided, that such documents (i) are the same documents to be entered into with the purchasers of Standard Preferred Stock, with appropriate variations for the Safe Preferred Stock if applicable, and (ii) have customary exceptions to any drag-along applicable to the Investor, including (without limitation) limited representations, warranties, liability and indemnification obligations for the Investor.

(b) **Liquidity Event.** If there is a Liquidity Event before the termination of this Safe, the Investor will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the "Cash-Out Amount") or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the "Conversion Amount"). If any of the Company's securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor's failure to satisfy any requirement or limitation generally applicable to the Company's securityholders, or under any applicable laws.

Notwithstanding the foregoing, in connection with a Change of Control intended to qualify as a tax-free reorganization, the Company may reduce the cash portion of Proceeds payable to the Investor by the amount determined by its board of directors in good faith for such Change of Control to qualify as a tax-free reorganization for U.S. federal income tax purposes, provided that such reduction (A) does not reduce the total Proceeds payable to such Investor and (B) is applied in the same manner and on a pro rata basis to all securityholders who have equal priority to the Investor under Section 1(d).

(c) **Dissolution Event.** If there is a Dissolution Event before the termination of this Safe, the Investor will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds equal to the Cash-Out Amount, due and payable to the Investor immediately prior to the consummation of the Dissolution Event.

(d) **Liquidation Priority** In a Liquidity Event or Dissolution Event, this Safe is intended to operate like standard non-participating Preferred Stock. The Investor's right to receive its Cash-Out Amount is:

(i) Junior to payment of outstanding indebtedness and creditor claims, including contractual claims for payment and convertible promissory notes (to the extent such convertible promissory notes are not actually or notionally converted into Capital Stock);

(ii) On par with payments for other Safes and/or Preferred Stock, and if the applicable Proceeds are insufficient to permit full payments to the Investor and such other Safes and/or Preferred Stock, the applicable Proceeds will be distributed pro rata to the Investor and such other Safes and/or Preferred Stock in proportion to the full payments that would otherwise be due; and

(iii) Senior to payments for Common Stock.

The Investor's right to receive its Conversion Amount is (A) on par with payments for Common Stock and other Safes and/or Preferred Stock who are also receiving Conversion Amounts or Proceeds on a similar as-converted to Common Stock basis, and (B) junior to payments described in clauses (i) and (ii) above (in the latter case, to the extent such payments are Cash-Out Amounts or similar liquidation preferences).

(e) **Termination.** This Safe will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this Safe) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this Safe under Section 1(a); or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to Section 1(b) or Section 1(c).

2. Definitions

"Capital Stock" means the capital stock of the Company, including, without limitation, the "Common Stock" and the "Preferred Stock".

"Change of Control" means (i) a transaction or series of related transactions in which any "person" or "group" (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the "beneficial owner" (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company's board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.

"Company Capitalization" is calculated as of immediately prior to the Equity Financing and (without double-counting, in each case calculated on an as-converted to Common Stock basis):

- Includes all shares of Capital Stock issued and outstanding;
- Includes all Converting Securities;
- Includes all (i) issued and outstanding Options and (ii) Promised Options; and
- Includes the Unissued Option Pool, except that any increase to the Unissued Option Pool in connection with the Equity Financing will only be included to the extent that the number of Promised Options exceeds the Unissued Option Pool prior to such increase.

"Conversion Price" means either: (1) the Safe Price or (2) the Discount Price, whichever calculation results in a greater number of shares of Safe Preferred Stock.

"Converting Securities" includes this Safe and other convertible securities issued by the Company, including but not limited to: (i) other Safes; (ii) convertible promissory notes and other convertible debt instruments; and (iii) convertible securities that have the right to convert into shares of Capital Stock.

"Direct Listing" means the Company's initial listing of its Common Stock (other than shares of Common Stock not eligible for resale under Rule 144 under the Securities Act) on a national securities exchange by means of an effective registration statement on Form S-1 filed by the Company with the SEC that registers shares of existing capital stock of the Company for resale, as approved by the Company's board of directors. For the avoidance of doubt, a Direct Listing will not be deemed to be an underwritten offering and will not involve any underwriting services.

"Discount Price" means the price per shares of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate.

"Dissolution Event" means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of the Company's creditors or (iii) any other liquidation, dissolution or winding up of the Company (excluding a Liquidity Event), whether voluntary or involuntary.

"Dividend Amount" means, with respect to any date on which the Company pays a dividend on its outstanding Common Stock, the amount of such dividend that is paid per share of Common Stock multiplied by (x) the Purchase Amount divided by (y) the Liquidity Price (treating the dividend date as a Liquidity Event solely for purposes of calculating such Liquidity Price).

"Equity Financing" means a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells Preferred Stock at a fixed valuation, including but not limited to, a pre-money or post-money valuation.

"Initial Public Offering" means the closing of the Company's first firm commitment underwritten initial public offering of Common Stock pursuant to a registration statement filed under the Securities Act.

"Liquidity Capitalization" is calculated as of immediately prior to the Liquidity Event, and (without double-counting, in each case calculated on an as-converted to Common Stock basis):

- Includes all shares of Capital Stock issued and outstanding;
- Includes all (i) issued and outstanding Options and (ii) to the extent receiving Proceeds, Promised Options;
- Includes all Converting Securities, other than any Safes and other convertible securities (including without limitation shares of Preferred Stock) where the holders of such securities are receiving Cash-Out Amounts or similar liquidation preference payments in lieu of Conversion Amounts or similar "as-converted" payments; and
- Excludes the Unissued Option Pool.

"Liquidity Event" means a Change of Control, a Direct Listing or an Initial Public Offering.

"Liquidity Price" means the price per share equal to the Post-Money Valuation Cap divided by the Liquidity Capitalization.

"Options" includes options, restricted stock awards or purchases, RSUs, SARs, warrants or similar securities, vested or unvested.

"Proceeds" means cash and other assets (including without limitation stock consideration) that are proceeds from the Liquidity Event or the Dissolution Event, as applicable, and

legally available for distribution.

"Promised Options" means promised but ungranted Options that are the greater of those (i) promised pursuant to agreements or understandings made prior to the execution of, or in connection with, the term sheet or letter of intent for the Equity Financing or Liquidity Event, as applicable (or the initial closing of the Equity Financing or consummation of the Liquidity Event, if there is no term sheet or letter of intent), (ii) in the case of an Equity Financing, treated as outstanding Options in the calculation of the Standard Preferred Stocks price per share, or (iii) in the case of a Liquidity Event, treated as outstanding Options in the calculation of the distribution of the Proceeds.

"Safe" means an instrument containing a future right to shares of Capital Stock, similar in form and content to this instrument, purchased by investors for the purpose of funding the Company's business operations. References to "this Safe" mean this specific instrument.

"Safe Preferred Stock" means the shares of the series of Preferred Stock issued to the Investor in an Equity Financing, having the identical rights, privileges, preferences, seniority, liquidation multiple and restrictions as the shares of Standard Preferred Stock, except that any price-based preferences (such as the per share liquidation amount, initial conversion price and per share dividend amount) will be based on the Safe Price.

"Safe Price" means the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization.

"Standard Preferred Stock" means the shares of the series of Preferred Stock issued to the investors investing new money in the Company in connection with the initial closing of the Equity Financing.

"Unissued Option Pool" means all shares of Capital Stock that are reserved, available for future grant and not subject to any outstanding Options or Promised Options (but in the case of a Liquidity Event, only to the extent Proceeds are payable on such Promised Options) under any equity incentive or similar Company plan.

## 3. Company Representations

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation, and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

(b) The execution, delivery and performance by the Company of this Safe is within the power of the Company and has been duly authorized by all necessary actions on the part of the Company (subject to section 3(d)). This Safe constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity. To its knowledge, the Company is not in violation of (i) its current certificate of incorporation or bylaws, (ii) any material statute, rule or regulation applicable to the Company or (iii) any material debt or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

(c) The performance and consummation of the transactions contemplated by this Safe do not and will not: (i) violate any material judgment, statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material debt or contract to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien on any property, asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business or operations.

(d) No consents or approvals are required in connection with the performance of this Safe, other than: (i) the Company's corporate approvals; (ii) any qualifications or filings under applicable securities laws; and (iii) necessary corporate approvals for the authorization of Capital Stock issuable pursuant to Section 1.

(e) To its knowledge, the Company owns or possesses (or can obtain on commercially reasonable terms) sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes and other intellectual property rights necessary for its business as now conducted and as currently proposed to be conducted, without any conflict with, or infringement of the rights of, others.

## 4. Investor Representations

(a) The Investor has full legal capacity, power and authority to execute and deliver this Safe and to perform its obligations hereunder. This Safe constitutes a valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity.

(b) The Investor has been advised that this Safe and the underlying securities have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available. The Investor is purchasing this Safe and the securities to be acquired by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor has such knowledge and experience in financial

and business matters that the Investor is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor's financial condition and is able to bear the economic risk of such investment for an indefinite period of time.

## 5. Miscellaneous

(a) Any provision of this Safe may be amended, waived or modified by written consent of the Company and either (i) the Investor or (ii) the majority-in-interest of all then-outstanding Safes with the same "Post-Money Valuation Cap" and "Discount Rate" as this Safe (and Safes lacking one or both of such terms will be considered to be the same with respect to such term(s)), provided that with respect to clause (ii): (A) the Purchase Amount may not be amended, waived or modified in this manner, (B) the consent of the Investor and each holder of such Safes must be solicited (even if not obtained), and (C) such amendment, waiver or modification treats all such holders in the same manner. "Majority-in-interest" refers to the holders of the applicable group of Safes whose Safes have a total Purchase Amount greater than 50% of the total Purchase Amount of all of such applicable group of Safes.

(b) Any notice required or permitted by this Safe will be deemed sufficient when delivered personally or by overnight courier or sent by email to the relevant address listed on their Wefunder account, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party's address listed on their Wefunder account, as subsequently modified by written notice.

(c) The Investor is not entitled, as a holder of this Safe, to vote or be deemed a holder of Capital Stock for any purpose other than tax purposes, nor will anything in this Safe be construed to confer on the Investor, as such, any rights of a Company stockholder or rights to vote for the election of directors or on any matter submitted to Company stockholders, or to give or withhold consent to any corporate action or to receive notice of meetings, until shares have been issued on the terms described in Section 1. However, if the Company pays a dividend on outstanding shares of Common Stock (that is not payable in shares of Common Stock) while this Safe is outstanding, the Company will pay the Dividend Amount to the Investor at the same time.

(d) Neither this Safe nor the rights in this Safe are transferable or assignable, by operation of law or otherwise, by either party without the prior written consent of the other; provided, however, that this Safe and/or its rights may be assigned without the Company's consent by the Investor (i) to the Investor's estate, heirs, executors, administrators, guardians and/or successors in the event of Investor's death or disability, or (ii) to any other entity who directly or indirectly, controls, is controlled by or is under common control with the Investor, including, without limitation, any general partner, managing member, officer or director of the Investor, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, the Investor.

(e) In the event any one or more of the provisions of this Safe is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Safe operate or would prospectively operate to invalidate this Safe, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision of this Safe and the remaining provisions of this Safe will remain operative and in full force and effect and will not be affected, prejudiced, or disturbed thereby.

(f) All rights and obligations hereunder will be governed by the laws of the State of Delaware, without regard to the conflicts of law provisions of such jurisdiction.

(g) The parties acknowledge and agree that for United States federal and state income tax purposes this Safe is, and at all times has been, intended to be characterized as stock, and more particularly as common stock for purposes of Sections 304, 305, 306, 354, 368, 1036 and 1202 of the Internal Revenue Code of 1986, as amended. Accordingly, the parties agree to treat this Safe consistent with the foregoing intent for all United States federal and state income tax purposes (including, without limitation, on their respective tax returns or other informational statements).

(Signature page follows)

IN WITNESS WHEREOF, the undersigned have caused this Safe to be duly executed and delivered.

COMPANY:
Viit Health Inc
By: *Powder Signature*
Name: Luis Fernando Gomez
Title: CEO

INVESTOR:
[INVESTOR NAME]
By: *Investor Signature*
Name: [INVESTOR NAME]
Title:
☐ Accredited Investor
☐ Unaccredited Investor

Read and Approved (for IRA use only)

By:
Name:

**Attachment 5:** `document_5.pdf`

ViiT Health III (THE "SPV"), a series of Wefunder SPV, LLC, a Delaware limited liability company (the "LLC")

# Subscription Agreement

## [INVESTMENT AMOUNT]

## [INVESTMENT DATE]

ViiT Health III (the "SPV"), a series of Wefunder SPV, LLC (the "LLC"), is a special purpose vehicle that will invest all of its assets in securities issued by ViiT Health Inc (the "Company"). By making an investment in the SPV through the Wefunder website, I understand and agree to the representations set forth below.

I have reviewed the following information and documents in connection with this Subscription Agreement:

1. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that none of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC, nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

2. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

3. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

4. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

5. The LLC Agreement, which sets forth other terms applicable to each SPV;

6. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

7. The Wefunder Investor Agreement; and

8. The Wefunder Terms of Service.

By making an investment in the SPV through the Wefunder website, I agree to be bound by this Subscription Agreement and the terms of the other agreements listed above with respect to my investment in the SPV.

# Subscription Agreement

## SCOPE OF AGREEMENT AND INVESTOR ELIGIBILITY REPRESENTATIONS

A. This agreement ("Agreement") applies to each investment in a series ("SPV") of Wefunder SPV, LLC (the "LLC"). Each series is a separate pool of assets from every other series. Each SPV will invest all of its assets in securities issued by a single company ("Company") as set forth in the applicable series appendix ("Series Appendix") to the Wefunder SPV, LLC limited liability company agreement ("LLC Agreement"). The terms of the Company securities to be purchased by the SPV are summarized in an appendix ("Terms Appendix") attached to this Agreement.

B. Each SPV is formed by and operated by Wefunder Admin, LLC on behalf of the Company in whose securities that SPV invests.

C. Important information about the Company, about the related SPV, and more generally about investments through the Wefunder website, is available through the Wefunder website. The Investor should review that information, and all relevant Company Information (as defined below), carefully before making an investment in any SPV.

D. Each SPV will offer membership interests ("Interests") in that SPV pursuant to Regulation Crowdfunding under the U.S. Securities Act of 1933, as amended (the "Securities Act").

E. You hereby agree that each time you make an investment in any SPV, you will be deemed to have entered into this Agreement, and will be deemed to have made each representation and covenant contained in this Agreement.

F. Except as the context otherwise requires, any reference in this Subscription Agreement to:

1. a "SPV" shall mean "The LLC acting solely on behalf of and for the account of the SPV";

2. "Investor" and "you" shall mean a person (whether individually, jointly with another person, or through his or her individual retirement account) who has agreed to invest, or has invested, in any SPV; and

3. "Company Information" means:

a. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC (together, the "Wefunder entities," nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

b. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

c. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

d. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

e. The LLC Agreement, which sets forth other terms applicable to each SPV;

f. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

g. The Wefunder Investor Agreement; and

h. The Wefunder Terms of Service.

INVESTOR'S REPRESENTATIONS AND COVENANTS

## 1. Investor's Review of Information and Investment Decision

1.1. The Investor has carefully read and understands the Company Information. The Investor acknowledges that it has made an independent decision to invest indirectly in the Company through the SPV and that, in making its decision to invest in a SPV, the Investor has relied solely upon the Company Information, any other relevant information on the Wefunder website, and independent investigations made by the Investor. The Investor understands that no representations or warranties have been made to the Investor by the LLC, the relevant SPV, any administrator appointed from time to time with respect to the SPV (the "Administrator"), any lead investor appointed from time to time with respect to the SPV (the "Lead Investor"), or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them regarding the Company.

1.2. The Investor has been provided an opportunity to request additional information concerning the Company and the offering through the Ask A Question feature on wefunder.com.

1.3. The Investor understands and agrees that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC, any of their affiliates, nor any director, manager, officer, shareholder, member, employee or agent of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or any of their affiliates (each, a "Wefunder Party," and collectively, "Wefunder Parties") shall be liable in connection with any information or omission of information contained in materials prepared or supplied by the Company. Such materials may include, but are not limited to, information provided by the Company in the Form C related to the offering, information available through the Wefunder website, and materials distributed to the Investor by the SPV on behalf of a Company.

1.4. The Investor represents and agrees that no Wefunder Party has recommended or suggested any investment in a SPV, or any investment related to a Company, to the Investor.

1.5. Investor understands that no Wefunder Party is an adviser to Investor, and that Investor is not an advisory or other client of any Wefunder Party.

1.6. The Investor is not relying on any Wefunder Party or any other person or entity with respect to the legal, accounting, business, investment, pension, tax or other economic considerations involved in this investment other than the Investor's own advisers that are not affiliated with any of the foregoing persons.

1.7. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor's investment in the SPV and is able to bear such risks. The Investor has obtained, in the Investor's judgment, sufficient information to evaluate the merits and risks of such investment. The Investor has evaluated the risks of investing in the SPV, understands there are substantial risks of loss incidental to the purchase of an Interest and has determined that the Interest is a suitable investment for the Investor and consistent with the general investment objectives of the Investor.

## 2. Investor's Representations Related To Investment in a SPV.

2.1. The Investor is acquiring the Interest for its own account, for investment purposes only and not with an intent to resell or distribute the Interest (or any distributions received from the SPV in whole or in part), and the Investor agrees that it will not sell or otherwise transfer the Interest unless in compliance with Regulation Crowdfunding and other applicable securities laws, and with the terms and conditions of this Agreement.

2.2. The Investor's investment in the Interest is consistent with the investment purposes, objectives and cash flow requirements of the Investor and will not adversely affect the Investor's overall need for diversification and liquidity.

2.3. The Investor has all requisite power, authority and capacity to acquire and hold the Interest and to execute, deliver and comply with the terms of each of the instruments required to be executed and delivered by the Investor in connection with the Investor's subscription for the Interest, including without limitation this Subscription Agreement, and such execution, delivery and compliance does not conflict with, or constitute a default under, any instruments governing the Investor, any law, regulation or order, or any agreement or other undertaking to which the Investor is a party or by which the Investor may be bound. If the Investor is an entity, the person executing and delivering

each of such instruments on behalf of the Investor has all requisite power, authority and capacity to execute and deliver such instruments, and, upon request by the SPV, will furnish to the SPV a true and correct copy of any instruments governing the Investor, including all amendments thereto. The signature on each of such instruments is genuine and each of such instruments constitutes a legal, valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms.

2.4. The Wefunder Parties are each hereby authorized and instructed to accept and execute any instructions in respect of the Interest given by the Investor in written or electronic form. The Wefunder Parties may rely conclusively upon and shall incur no liability in respect of any action taken upon any notice, consent, request, instructions or other instrument believed in good faith to be genuine or to be signed by properly authorized persons of the Investor.

2.5. Pursuant to the requirements of Treas. Reg. § 301.6109-1(c), the Investor has provided, or agrees to provide upon the earlier of (i) two years of an acquisition of an Interest or (ii) twenty (20) days before any distribution is to be made from the SPV, his, her or its taxpayer identification number (e.g., social security number or employer identification number) under penalties of perjury and has or will attest that the Internal Revenue Service has not notified the Investor that he, she or it is subject to backup withholding.

# 3. The Manager Has The Right To Reject Any Subscription, In Whole Or In Part.

3.1. The Investor understands that the SPV will not register as an investment company under the U.S. Investment Company Act of 1940, as amended (the "Investment Company Act"), nor will it make a public offering of its securities within the United States.

3.2. The Investor understands that the value of all investments in any SPV made through individual retirement accounts ("IRAs") must be less than 25% of the value of the SPV's assets.

3.3. If the Investor is investing in a SPV through an employee benefit plan of any kind, including an individual retirement account (the "Plan"), and an individual or entity (the "Fiduciary") has entered into this Agreement on behalf of the Plan, the Fiduciary hereby makes the following representations, warranties, and covenants:

i. The Fiduciary is a fiduciary of the Plan who is authorized to invest Plan assets or is acting at the direction of a Plan fiduciary authorized to invest Plan assets. The Fiduciary has determined that an investment in the Fund is consistent with the Fiduciary's responsibilities to the Plan under Employee Retirement Income Security Act of 1974, as amended ("ERISA") or other applicable law, and is qualified to make such investment decision. The Fiduciary is authorized to make all representations, covenants and agreements set forth in this Agreement about and on behalf of the Investor, and the Fiduciary hereby agrees that, except for the representations, covenants and agreements contained in this section 3.3. all representations, covenants and agreements contained in this Agreement are made on behalf of the Investor who is investing through the Plan.

ii. The execution and delivery of this Subscription Agreement, and the investment contemplated hereby has been duly authorized by all appropriate and necessary parties pursuant to the provisions of the instrument or instruments governing the Plan and any related trust; and (B) will not violate, and is not otherwise inconsistent with, the terms of such instrument or instruments.

iii. The Fiduciary acknowledges that the assets of the Fund will be invested in accordance with the Company Information related to that Fund.

iv. The Plan's purchase and holding of an Interest will not constitute a non-exempt transaction prohibited under ERISA, Section 4975 of the Internal Revenue Code (the "Code"), or any similar laws or other federal, state, local, foreign or other laws or regulations applicable to the Plan and its investments. None of the Wefunder entities nor any of their affiliates, agents, or employees: (A) exercises any authority or control with respect to the management or disposition of assets of the Plan used to purchase an Interest, (B) renders investment advice for a fee (pursuant to an agreement or understanding that such advice will serve as a primary basis for investment decisions and that such advice will be based on the particular investment needs of the Plan), with respect to such assets of the Plan, or has the authority to do so, or (C) is an employer maintaining or contributing to, or any of whose employees are covered by, the Plan.

v. The Fiduciary understands and agrees to the fee arrangements described in the Company Information.

vi. The Fiduciary understands and agrees that, to prevent the assets of the SPV from being treated as "plan assets" for purposes of ERISA and Section 4975 of the Code, the Investor may be prohibited from purchasing or acquiring an Interest or may be required to redeem its Interest or a portion thereof.

3.4. The Investor acknowledges that the SPV and any Administrator, on the SPV's behalf, may not accept any investment from an Investor if the Investor cannot truthfully make the representations contained herein.

# 4. The Correctness And Accuracy Of All Information Provided By Investor To The LLC Or The SPV.

4.1. The Investor confirms that all information and documentation provided to the LLC, the SPV, and any Administrator, including, but not limited to, all information regarding the Investor's identity, taxpayer identification number, the source of the funds to be invested in the SPV, and the Investor's eligibility to invest in offerings under Regulation Crowdfunding, is true, correct and complete. Should any such information change or no longer be accurate, the Investor agrees and covenants that they will promptly notify the Wefunder Parties of such changes via the wefunder.com platform. The Investor agrees and covenants that he, she or it will maintain accurate and up-to-date contact information (including email and mailing address) on the wefunder.com platform and will promptly update such information in the event it changes or is no longer accurate.

4.2. The representations, warranties, agreements, undertakings and acknowledgments made by the Investor in this Subscription Agreement will be relied upon by the LLC, the SPV, and any Administrator in determining the Fund's compliance with federal and state securities laws, and shall survive the Investor's admission as a Member of the SPV.

4.3. All information that the Investor has provided to the LLC, the SPV, and any Administrator concerning the knowledge and experience of financial, tax and business matters of the Investor is correct and complete.

# 5. The Wefunder Parties' Right To Use Investor Information.

5.1. The Investor agrees and consents to the Wefunder Parties, their delegates and their duly authorized agents and any of their respective related, associated or affiliated companies obtaining, holding, using, disclosing and processing the Investor's data:

a. to facilitate the acceptance, management and administration of the Investor's subscription for an Interest on an on-going basis;

b. for any other specific purposes where the Investor has given specific consent to do so;

c. to carry out statistical analysis, market research, and tracking of investment performance over time;

d. to comply with legal or regulatory requirements applicable to the SPV and any Administrator or the Investor, including, but not limited to, in connection with anti-money laundering and similar laws;

e. for disclosure or transfer to third parties including the Investor's financial adviser (where appropriate), regulatory bodies, auditors, technology providers or to the SPV, any Administrator, any Lead Investor, and their delegates or their duly appointed agents and any of their respective related, associated or affiliated companies for the purposes specified above;

f. if the contents thereof are relevant to any issue in any action, suit or proceeding to which the LLC, the SPV, any Administrator, any Lead Investor, or their affiliates are a party or by which they are or may be bound;

g. for other legitimate business of the LLC, the SPV, any Administrator, or any Lead Investor.

5.2. The Investor acknowledges and agrees that it will provide additional information or take such other actions as may be necessary or advisable for the SPV or any Administrator (in the sole judgment of the SPV and/or any Administrator) to comply with any disclosure and compliance policies, related legal process or appropriate requests (whether formal or informal) or otherwise.

5.3. The Investor agrees and consents to disclosure by the LLC, the SPV and any of their agents, including any Administrator or any Lead Investor, to relevant third parties of information pertaining to the Investor in respect of disclosure and compliance policies or information requests related thereto. Without limiting the generality of the foregoing, the Investor agrees that information about the Investor may be provided to the Company in whose securities a SPV will or proposes to invest.

5.4. The Investor authorizes the LLC, the SPV, any Administrator, and each SPV service provider to disclose the Investor's nonpublic personal information to comply with regulatory and contractual requirements applicable to the SPV and its investments. Any such disclosure shall be permitted notwithstanding any privacy policy or similar restrictions regarding the disclosure of the Investor's nonpublic personal information.

## 6. Key Risk Factors

6.1. The Investor understands that investment in a SPV may involve a complete loss of the Investor's investment. In this regard, the Investor understands that such venture investments involve a high degree of risk, and that many or most venture company investments lose money. An Investor may ultimately receive cash, securities, or a combination of cash and securities (and in many cases nothing at all). If the Investor receives securities, the securities may not be publicly traded, and may not have any significant value.

6.2. The Investor understands and agrees that the Interests are subject to restrictions on transfer and cannot be redeemed. Instead, an Investor typically must hold his or her Interest in a SPV until the SPV has sold or otherwise disposed of its investments and the SPV distributes its investments to the investors in the SPV (a "Liquidation Event"). An Investor typically will not receive any distributions until such a Liquidation Event (and may not receive anything even upon a Liquidation Event), which may not occur for many years. The Investor must therefore bear the economic risk of holding their investment for an indefinite period of time.

6.3. The Investor understands and agrees that the Interests: (a) have not been registered under the Securities Act or any other law of the United States, or under the securities laws of any state or other jurisdiction, and therefore an Interest cannot be resold, pledged, assigned or otherwise disposed of unless it is so registered or an exemption from registration is available; and (b) can only be transferred as permitted under Regulation Crowdfunding and subject to the terms and conditions of this Agreement.

6.4. The Investor understands that no guarantees have been made to the Investor about future performance or financial results of the SPV, and an investment in the SPV may result in a gain or loss upon termination or liquidation of the SPV. It is possible that the investors in a SPV will have "phantom income," which could require them to pay taxes on their investment in a SPV even though the SPV does not distribute any income (or does not distribute sufficient income to pay the taxes).

6.5. The Investor understands and agrees that the SPV was formed by and is operated by Wefunder Admin, LLC on behalf of the Company. Investors will have no right to manage or influence the management of any SPV or of the LLC.

6.6. The Investor understands the Issuer may be required to pay an administrative fee for maintenance and operation of the SPV. Failure of the Issuer to pay such a fee could result in the dissolution of the SPV (an "SPV Dissolution Event"). Subsequent to an SPV Dissolution Event, the securities held by the SPV would be distributed directly and proportionally to the individual investors. The Investor understands that dissolution of the SPV pursuant to an SPV Dissolution Event could create administrative complexities, as investors would need to manage the securities themselves rather than having them held and administered by the SPV. Additionally, the unplanned distribution of securities may not align with investors' intended investment strategy or asset allocation. Upon an SPV Dissolution Event, the Investor hereby consents to and agrees to accept direct assignment of the SPV's rights and obligations under any investment agreements between the SPV and the Issuer that is located in the Form C or C/A offering materials. The Investor acknowledges they will be bound by all terms and conditions of such agreements as if they were an original party thereto.

6.7. The Investor understands and agrees that the Company may appoint a Lead Investor and that, if appointed, pursuant to a power of attorney granted by the Investor in the Investor Agreement, the Lead Investor will exercise voting authority on behalf of the Investor with respect to the SPV securities the Investor owns.

6.8. The Investor represents that he or she has read and understands the risk factors contained in the Company Information. The Investor understands and agrees that each Company is solely responsible for providing risk factors, conflicts of interest, and other disclosures that investors should consider when investing in securities issued by that Company (including through a SPV), and that the Wefunder Parties have no ability to assure, and have not in any way assured, that any or all such risk factors, conflicts of interest and other disclosures have been presented fully and fairly, or have been presented at all.

6.9. The Investor understands that any privacy statements, reports or other communications regarding the SPV and the Investor's investment in the SPV (including annual and other updates, and tax documents) will be delivered via electronic means, including through wefunder.com. The Investor hereby consents to electronic delivery as described in the preceding sentence. In so consenting, the Investor acknowledges that email messages are not secure and may contain computer viruses or other defects, may not be accurately replicated on other systems, or may be intercepted, deleted or interfered with, with or without the knowledge of the sender or the intended recipient. The Investor also acknowledges that an email from the Wefunder Parties may be accessed by recipients other than the Investor and may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. No Wefunder Party gives any warranties in relation to these matters.

6.10. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number under penalties of perjury, and attest that the Investor has not been notified by the Internal Revenue Service that he, she or it is subject to backup withholding, the SPV will be required to withhold from any proceeds otherwise payable to the Investor an amount necessary to satisfy the SPV's backup withholding obligations.

6.11. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number to the SPV, the SPV will withhold from any proceeds otherwise payable to the Investor an amount necessary for the SPV to satisfy its tax withholding obligations with respect to such amount. The SPV may also withhold any other amounts representing the SPV's reasonable estimation of penalties that may be charged by the Internal Revenue Service or any other taxing authority as a result of the Investor's failure to provide a valid taxpayer identification number.

6.12. The Investor understands that the Issuer may be required to pay to Wefunder certain fees for the rendering of tax services and may be required to furnish Wefunder with certain tax documents in connection with these services. These obligations are specified in the Tax Services Agreement ("TSA"), where applicable. The Investor further understands and agrees that failure by the Issuer to pay such fees or failure to deliver required tax documents in the manner prescribed in the TSA, may each constitute an SPV Dissolution Event, the consequences of which are detailed in Section 6.6.

7. Compliance With Anti-Money Laundering Laws.

7.1. The Investor represents and warrants that the Investor's investment was not directly or indirectly derived from illegal activities, including any activities that would violate U.S. Federal or State laws or any laws and regulations of other countries.

7.2. The Investor acknowledges that U.S. Federal law, regulations and Executive Orders administered by the U.S. Treasury Department's Office of Foreign Assets Control ("OFAC") may prohibit the SPV, any Administrator, or any Lead Investor from, among other things, engaging in transactions with, and the provision of services to, persons on the list of Specially Designated Nationals and Blocked Persons and persons, foreign countries and territories that are the subject of U.S. sanctions administered by OFAC (collectively, the "OFAC Maintained Sanctions").

7.3. The Investor acknowledges that the SPV prohibits the investment of funds by any persons or entities that are (i) the subject of OFAC Maintained Sanctions, (ii) acting, directly or indirectly, in contravention of any applicable laws and regulations, including anti-money laundering regulations or conventions, or on behalf of persons or entities subject to an OFAC Maintained Sanction, (iii) acting, directly or indirectly, for a senior foreign political figure, any member of a senior foreign political figure's immediate family or any close associate of a senior foreign political figure, unless the SPV, after being specifically notified by the Investor in writing that it is such a person, conducts further due diligence, and determines that such investment shall be permitted, or (iv) acting, directly or indirectly, for a foreign shell bank (such persons or entities in (i) - (iv) are collectively referred to as "Prohibited Persons"). The Investor represents and warrants that it is not, and is not acting directly or indirectly on behalf of, a Prohibited Person.

7.4. To the extent the Investor has any beneficial owners, (i) it has carried out thorough

due diligence to establish the identities of such beneficial owners, (ii) based on such due diligence, the Investor reasonably believes that no such beneficial owners are Prohibited Persons, (iii) it holds the evidence of such identities and status and will maintain all such evidence for at least five years from the date of the liquidation or termination of the SPV, and (iv) it will make available such information and any additional information requested by the SPV that is required under applicable regulations.

7.5. The Investor acknowledges and agrees that the SPV or any Administrator may "freeze the account" of the Investor, including, but not limited to, by suspending distributions from the SPV to which the Investor would otherwise be entitled, if necessary to comply with anti-money laundering statutes or regulations.

7.6. The Investor acknowledges and agrees that the SPV and/or any Administrator, in complying with anti-money laundering statutes, regulations and goals, may file voluntarily and/or as required by law suspicious activity reports ("SARs") or any other information with governmental and law enforcement agencies that identify transactions and activities that the SPV or any Administrator or their agents reasonably determine to be suspicious, or is otherwise required by law. The Investor acknowledges that the LLC, the SPV, and any Administrator are prohibited by law from disclosing to third parties, including the Investor, any filing or the substance of any SARs.

7.7. The Investor agrees that, upon the request of the LLC, the SPV, or any Administrator, it will provide such information as the LLC, the SPV, or any Administrator requires to satisfy applicable anti-money laundering laws and regulations, including, without limitation, background documentation about the Investor

## 8. Regulatory Provisions

8.1. The Investor understands that no federal or state agency has passed upon the Interests or made any findings or determination as to the fairness of this investment.

8.2. The Investor certifies that the information contained in the executed copy of Form W-9 submitted to the SPV (if any) and/or the taxpayer identification provided to the SPV is correct. The Investor agrees to provide such other documentation as the SPV determines may be necessary for the SPV to fulfill any tax reporting and/or withholding requirements.

8.3. The Investor understands and agrees that the Company may cause the SPV to make an election under Section 754 of the Internal Revenue Code (the "Code") or an election to be treated as an "electing investment partnership" for purposes of Section 743 of the Code. If the SPV elects to be treated as an electing investment partnership, the Investor shall cooperate with the SPV to maintain that status and shall not take any action that would be inconsistent with such election. Upon request, the Investor shall provide the SPV with any information necessary to allow the SPV to comply with (a) its obligations to make tax basis adjustments under Section 734 or 743 of the Code and (b) its obligations as an electing investment partnership.

8.4. The Investor consents to receive any Schedule K-1 (Partner's Share of Income, Deductions, Credits, etc.) from the SPV electronically via email, the Internet and/or another electronic reporting medium in lieu of paper copies. The Investor agrees that it will confirm this consent electronically at a future date in a manner set forth by the Company at such time and as required by the electronic receipt consent rules set forth by the Internal Revenue Service. The Investor may request a paper copy of the Investor's Schedule K-1 by contacting Wefunder Inc. at support@wefunder.com or such other email address as specified on the wefunder.com platform. Requesting a paper copy will not constitute a withdrawal of the Investor's consent to receive reports or other communications, including Schedule K-1, electronically. The Investor may withdraw its consent for electronic delivery or change its contact preferences for such delivery at any time by writing to support@wefunder.com or such other email address as specified on the wefunder.com platform. Such withdrawal will take effect promptly after receipt, unless otherwise agreed upon. Upon receipt of a withdrawal request, the SPV will confirm the withdrawal and the date on which it takes effect in writing (either electronically or on paper). A withdrawal of consent does not apply to a statement that was furnished electronically before the date on which the withdrawal of consent takes effect. The SPV will cease providing information electronically upon termination of the SPV. Notwithstanding the Investor's consent to receive materials electronically, the Investor still may be required to print and attach its Schedule K-1 to a federal, state or local tax return.

## 9. Miscellaneous Provisions

### 9.1. Indemnification

9.1.1. The Investor agrees to indemnify and hold harmless the LLC, the SPV, any Administrator, any Lead Investor, or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them, and each other person, if any, who controls, is controlled by, or is under common control with, any of the foregoing, within the meaning of Section 15 of the Securities Act, and their respective officers, directors, partners, members, shareholders, owners, employees and agents (collectively, the "Indemnified Parties") against any and all loss, liability, claim, damage and expense whatsoever (including all expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) arising out of or based upon (i) any false representation or warranty made by the Investor, or breach or failure by the Investor to comply with any covenant or agreement made by the Investor, in this Subscription Agreement or in any other document furnished by the Investor to any of the foregoing in connection with this transaction, or (ii) any action for securities law violations instituted by the Investor that is finally resolved by judgment against the Investor.

9.1.2. The Investor also agrees to indemnify each Indemnified Party for any and all costs, fees and expenses (including legal fees and disbursements) in connection with any damages resulting from the Investor's misrepresentation or misstatement contained herein, or the assertion of the Investor's lack of proper authorization from the beneficial owner to enter into this Subscription Agreement or perform the obligations thereof.

9.1.3. The Investor agrees to indemnify and hold harmless each Indemnified Party from and against any tax, interest, additions to tax, penalties, reasonable attorneys' and accountants' fees and disbursements, together with interest on the foregoing amounts at a rate determined by the SPV or any Administrator computed from the date of payment through the date of reimbursement, arising from the failure to withhold and pay over to the U.S. Internal Revenue Service or the taxing authority of any other jurisdiction any amounts computed, as required by applicable law, with respect to the income or gains allocated to or amounts distributed to the Investor with respect to its Interest during the period from the Investor's acquisition of the Interest until the Investor's transfer of the Interest in accordance with this Agreement, the LLC Agreement, and Regulation Crowdfunding.

9.1.4. If for any reason (other than the willful misfeasance or gross negligence of the entity that would otherwise be indemnified) the foregoing indemnification is unavailable to, or is insufficient to hold such Indemnified Party harmless, then the Investor shall contribute to the amount paid or payable by the Indemnified Party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the Investor on the one hand and the Indemnified Parties on the other but also the relative fault of the Investor and the Indemnified Parties, as well as any relevant equitable considerations.

9.1.5. The reimbursement, indemnity and contribution obligations of the Investor under this section shall be in addition to any liability that the Investor may otherwise have, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Indemnified Parties.

9.2. **Limitation of Liability.** The LLC is a Delaware "multi-series" limited liability company. As a multi-series limited liability company, the LLC may operate multiple series with the benefit of segregation of assets and liabilities among each of its series pursuant to the Delaware Limited Liability Company Act, as amended (the "Delaware Act"). Accordingly, the Investor hereby agrees that the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to a series (including the SPV) shall be enforceable against the assets of that series only and not against the LLC generally or the assets of any other series. In addition, none of the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to the LLC generally, or any particular series, shall be enforceable against the assets of any other series.

9.3. **Counsel.** The Investor understands that Morrison &amp; Foerster LLP serves as legal counsel on certain matters to Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC and Wefunder Advisors, LLC and not to the SPV or any Investor by virtue of its investment in the SPV, and that no independent counsel has been retained to represent the SPV or Investors in the SPV. The Investor also understands that Morrison &amp; Foerster LLP has not independently verified any factual assertions made in the Company Information or on the Wefunder website and is not responsible for the SPV's compliance with its investment program or applicable law.

9.4. **Power of Attorney.** The Investor hereby appoints each of the Company and Wefunder Admin, LLC as its true and lawful representative and attorney-in-fact, in its name,

place and stead to make, execute, sign, acknowledge, swear to and file:

9.4.1. a Certificate of Formation of the LLC and any amendments required under the Delaware Act

9.4.2. the LLC Agreement and any duly adopted amendments;

9.4.3. any and all instruments, certificates and other documents that may be deemed necessary or desirable to effect the winding-up and termination of the LLC or the SPV (including a Certificate of Cancellation of the Certificate of Formation); and

9.4.4. any business certificate, fictitious name certificate, related amendment or other instrument or document of any kind necessary or desirable to accomplish the LLC's or the SPV's business, purpose and objectives or required by any applicable U.S., state, local or other law.

This power of attorney is coupled with an interest, is irrevocable, and shall survive and shall not be affected by the subsequent death, disability, incompetence, termination, bankruptcy, insolvency or dissolution of the Investor; provided, however, that this power of attorney will terminate upon the substitution of another SPV member for all of the Investor's investment in the LLC or the SPV or upon the liquidation or termination of the LLC or the SPV. The Investor hereby waives any and all defenses that may be available to contest, negate or disaffirm the actions of the LLC, the SPV, and any Administrator taken in good faith under this power of attorney.

## 9.5. Confidentiality.

9.5.1. The Investor agrees that the Company Information and all financial statements (if any), tax reports (if any), portfolio valuations (if any), private placement memoranda (if any), reviews or analyses of potential or actual investments (if any), reports or other materials prepared or produced by the SPV and/or any Administrator and all other documents and information concerning the affairs of the SPV and/or the Fund's investments, including, without limitation, information about the Company, and/or the persons directly or indirectly investing in the SPV (collectively, the "Confidential Information") that the Investor may receive pursuant to or in accordance with the use of the Wefunder website, an investment in one or more SPVs, or otherwise as a result of its ownership of an Interest in the SPV, constitute proprietary and confidential information about the SPV, any Administrator, and/or any Lead Investor (the "Affected Parties").

9.5.2. The Investor acknowledges that the Affected Parties derive independent economic value from the Confidential Information not being generally known and that the Confidential Information is the subject of reasonable efforts to maintain its secrecy. The Investor further acknowledges that the Confidential Information is a trade secret, the disclosure of which is likely to cause substantial and irreparable competitive harm to the Affected Companies or their respective businesses. The Investor shall not reproduce any of the Confidential Information or portion thereof or make the contents thereof available to any third party other than a disclosure on a need-to-know basis to the Investor's legal, accounting or investment advisers, auditors and representatives (collectively, "Advisers"), except to the extent compelled to do so in accordance with applicable law (in which case the Investor shall promptly notify the SPV of the Investor's obligation to disclose any Confidential Information) or with respect to Confidential Information that otherwise becomes publicly available other than through breach of this provision by the Investor.

9.5.3. To the fullest extent permitted by law, the Investor agrees not to request disclosure or inspection of any such information after the Investor is notified (whether in response to the Investor's request for information or otherwise) that the SPV has determined not to disclose such information.

9.5.4. The Investor agrees that the LLC, the SPV, and the SPV service providers would be subject to potentially irreparable injury as a result of any breach by the Investor of the covenants and agreements set forth in this Item 9.5, and that monetary damages would not be sufficient to compensate or make whole the LLC, the SPV, and the SPV services providers for any such breach. Accordingly the Investor agrees that the LLC, the SPV, and the SPV service providers shall be entitled to equitable and injunctive relief, on an emergency, temporary, preliminary and/or permanent basis, to prevent any such breach or the continuation thereof.

9.6. Amendments. Neither this Subscription Agreement nor any term hereof may be

supplemented, changed, waived, discharged or terminated except with the written consent of the Investor and the Company on behalf of the relevant SPV. For the sake of clarity, the restriction on the Company in the preceding sentence applies solely to the form of this Subscription Agreement applicable to SPVs that have had a closing, and does not prevent the Company from changing the form and content of this Subscription Agreement for use in offerings of SPVs that have not had a closing.

9.7. **Assignability and Transferability.** This Subscription Agreement is not transferable or assignable by the Investor without the prior written consent of the Company on behalf of the SPV, and any transfer or assignment in violation of this provision shall be null and void. The Interests in the SPV being acquired by Investor herein may only be transferred by Investor in compliance with Regulation Crowdfunding and the terms and conditions of this Agreement. If Investor seeks to transfer the Interests, Investor shall first give written notice to the Company and Wefunder Admin, LLC, including the number of Interests that Investor desires to transfer, the proposed price, the name and contact information of the proposed buyer, and any other information that the Company or Wefunder Admin, LLC may reasonably request. To the extent possible, such notice shall be provided through the Wefunder.com website. Any transfer of Interests shall be subject to execution by Investor and the proposed transferee of appropriate documentation, as may be required by the Company or Wefunder Admin, LLC, in their discretion. Investor further acknowledges that pursuant to the LLC Agreement, Wefunder Admin, LLC (as Series Manager of the SPV), may impose additional restrictions on or prohibit the Transfer of Interests for any reason or no reason, in its sole discretion.

9.8. **Repurchase.** In the event that the SPV or any Administrator determines that it is likely that within twelve (12) months the securities of the SPV or the Company will be held of record by a number of persons that would require the SPV or the Company to register a class of its equity securities under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as required by Section 12(g) or 15(d) thereof, the SPV shall have the option to repurchase the Interests from each Investor to the extent necessary to avoid the requirement to register a class of its securities under the Exchange Act. Such repurchase of Interests shall be for the greater of (i) the purchase price of the Interests, or (ii) the fair market value of the Interests, as determined by an independent appraiser of securities chosen by the Administrator. Any such repurchase may only occur with the consent of Wefunder Admin, LLC, as Series Manager of the SPV.

9.9. **Governing Law:** Consent to Jurisdiction. Notwithstanding the place where this Subscription Agreement may be executed by any of the parties hereto, the parties expressly agree that all the terms and provisions hereof shall be construed under the laws of the State of Delaware. Any action or proceeding brought by the SPV or any SPV service provider against one or more investors in the SPV relating in any way to this Subscription Agreement or the LLC Agreement may, and any action or proceeding brought by any other party against the SPV or any SPV service provider relating in any way to this Subscription Agreement or the Company Information shall, be brought and enforced in the state courts of the State of Delaware located in Wilmington or (to the extent subject matter jurisdiction exists therefore) in the courts of the United States located in the District of Delaware; and the Investor and the SPV irrevocably submit to the jurisdiction of both such state and federal courts in respect of any such action or proceeding. The Investor and the SPV irrevocably waive, to the fullest extent permitted by law, any objection that they may now or hereafter have to laying the venue of any such action or proceeding in the courts of the State of Delaware located in Wilmington or in the courts of the United States located in the District of Delaware and any claim that any such action or proceeding brought in any such court has been brought in an inconvenient forum.

9.10. **Severability.** If any provision of this Subscription Agreement is invalid or unenforceable under any applicable law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such applicable law. Any provision hereof that may be held invalid or unenforceable under any applicable law shall not affect the validity or enforceability of any other provisions hereof, and to this extent the provisions hereof shall be severable.

9.11. **Headings.** The headings in this Subscription Agreement are for convenience of reference only, and shall not limit or otherwise affect the meaning hereof.

9.12. **General.** This Subscription Agreement shall be binding upon the Investor and the legal representatives, successors and assigns of the Investor, shall survive the admission of the Investor as a member of a SPV, and shall, if the Investor consists of more than one person, be the joint and several obligation of all such persons.

[Remainder of page intentionally left blank. Signature page follows.]

The undersigned have executed this instrument as of the date first above written.

SPV

ViiT Health III, as series of Wefunder SPV, LLC
By: Wefunder Admin, LLC, its Manager

By: Wefunder Signature
Date:

Name: Nicholas Tommarello
Title: Chief Executive Officer

Investor

[INVESTOR NAME]

By: Investor Signature
Date:

CONTACT INFORMATION:

Name: [INVESTOR NAME]

Mailing Address:

City:

Country:

E-mail:

# TERMS APPENDIX FOR THE PURCHASE OF Viit Health Inc SECURITIES BY ViIT Health III. A SERIES OF WEFUNDER SPV. LLC. A DELAWARE LIMITED LIABILITY COMPANY

Type of Security: Future Equity

Terms $20M valuation cap and 20% discount

{ To view a copy of the contract, please see <b>Appendix B, Investor Contracts</b> of the Form C. The latest Form C or C/A filing be found here:<br/>
<a target='blank' href="https://www.sec.gov/cgi-bin/srch-edgar?text=%28FORM-TYPE%3DC%2FA+or+FORM-TYPE%3DC%29+and+CIK%3D0001881570&amp;first=2016">https://www.sec.gov/cgi-bin/srch-edgar?text=%28FORM-TYPE%3DC%2FA+or+FORM-TYPE%3DC%29+and+CIK%3D0001881570&amp;first=2016</a> }

**Attachment 6:** `document_6.pdf`

THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS SAFE AND UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

## Viit Health Inc

## SAFE (Simple Agreement for Future Equity)

THIS CERTIFIES THAT in exchange for the payment by [INVESTOR NAME] (the "Investor") of $[INVESTMENT AMOUNT] (the "Purchase Amount") on or about [EFFECTIVE DATE], Viit Health Inc, a Delaware corporation (the "Company"), issues to the Investor the right to certain shares of the Company's Capital Stock, subject to the terms described below.

This Safe is one of the forms available at http://ycombinator.com/documents and the Company and the Investor agree that neither one has modified the form, except to fill in blanks and bracketed terms, and remove the requirement to be an accredited investor.

The "Post-Money Valuation Cap" is $20,000,000.00

The "Discount Rate" is 80.000%

See Section 2 for certain additional defined terms.

## 1. Events

(a) **Equity Financing.** If there is an Equity Financing before the termination of this Safe, on the initial closing of such Equity Financing, this Safe will automatically convert into the number of shares of Safe Preferred Stock equal to the Purchase Amount divided by the Conversion Price.

In connection with the automatic conversion of this Safe into shares of Safe Preferred Stock, the Investor will execute and deliver to the Company all of the transaction documents related to the Equity Financing; provided, that such documents (i) are the same documents to be entered into with the purchasers of Standard Preferred Stock, with appropriate variations for the Safe Preferred Stock if applicable, and (ii) have customary exceptions to any drag-along applicable to the Investor, including (without limitation) limited representations, warranties, liability and indemnification obligations for the Investor.

(b) **Liquidity Event.** If there is a Liquidity Event before the termination of this Safe, the Investor will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds, due and payable to the Investor immediately prior to, or concurrent with, the consummation of such Liquidity Event, equal to the greater of (i) the Purchase Amount (the "Cash-Out Amount") or (ii) the amount payable on the number of shares of Common Stock equal to the Purchase Amount divided by the Liquidity Price (the "Conversion Amount"). If any of the Company's securityholders are given a choice as to the form and amount of Proceeds to be received in a Liquidity Event, the Investor will be given the same choice, provided that the Investor may not choose to receive a form of consideration that the Investor would be ineligible to receive as a result of the Investor's failure to satisfy any requirement or limitation generally applicable to the Company's securityholders, or under any applicable laws.

Notwithstanding the foregoing, in connection with a Change of Control intended to qualify as a tax-free reorganization, the Company may reduce the cash portion of Proceeds payable to the Investor by the amount determined by its board of directors in good faith for such Change of Control to qualify as a tax-free reorganization for U.S. federal income tax purposes, provided that such reduction (A) does not reduce the total Proceeds payable to such Investor and (B) is applied in the same manner and on a pro rata basis to all securityholders who have equal priority to the Investor under Section 1(d).

(c) **Dissolution Event.** If there is a Dissolution Event before the termination of this Safe, the Investor will automatically be entitled (subject to the liquidation priority set forth in Section 1(d) below) to receive a portion of Proceeds equal to the Cash-Out Amount, due and payable to the Investor immediately prior to the consummation of the Dissolution Event.

(d) **Liquidation Priority** In a Liquidity Event or Dissolution Event, this Safe is intended to operate like standard non-participating Preferred Stock. The Investor's right to receive its Cash-Out Amount is:

(i) Junior to payment of outstanding indebtedness and creditor claims, including contractual claims for payment and convertible promissory notes (to the extent such convertible promissory notes are not actually or notionally converted into Capital Stock);

(ii) On par with payments for other Safes and/or Preferred Stock, and if the applicable Proceeds are insufficient to permit full payments to the Investor and such other Safes and/or Preferred Stock, the applicable Proceeds will be distributed pro rata to the Investor and such other Safes and/or Preferred Stock in proportion to the full payments that would otherwise be due; and

(iii) Senior to payments for Common Stock.

The Investor's right to receive its Conversion Amount is (A) on par with payments for Common Stock and other Safes and/or Preferred Stock who are also receiving Conversion Amounts or Proceeds on a similar as-converted to Common Stock basis, and (B) junior to payments described in clauses (i) and (ii) above (in the latter case, to the extent such payments are Cash-Out Amounts or similar liquidation preferences).

(e) **Termination.** This Safe will automatically terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this Safe) immediately following the earliest to occur of: (i) the issuance of Capital Stock to the Investor pursuant to the automatic conversion of this Safe under Section 1(a); or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to Section 1(b) or Section 1(c).

2. Definitions

"Capital Stock" means the capital stock of the Company, including, without limitation, the "Common Stock" and the "Preferred Stock".

"Change of Control" means (i) a transaction or series of related transactions in which any "person" or "group" (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the "beneficial owner" (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company's board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.

"Company Capitalization" is calculated as of immediately prior to the Equity Financing and (without double-counting, in each case calculated on an as-converted to Common Stock basis):

- Includes all shares of Capital Stock issued and outstanding;
- Includes all Converting Securities;
- Includes all (i) issued and outstanding Options and (ii) Promised Options; and
- Includes the Unissued Option Pool, except that any increase to the Unissued Option Pool in connection with the Equity Financing will only be included to the extent that the number of Promised Options exceeds the Unissued Option Pool prior to such increase.

"Conversion Price" means either: (1) the Safe Price or (2) the Discount Price, whichever calculation results in a greater number of shares of Safe Preferred Stock.

"Converting Securities" includes this Safe and other convertible securities issued by the Company, including but not limited to: (i) other Safes; (ii) convertible promissory notes and other convertible debt instruments; and (iii) convertible securities that have the right to convert into shares of Capital Stock.

"Direct Listing" means the Company's initial listing of its Common Stock (other than shares of Common Stock not eligible for resale under Rule 144 under the Securities Act) on a national securities exchange by means of an effective registration statement on Form S-1 filed by the Company with the SEC that registers shares of existing capital stock of the Company for resale, as approved by the Company's board of directors. For the avoidance of doubt, a Direct Listing will not be deemed to be an underwritten offering and will not involve any underwriting services.

"Discount Price" means the price per shares of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate.

"Dissolution Event" means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of the Company's creditors or (iii) any other liquidation, dissolution or winding up of the Company (excluding a Liquidity Event), whether voluntary or involuntary.

"Dividend Amount" means, with respect to any date on which the Company pays a dividend on its outstanding Common Stock, the amount of such dividend that is paid per share of Common Stock multiplied by (x) the Purchase Amount divided by (y) the Liquidity Price (treating the dividend date as a Liquidity Event solely for purposes of calculating such Liquidity Price).

"Equity Financing" means a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells Preferred Stock at a fixed valuation, including but not limited to, a pre-money or post-money valuation.

"Initial Public Offering" means the closing of the Company's first firm commitment underwritten initial public offering of Common Stock pursuant to a registration statement filed under the Securities Act.

"Liquidity Capitalization" is calculated as of immediately prior to the Liquidity Event, and (without double-counting, in each case calculated on an as-converted to Common Stock basis):

- Includes all shares of Capital Stock issued and outstanding;
- Includes all (i) issued and outstanding Options and (ii) to the extent receiving Proceeds, Promised Options;
- Includes all Converting Securities, other than any Safes and other convertible securities (including without limitation shares of Preferred Stock) where the holders of such securities are receiving Cash-Out Amounts or similar liquidation preference payments in lieu of Conversion Amounts or similar "as-converted" payments; and
- Excludes the Unissued Option Pool.

"Liquidity Event" means a Change of Control, a Direct Listing or an Initial Public Offering.

"Liquidity Price" means the price per share equal to the Post-Money Valuation Cap divided by the Liquidity Capitalization.

"Options" includes options, restricted stock awards or purchases, RSUs, SARs, warrants or similar securities, vested or unvested.

"Proceeds" means cash and other assets (including without limitation stock consideration) that are proceeds from the Liquidity Event or the Dissolution Event, as applicable, and

legally available for distribution.

"Promised Options" means promised but ungranted Options that are the greater of those (i) promised pursuant to agreements or understandings made prior to the execution of, or in connection with, the term sheet or letter of intent for the Equity Financing or Liquidity Event, as applicable (or the initial closing of the Equity Financing or consummation of the Liquidity Event, if there is no term sheet or letter of intent), (ii) in the case of an Equity Financing, treated as outstanding Options in the calculation of the Standard Preferred Stocks price per share, or (iii) in the case of a Liquidity Event, treated as outstanding Options in the calculation of the distribution of the Proceeds.

"Safe" means an instrument containing a future right to shares of Capital Stock, similar in form and content to this instrument, purchased by investors for the purpose of funding the Company's business operations. References to "this Safe" mean this specific instrument.

"Safe Preferred Stock" means the shares of the series of Preferred Stock issued to the Investor in an Equity Financing, having the identical rights, privileges, preferences, seniority, liquidation multiple and restrictions as the shares of Standard Preferred Stock, except that any price-based preferences (such as the per share liquidation amount, initial conversion price and per share dividend amount) will be based on the Safe Price.

"Safe Price" means the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization.

"Standard Preferred Stock" means the shares of the series of Preferred Stock issued to the investors investing new money in the Company in connection with the initial closing of the Equity Financing.

"Unissued Option Pool" means all shares of Capital Stock that are reserved, available for future grant and not subject to any outstanding Options or Promised Options (but in the case of a Liquidity Event, only to the extent Proceeds are payable on such Promised Options) under any equity incentive or similar Company plan.

## 3. Company Representations

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation, and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

(b) The execution, delivery and performance by the Company of this Safe is within the power of the Company and has been duly authorized by all necessary actions on the part of the Company (subject to section 3(d)). This Safe constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity. To its knowledge, the Company is not in violation of (i) its current certificate of incorporation or bylaws, (ii) any material statute, rule or regulation applicable to the Company or (iii) any material debt or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

(c) The performance and consummation of the transactions contemplated by this Safe do not and will not: (i) violate any material judgment, statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material debt or contract to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien on any property, asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business or operations.

(d) No consents or approvals are required in connection with the performance of this Safe, other than: (i) the Company's corporate approvals; (ii) any qualifications or filings under applicable securities laws; and (iii) necessary corporate approvals for the authorization of Capital Stock issuable pursuant to Section 1.

(e) To its knowledge, the Company owns or possesses (or can obtain on commercially reasonable terms) sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes and other intellectual property rights necessary for its business as now conducted and as currently proposed to be conducted, without any conflict with, or infringement of the rights of, others.

## 4. Investor Representations

(a) The Investor has full legal capacity, power and authority to execute and deliver this Safe and to perform its obligations hereunder. This Safe constitutes a valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity.

(b) The Investor has been advised that this Safe and the underlying securities have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available. The Investor is purchasing this Safe and the securities to be acquired by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor has such knowledge and experience in financial

and business matters that the Investor is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor's financial condition and is able to bear the economic risk of such investment for an indefinite period of time.

## 5. Miscellaneous

(a) Any provision of this Safe may be amended, waived or modified by written consent of the Company and either (i) the Investor or (ii) the majority-in-interest of all then-outstanding Safes with the same "Post-Money Valuation Cap" and "Discount Rate" as this Safe (and Safes lacking one or both of such terms will be considered to be the same with respect to such term(s)), provided that with respect to clause (ii): (A) the Purchase Amount may not be amended, waived or modified in this manner, (B) the consent of the Investor and each holder of such Safes must be solicited (even if not obtained), and (C) such amendment, waiver or modification treats all such holders in the same manner. "Majority-in-interest" refers to the holders of the applicable group of Safes whose Safes have a total Purchase Amount greater than 50% of the total Purchase Amount of all of such applicable group of Safes.

(b) Any notice required or permitted by this Safe will be deemed sufficient when delivered personally or by overnight courier or sent by email to the relevant address listed on their Wefunder account, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party's address listed on their Wefunder account, as subsequently modified by written notice.

(c) The Investor is not entitled, as a holder of this Safe, to vote or be deemed a holder of Capital Stock for any purpose other than tax purposes, nor will anything in this Safe be construed to confer on the Investor, as such, any rights of a Company stockholder or rights to vote for the election of directors or on any matter submitted to Company stockholders, or to give or withhold consent to any corporate action or to receive notice of meetings, until shares have been issued on the terms described in Section 1. However, if the Company pays a dividend on outstanding shares of Common Stock (that is not payable in shares of Common Stock) while this Safe is outstanding, the Company will pay the Dividend Amount to the Investor at the same time.

(d) Neither this Safe nor the rights in this Safe are transferable or assignable, by operation of law or otherwise, by either party without the prior written consent of the other; provided, however, that this Safe and/or its rights may be assigned without the Company's consent by the Investor (i) to the Investor's estate, heirs, executors, administrators, guardians and/or successors in the event of Investor's death or disability, or (ii) to any other entity who directly or indirectly, controls, is controlled by or is under common control with the Investor, including, without limitation, any general partner, managing member, officer or director of the Investor, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, the Investor.

(e) In the event any one or more of the provisions of this Safe is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Safe operate or would prospectively operate to invalidate this Safe, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision of this Safe and the remaining provisions of this Safe will remain operative and in full force and effect and will not be affected, prejudiced, or disturbed thereby.

(f) All rights and obligations hereunder will be governed by the laws of the State of Delaware, without regard to the conflicts of law provisions of such jurisdiction.

(g) The parties acknowledge and agree that for United States federal and state income tax purposes this Safe is, and at all times has been, intended to be characterized as stock, and more particularly as common stock for purposes of Sections 304, 305, 306, 354, 368, 1036 and 1202 of the Internal Revenue Code of 1986, as amended. Accordingly, the parties agree to treat this Safe consistent with the foregoing intent for all United States federal and state income tax purposes (including, without limitation, on their respective tax returns or other informational statements).

(Signature page follows)

IN WITNESS WHEREOF, the undersigned have caused this Safe to be duly executed and delivered.

COMPANY:
Viit Health Inc
By: *Powder Signature*
Name: Luis Fernando Gomez
Title: CEO

INVESTOR:
[INVESTOR NAME]
By: *Investor Signature*
Name: [INVESTOR NAME]
Title:
☐ Accredited Investor
☐ Unaccredited Investor

Read and Approved (for IRA use only)

By:
Name:

**Attachment 7:** `document_7.pdf`

# VIIT HEALTH INC.

## Financial Statements

For Year Ended December 31, 2024 and 2023

(Unaudited)

VIIT HEALTH INC

# BALANCE SHEET

| As of December 31, | 2024 | 2023 |
| --- | --- | --- |
| (USD $ in Dollars) |  |  |
| ASSETS |  |  |
| Current Assets: |  |  |
| Cash & Cash Equivalents | $25,065 | $13,044 |
| Total Current Assets | 25,065 | 13,044 |
| Total Assets | $25,065 | $13,044 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Long-Term Liabilities | 188,846 | 54,417 |
| Simple Agreement for Future Equity (SAFEs) | 1,500,052 | 1,275,866 |
| Total Liabilities | 1,688,898 | 1,330,283 |
| STOCKHOLDERS' EQUITY |  |  |
| Common Stock | 150,000 | 150,000 |
| Preferred Stock | - | - |
| Subscription Receivable | (150,000) | (150,000) |
| Retained Earnings/(Accumulated Deficit) | (1,663,833) | (1,317,239) |
| Total Stockholders' Equity | (1,663,833) | (1,317,239) |
| Total Liabilities and Stockholders' Equity | $25,065 | $13,044 |

Balance Sheet Overview (2023-2024)

As of December 31, 2024, Viit Health Inc. reported total assets of $25,065, composed entirely of cash and cash equivalents, compared to $13,044 at the end of 2023. This 92% year-over-year increase reflects additional SAFE-based financing.

Total liabilities increased from $1,330,283 in 2023 to $1,688,898 in 2024. This growth was driven by an increase in SAFE obligations (from $1,275,866 to $1,500,052 including fair value adjustments), and a rise in long-term liabilities (from $54,417 to $134,429), incurred to support research and development activities. These liabilities are non-interest-bearing and contingent upon payment availability, with potential convertibility into equity.

Accumulated deficit rose from $(1,317,239) in 2023 to $(1,663,833) in 2024, consistent with continued operating losses.

VIIT HEALTH INC

# STATEMENT OF OPERATIONS

| For Fiscal Year Ended December 31, | 2024 | 2023 |
| --- | --- | --- |
| (USD $ in Dollars) |  |  |
| Net Revenue | $ - | $ - |
| Cost of Goods Sold | - | - |
| Gross profit | - | - |
| Operating expenses |  |  |
| General and Administrative | 18,586 | 29,711 |
| Research and Development | 310,762 | 466,847 |
| Total operating expenses | 329,349 | 496,558 |
| Operating Income/(Loss) | (329,349) | (496,558) |
| Interest Expense | - | - |
| Other Loss/(Income) | 17,245 | 37,210 |
| Income/(Loss) before provision for income taxes | (346,594) | (533,768) |
| Provision/(Benefit) for income taxes | - | - |
| Net Income/(Net Loss) | $(346,594) | $(533,768) |

# Statement of Operations Summary (2023-2024)

Viit Health Inc. recorded no revenue for 2023 or 2024, consistent with its pre-commercialization phase.

Operating expenses decreased from $496,558 in 2023 to $329,349 in 2024, a 33% reduction. This was primarily due to a decrease in research and development expenses (from $466,847 to $310,762), reflecting the completion of major development milestones. General and administrative costs also fell from $29,711 to $18,586.

The net loss for 2024 was $(346,594), compared to $(533,768) in 2023. Other non-operating losses, largely mark-to-market adjustments related to SAFE instruments, declined from $37,210 in 2023 to $17,245 in 2024.

# VIIT HEALTH INC

## STATEMENTS OF CASH FLOWS

| For Fiscal Year Ended December 31, | 2024 | 2023 |
| --- | --- | --- |
| (USD $ in Dollars) |  |  |
| CASH FLOW FROM OPERATING ACTIVITIES |  |  |
| Net income/(loss) | $(346,594) | $(533,768) |
| Adjustments to reconcile net income to net cash provided/(used) by operating activities: |  |  |
| Fair value in excess of stated value of derivative instrument | 17,245 | 37,210 |
| Net cash provided/(used) by operating activities | (329,349) | (496,558) |
| CASH FLOW FROM INVESTING ACTIVITIES |  |  |
| Net cash provided/(used) in investing activities | - | - |
| CASH FLOW FROM FINANCING ACTIVITIES |  |  |
| Long-Term Liabilities | 134,429 | 54,417 |
| Borrowing on Simple Agreement for Future Equity (SAFEs) | 206,941 | 446,515 |
| Net cash provided/(used) by financing activities | 341,370 | 500,932 |
| Change in Cash | 12,021 | 4,373 |
| Cash-beginning of year | 13,044 | 8,670 |
| Cash-end of year | $25,065 | $13,044 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION |  |  |
| Cash paid during the year for interest | $ - | $ - |
| Cash paid during the year for income taxes | $ - | $ - |
| OTHER NONCASH INVESTING AND FINANCING ACTIVITIES AND SUPPLEMENTAL DISCLOSURES |  |  |
| Purchase of property and equipment not yet paid for | $ - | $ - |
| Issuance of equity in return for note | - | - |
| Issuance of equity in return for accrued payroll and other liabilities |  |  |

## Cash Flow Summary (2023-2024)

Net cash used in operating activities was $(329,349)$ in 2024 versus $(496,558)$ in 2023. Financing activities generated $341,370$ in 2024, primarily from new SAFE contributions and long-term liabilities. This compares to $500,932$ in financing cash flow in 2023.

Ending cash balance improved to $25,065$ in 2024 from $13,044$ in 2023. No investing activity was recorded in either year.

VIIT HEALTH INC

For Fiscal Year Ended December 31, 2024

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

| (in $US) | Common Stock |  | Preferred Stock |  | Subscription Receivable | Retained earnings/ (Accumulated Deficit) | Total Shareholder Equity |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Shares | Amount | Shares | Amount |  |  |  |
| Balance-December 31, 2021 | 10,200,000 | $102,000 | - | $ - | $(102,000) | $(60,048) | $(60,048) |
| Net income/(loss) |  |  |  |  |  | (723,423) | (723,423) |
| Balance-December 31, 2022 | 10,200,000 | 102,000 | - | - | (102,000) | $(783,471) | $(783,471) |
| Issuance of Stock | 4,800,000 | 48,000 | - | - | (48,000) |  | - |
| Net income/(loss) |  |  |  |  |  | (533,768) | (533,768) |
| Balance-December 31, 2023 | 15,000,000 | $150,000 | - | $ - | $(150,000) | $(1,317,239) | $(1,317,239) |
| Issuance of Stock | - | - | - | - | - |  | - |
| Net income/(loss) |  |  |  |  |  | (346,594) | (346,594) |
| Balance-December 31, 2024 | 15,000,000 | $150,000 | - | $ - | $(150,000) | $(1,663,833) | $(1,663,833) |

## Statement of Changes in Shareholders' Equity

There were no new equity issuances during FY 2024. The Company's common stock remained at 15,000,000 shares issued and outstanding as of December 31, 2024, following the issuance of 4,800,000 shares in FY 2023. The net loss for 2024 of $(346,594) increased the accumulated deficit to $(1,663,833), reducing total shareholders' equity accordingly.

# VIIT HEALTH INC.

## NOTES TO THE FINANCIAL STATEMENTS

For the year ended December 31, 2024 and 2023
(Unaudited)

## 1. NATURE OF OPERATIONS

ViiT Health Inc. ("the Company") was incorporated in the State of Delaware on June 15, 2021. The Company develops non-invasive health monitoring technology based on light-based spectroscopy and AI-powered analytics. Its flagship product is designed to estimate biomarkers such as blood glucose, oxygen saturation, heart rate, and other physiological metrics. As of December 31, 2024, the Company remains in the research and development stage and has not generated revenue from product sales.

## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and on a calendar year-end basis.

### Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.

### Cash and Cash Equivalents

Cash consists of amounts held in checking accounts at reputable financial institutions. The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.

### Revenue Recognition

As of December 31, 2024, the Company is pre-revenue. Once commercialization begins, the Company will recognize revenue in accordance with ASC 606 based on satisfaction of performance obligations.

### Research and Development Expenses

Research and development expenses are expensed as incurred. These include personnel costs, third-party development, prototyping, and testing expenditures.

Fair Value of Financial Instruments

The Company categorizes financial instruments using a fair value hierarchy with three levels, prioritizing observable inputs. SAFEs and derivative liabilities are classified as Level 3.

## 3. CAPITALIZATION AND EQUITY TRANSACTIONS

As of December 31, 2024, the Company was authorized to issue up to 15,000,000 shares of common stock ($0.01 par value), all of which were issued and outstanding. The Company is also authorized to issue up to 2,000,000 shares of preferred stock ($0.01 par value), of which none were issued as of year-end.

A total of $150,000 in subscription receivables remained outstanding as of December 31, 2024.

## 4. DEBT

The Company has issued Simple Agreements for Future Equity ("SAFEs") to investors with a principal value of $1,384,663 as of December 31, 2024. These SAFEs include valuation caps ranging from $15 million to $20 million and offer an 80% discount upon conversion. For accounting purposes, the SAFEs are reported at a fair value of $1,500,052, which includes $115,389 in fair value in excess of the stated value of the derivative instruments. These SAFEs are classified as liabilities under ASC 480 due to their cash settlement features in liquidity events.

In addition, the Company recorded $134,429 in long-term liabilities as of December 31, 2024, up from $54,417 in 2023. These liabilities were incurred primarily to sustain the Company's research and development activities. They do not bear interest and include a repayment obligation contingent upon available funds. Management notes that these liabilities may be converted into SAFEs in the future, at which point their corresponding fair market value would be determined and disclosed accordingly.

## 5. INCOME TAXES

The Company is a C Corporation and accounts for income taxes using the asset and liability method. As of December 31, 2024, the Company had federal and state net operating loss (NOL) carryforwards totaling approximately $1,663,833. A full valuation allowance has been applied to the deferred tax assets due to uncertainty regarding future profitability.

A minimal amount of taxes was paid during the year, primarily related to state or franchise tax obligations. However, no provision for income taxes has been recorded in the financial statements for the year ended December 31, 2024, as the Company incurred an operating loss

and a full valuation allowance has been maintained against deferred tax assets.

## 6. COMMITMENTS AND CONTINGENCIES

The Company may be subject to regulatory compliance obligations and intellectual property filings. As of the reporting date, there are no known material commitments or contingencies.

## 7. RELATED PARTY TRANSACTIONS

In 2023, three related party transactions were recorded:

- Luis Gomez Sanchez (Director) and Gerardo Rioseco Rubio (Treasurer) invested $8,500 and $20,000 respectively through SAFE agreements under the same terms and conditions as other investors.
- Softeq Development Corporation, a related party to our investor Softeq Venture Fund, extended credit for product development services totaling $54,417. These balances are non-interest-bearing, have no maturity date, and may be settled through future SAFE agreements under the same terms offered to other investors.

In 2024, four related party transactions were recorded:

- Luis Gomez Sanchez (Director) invested $2,035 through a SAFE agreement under the same terms and conditions as other investors.
- Shaun Rosenthal (Director) provided a $14,000 loan, and Lorena de la Maza (Director) provided a $42,000 loan. Both are non-interest-bearing, have no maturity date, are contingent upon the availability of funds for repayment, and may be converted into SAFE agreements in the future.
- Softeq Development Corporation, a related party to our investor Softeq Venture Fund, extended credit for product development services totaling $56,105. These balances are non-interest-bearing, have no maturity date, and may be settled through future SAFE agreements under the same terms offered to other investors.

Although not a related party under GAAP definitions, Fresh Consulting Inc., a long-term service provider, has extended credit for software development services totaling $22,324 by the end of 2024. These amounts are also non-interest-bearing, have no maturity date, are contingent on fund availability, and may be converted into SAFE agreements on investor-equivalent terms.

## 8. SUBSEQUENT EVENTS

Management has evaluated subsequent events through April 10, 2025, the date the internal financial statements were finalized. Key subsequent events include:

- Formalization of advisory board stock option agreements totaling at least $365,000 in value.
- In March 2025, the Company signed a new SAFE agreement totaling $215,000.
- The Company is actively working to finalize a Seed Round of $2.285 million, anticipated to close by June 2025.
- The Company is evaluating the reclassification of R&amp;D and development expenses as capital assets pending further review.

No other material subsequent events were identified.

## 9. GOING CONCERN

The Company incurred a net loss of $346,594 in 2024 and had an accumulated deficit of $1,663,833 as of December 31, 2024. Current cash reserves total $25,065, which is not sufficient to fund operations for the next twelve months. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management intends to secure additional financing through SAFE agreements or equity raises and to begin commercial sales activities. However, there is no assurance that such efforts will be successful.

**Attachment 8:** `document_8.pdf`

Page 1 of 1

# Contactar

www.linkedin.com/in/rioseco-gerardo-18698a2b (LinkedIn)

# Aptitudes principales

Planificación estratégica

Negociación

Estrategia de mercadotecnia

# Rioseco Gerardo

VP Lealtad Grupo Posadas

Naucalpan de Juárez, México, México

# Experiencia

Grupo Posadas

26 años 1 mes

Vice Presidente Provac

noviembre de 2011 - Present (13 años 8 meses)

Dir Comercial Provac

junio de 1999 - noviembre de 2011 (12 años 6 meses)

# Educación

Universidad Anáhuac Mexico Sur

Ingeniero Industrial (1982 - 1986)

**Attachment 9:** `document_9.pdf`

Page 1 of 2

# Contactar

www.linkedin.com/in/gerardo-rioseco-rubio (LinkedIn)

# Aptitudes principales

Dirección general

Estrategia

Espíritu empresarial

# Gerardo Rioseco Rubio

Entrepreneur

Ciudad de México, México

# Extracto

He estado involucrado como socio fundador en 7 empresas en los últimos 6 años. Con algunas de ellas hemos recibido premios y reconocimientos en la Asamblea General de la ONU, premio al mejor emprendimiento por Santander X, Foro Internacional de La Paz en París.

Destaca mi habilidad en entender dónde está la oportunidad de negocio en las ideas para poder ponerlas en práctica.

# Experiencia

Sampa Explore

4 años 8 meses

CEO

septiembre de 2024 - Present (10 meses)

Los Cabos, Baja California Sur, México

Co-founder

noviembre de 2020 - Present (4 años 8 meses)

Los Cabos, Baja California Sur, México

WIDU

Co-Founder

mayo de 2020 - Present (5 años 2 meses)

Deq Innovation

9 años 4 meses

Cofounder

marzo de 2016 - Present (9 años 4 meses)

Ciudad de México, México

CEO

enero de 2017 - octubre de 2020 (3 años 10 meses)

México

Page 2 of 2

ViiT Health
Group CFO
mayo de 2021 - enero de 2025 (3 años 9 meses)
Nuevo México, Estados Unidos

---

Educación

IBERO
Licenciatura, Negocios Internacionales · (2012 - 2017)

**Attachment 10:** `document_10.pdf`

Page 1 of 1

Contactar

www.linkedin.com/in/mtro-jorge-villegas-rodriguez-346b7b50 (LinkedIn)

Mtro. Jorge Villegas Rodríguez

México

Experiencia

CONACYT
director de Desarrollo Estatal y Regional
2004 - Present (21 años)
Av. Insurgentes Sur 1582, 6o piso, ala norte. México, DF, Cp 03940

**Attachment 11:** `document_11.pdf`

Page 1 of 2

# Contactar

www.linkedin.com/in/lorena-de-la-maza-krzeptowsky-a0a0b6222 (LinkedIn)

# Aptitudes principales

Atención al detalle

Observadora

Responsable

# Lorena de la Maza
Krzeptowsky

Medical Director
Ciudad de México, México

# Extracto

Egresada de Medicina por la Universidad Autónoma de México. Cuento con una Maestría en Microbiología por el Hospital General de Massachusetts, Boston. Tengo experiencia en dirección de empresas comerciales, Tecnologías de la Información, Recursos Humanos y he publicado 3 artículos académicos relacionados a Microbiología.

Mi principal interés es crear proyectos innovadores con impacto social que impulsen el esfuerzo y trabajo de minorías y grupos vulnerables, en particular de mujeres mexicanas. Mi objetivo es promover las raíces y la cultura mexicana alrededor del mundo. En 2005 fundé por cuenta propia Delmark, empresa enfocada en proyectos sociales y culturales, destacando mi participación en 2012 como responsable de la Exhibición virtual de la Cultura Maya en Baja California para representantes de Estado del G20.

Posteriormente, mi creciente interés en las personas y el capital humano me motivó a asociarse con un grupo de expertos en Tecnologías de la Información y Recursos humanos y juntos establecimos Persona Report, empresa de Desarrollo Humano con tecnología innovadora, que potencializa el desarrollo de personas y organizaciones.

En 2013 decidí continuar en el campo de Tecnologías de la Información y fundé con otros socios SolexVintel, empresa de Tecnología en Inteligencia Artificial, enfocada en sectores de Salud, Monitoreo Inteligente y Agroindustria.

Finalmente, en 2021 me asocié en el desarrollo de ViiT Health, empresa dedicada a identificar glucosa en sangre a través de métodos no invasivos. Por medio de espectrometría logramos identificar el nivel de glucosa en sangre de las personas.

# Experiencia

Page 2 of 2

ViiT Health
Medical Director
mayo de 2021 - Present (4 años 2 meses)

SolexVintel
Cofundadora
febrero de 2013 - Present (12 años 5 meses)
Ciudad de México, México

Delmark
Fundadora
agosto de 2005 - Present (19 años 11 meses)

Personna Report
Cofundadora
enero de 2012 - Present (13 años 6 meses)

Exhibición Virtual Universo Maya
Coordinación General
enero de 2012 - diciembre de 2012 (1 año)
Baja California, México

---

Educación

Harvard Medical School - Massachusetts General Hospital
Master's degree, Microbiología, general · (agosto de 1988 - 1990)

Universidad Nacional Autónoma de México
Doctor's Degree, Medicina · (1980 - 1986)

CESSA Universidad
Diplomado, Psicología Positiva · (2017 - 2017)

Colegio de Imagen Pública
Diplomado, Imagen Ambiental · (2015 - 2015)

Teatro Helénico
Diplomado, Religiones del Mundo · (2016 - 2016)

**Attachment 12:** `document_12.pdf`

Contactar

www.linkedin.com/in/luis-fernando-gomez-259b15162 (LinkedIn)

# Luis Fernando Gomez

Desarrollo de Negocio

Cuauhtémoc, Ciudad de México, México

## Extracto

Entrepreneur and Social Activist. CEO at ViiT Health; biotech company for disease prevention and health improvement. Co-founder of Deq; venture builder for impact entrepreneurship. Co-founder and former Director of Bauns; digital ecosystem for the future of work. Active collaborator at the National Center for Support in Epidemic Emergencies and Natural Disasters in Mexico (CENACED - CBI partner for Mexico) and Fideicomiso Fuerza Mexico (Private trust fund for reconstruction created by the Mexican Council for Business Coordination) in logistics for humanitarian aid and natural disaster recovery practices. Served as volunteering coordinator and head of communications for CENACED during the September 2017 earthquakes in Mexico. Awardee from the National Entrepreneurship Institute of Mexico, Santander Global Entrepreneurship Program, finalist in the 2022 Startup World Cup in Silicon Valley, 2023 cohort of the Softeq Venture Studio acceleration program in Houston. Collaborator in data mapping for aid distribution with CBI network members in Mexico. Speaker at the 2018 UN General Assembly and Mexican representative at the Paris Peace Forum 2019.

## Experiencia

ViiT Health

Director general

mayo de 2021 - Present (4 años 2 meses)

Nuevo México, Estados Unidos

Bauns

6 años

Presidente del Consejo

mayo de 2021 - Present (4 años 2 meses)

Ciudad de México, México

Director General

Page 1 of 2

Page 2 of 2

julio de 2019 - mayo de 2021 (1 año 11 meses)
Ciudad de México, México

## Bildout

### Cofundador

junio de 2020 - Present (5 años 1 mes)
Ciudad de México

Desarrollo de negocio para Bildout Group, empresa dedicada a la expansión comercial en México y Latinoamérica para empresas de tecnología internacionales.

## Deq Innovation

### Director General

marzo de 2016 - junio de 2019 (3 años 4 meses)
Ciudad de México, México

**Attachment 13:** `document_13.pdf`

Page 1 of 3

# Contactar

www.linkedin.com/in/luis-gómez-sanchez-03209a74 (LinkedIn)

# Aptitudes principales

- Asuntos públicos
- Gestión operativa
- Capacidad de análisis

# Honors-Awards

- Magna Cum Laude
- Beca

# Publications

- Desarrollo de un B.A.T.N.A. para México como Nación Deudora. Un Complemento Fundamental en la postura de negociación de la Deuda Externa de México

# Luis Gómez Sanchez

Director de Asuntos Corporativos en ViiT Health Director General de SolexVintel

Álvaro Obregón, Ciudad de México, México

# Extracto

Abogado corporativo con especialización en el sector multinacional y especialista en asuntos gubernamentales con perspectiva de gestión y defensa de organismos empresariales. Con un interés particular en la industria automotriz y en desarrollo de tecnologías de inteligencia artificial. Emprendedor vanguardista de proyectos de inversión productiva y tecnológica. Promotor de acciones de impacto social y compromiso filantrópico.

# Experiencia

## ViiT Health

Director de asuntos corporativos

junio de 2021 - Present (4 años 1 mes)

México

## SolexVintel

Director General Solexvintel

agosto de 2013 - Present (11 años 11 meses)

Ciudad de México y alrededores, México

## Walmart

Vicepresidente Latinoamérica

enero de 2012 - julio de 2013 (1 año 7 meses)

México

Director de Asuntos gubernamentales. Director Corporativo para México y Centro América. Representante ante ANTAD. Presidente de la Fundación Walmart. Director de Sostenibilidad. Comunicación Corporativa.

## V&amp;V México

Consultor

octubre de 2010 - octubre de 2011 (1 año 1 mes)

México

Page 2 of 3

Consultor en gestión de proyectos estratégicos de inversión y facilitación gubernamental.

Daimler Chi
Director de Asuntos Corporativos
1998 - 2009 (11 años)
México

Director de Relaciones Gubernamentales. Director Jurídico. Director de Comunicación Corporativa. Presidente de la Fundación Daimler Chrysler. Miembro y Secretario del Consejo Consultivo. Miembro y Secretario del Consejo de Administración. Fundador del Consejo de Empresas Globales (CEEG). Presidente de la Asociación de Abogados Generales de Empresa.

AT&amp;T
Director Jurídico
1994 - 1997 (3 años)
México

Shearman &amp; Sterling LLP
Foreign Associate
1989 - 1993 (4 años)
Washington, Estados Unidos

Washington D.C.- NAFTA Comercio Internacional. Litigios
Nueva York- Finanzas Internacionales Reestructura Deuda Externa México

---

# Educación

Harvard Business School
Advanced Management Program- AMP, Administración y gestión de empresas, general · (abril de 2002 - julio de 2002)

IPADE Business School
AD-2, Administración y gestión de empresas, general · (septiembre de 1998 - julio de 1999)

Harvard Law School
Maestría en Derecho Internacional · (1988 - 1989)

Universidad Panamericana
Licenciado en Derecho

Page 3 of 3

**Attachment 14:** `document_14.pdf`

Contact

www.linkedin.com/in/roberto-jones-arakelian-77abb34 (LinkedIn)

# Roberto Jones Arakelian

Co Owner at IMASS (Insurance Mass Solutions Group)
Cuajimalpa de Morelos, Mexico City, Mexico

## Experience

IMASS (Insurance Mass Solutions Group)
Co Owner
December 2014 - Present (10 years 7 months)

## Results

Co-Owner
January 2007 - January 2019 (12 years 1 month)

## Goodnews

Owner
January 2005 - January 2007 (2 years 1 month)

## Education

Instituto Tecnológico Autónomo de México
Administracion · (1984 - 1992)

Page 1 of 1

**Attachment 15:** `document_15.pdf`

Page 1 of 2

# Contact

www.linkedin.com/in/shaun-rosenthal-03205185 (LinkedIn)

## Top Skills

- Teamwork
- Team Leadership
- Team Management

# Shaun Rosenthal

Founder, Climb Onsight
North York, Ontario, Canada

## Experience

Sanford Heisler Sharp McKnight, LLP
Of Counsel
March 2024 - Present (1 year 4 months)
Washington, District of Columbia, United States

Viit Health
2 years 1 month

Board Member
January 2024 - Present (1 year 6 months)
Delaware, United States

Advisor
June 2023 - Present (2 years 1 month)
Delaware, United States

Climb Onsight
Founder
February 2023 - Present (2 years 5 months)
Toronto, Ontario, Canada

Sanford Heisler Sharp, LLP
4 years 4 months

Associate
September 2019 - December 2022 (3 years 4 months)
Washington D.C. Metro Area

Litigation Fellow
September 2018 - August 2019 (1 year)
Washington, DC

Lawyers for Human Rights
Statelessness Intern
May 2016 - July 2016 (3 months)

Brookfield Renewable Energy Group

Student Rotational Intern
May 2014 - August 2014 (4 months)

# Education

University of Pennsylvania
Doctor of Law (JD), Law · (2015 - 2018)

Copenhagen Business School
Business Administration and Management, General · (2015 - 2015)

Ivey Business School at Western University
Bachelor of Arts, Honors Business Administration · (2013 - 2015)

Western University
Psychology · (2011 - 2012)

Page 2 of 2

**Attachment 16:** `document_16.pdf`

Page 1 of 2

# Contactar

www.linkedin.com/in/sofia-alvarez-cano-a13396128 (LinkedIn)

## Aptitudes principales

- Planificación estratégica
- Aptitudes de organización
- Coordinación de proyectos

## Languages

- Español (Native or Bilingual)
- Inglés (Professional Working)

# Sofia Alvarez Cano

Administración de Empresas
Ciudad de México, México

# Extracto

Objetivo profesional: Desarrollarme en un ambiente profesional que represente nuevos retos, para poder poner en práctica los conocimientos adquiridos hasta el momento, además de obtener una buena formación y experiencia.

# Experiencia

- ViiT Health
- Operations
- octubre de 2022 - Present (2 años 9 meses)
- Ciudad de México, México

- DEQ
- Chief Administrative Officer
- enero de 2017 - Present (8 años 6 meses)
- México

- Bauns
- Co-founder y Head of Human Resources
- octubre de 2020 - septiembre de 2022 (2 años)
- Ciudad de México, México

- Estratégica smarter marketing
- Project Manager Trainee
- febrero de 2017 - agosto de 2017 (7 meses)

- SolexVintel S.A. de C.V
- Auxiliar de compras
- abril de 2015 - enero de 2016 (10 meses)
- Cotización y proceso de compras
- Organización y actualización de base de datos de proyectos y proveedores

- MVS Radio
- Auxiliar de facturación

enero de 2013 - julio de 2013 (7 meses)

Conciliación de las cuentas bancarias de la empresa

Organización y actualización de la base de datos de clientes y trabajadores

Proceso de alta de clientes nuevos

---

Educación

Instituto Tecnológico Autónomo de México

Licenciatura en administración · (2013 - 2018)

Page 2 of 2

**Attachment 17:** `document_17.pdf`

![img-0.jpeg](img-0.jpeg)

# viit health

Painless Monitoring for Personalized Prevention

# Index

Objective P.1
Team &amp; Traction P.2
Technology P.3
Detection P.4
Prediction P.5
Go-to-Market P.6
Commercial Plan P.7
Company Structure P.8
Competitive Landscape P.9
Stage of Development P.10
Financial Position P.12
Financial Projections P.13

WHO - Noncommunicable Disease Fact Sheet

# Objective

Non Communicable Diseases are the largest cause of death

41 M
deaths per year

80%
are preventable

Cardiovascular 17.9 M
Cancers 9.3 M
Respiratory 4.1 M
Diabetes 2 M
Liver Cirrhosis 1.3 M
Kidney 1.2 M
Digestive 1.1 M
Neurological 1 M
Mental .8 M
Other 2.3 M

# "Empower healthier lives through effortless prevention"

Extend 1 million lives by 10 healthy years

![img-1.jpeg](img-1.jpeg)

HRV · Arterial Compliance · Vascular Aging · Perfusion Index · Respiratory Rate

P.1

# Team &amp; Traction

![img-2.jpeg](img-2.jpeg)
MS Mayra Mora
MS - Arts et Métiers
Technology Director

![img-3.jpeg](img-3.jpeg)
Antonio García
PhD - UC.Berkeley
Science Director

![img-4.jpeg](img-4.jpeg)
MS Victoria Merino
MS - U.Pennsylvania
Research Director

![img-5.jpeg](img-5.jpeg)
Fernando Gomez
Entrepreneur
Executive Director

![img-6.jpeg](img-6.jpeg)
Felix Agakov
PhD - U.Edinburgh
Artificial Intelligence

![img-7.jpeg](img-7.jpeg)
Adriana Monroy
MD/PhD - UNAM/UT
Clinical Research

![img-8.jpeg](img-8.jpeg)
Lorena de la Maza
MD - UNAM/Harvard Med
Medical Strategy

![img-9.jpeg](img-9.jpeg)
Luis Gomez
JD - Harvard Law
Corporate Affairs

**SOFTEQ**
**InBody**

**HAMAMATSU**
**PHARMATICS**

**Fresh**
**SABACICA**

![img-10.jpeg](img-10.jpeg)
Global Finalist
2022
4°/15,000

![img-11.jpeg](img-11.jpeg)
President Claudia Sheinbaum · Support from the Mexican Government (SECTEI / SEDESA)

# 5 Institutional Collaborations

![img-12.jpeg](img-12.jpeg)
GOBIERNO DE LA CIUDAD DE MEXICO
HOSPITAL GENERAL de MEXICO DE EDUARDO LOZAGA
IMSS

![img-13.jpeg](img-13.jpeg)

$4.7 M raised
Patent Pending
4 R&amp;D Grants
TRL 5/6

4 Iterations
4 Clinical Trials
+3,700 patients
180u requested

# Technology

# Near Infrared Spectroscopy · Quantum Light Rotation

![img-14.jpeg](img-14.jpeg)

![img-15.jpeg](img-15.jpeg)
Molecular Vibrational Absorption (NIR)
Electronic Absorption (Visible)

![img-16.jpeg](img-16.jpeg)
Right Rotation (Dextrorotatory)
Left Rotation (Levorotatory)

![img-17.jpeg](img-17.jpeg)
Processed SF

![img-18.jpeg](img-18.jpeg)
Correlated SF

![img-19.jpeg](img-19.jpeg)

![img-20.jpeg](img-20.jpeg)

![img-21.jpeg](img-21.jpeg)

Detection

Multi-metric Competitors

Apple Watch

Galaxy Watch

Omron H.Guide

Withings

iHealth

BodiMetrics

2

3

2

1

1

3

Fully Non Invasive Integrated Biomarker Landscape

Viit Health (4 biomarkers) - Our optical components allow for a high quality PPG signal

![img-22.jpeg](img-22.jpeg)

![img-23.jpeg](img-23.jpeg)

![img-24.jpeg](img-24.jpeg)

![img-25.jpeg](img-25.jpeg)

| MC | Heart Rate | SpO2 | Blood Pressure | Blood Glucose |
| --- | --- | --- | --- | --- |
| C. MAE | 2.4 BPMs | 0.5% | 4.87 - 4.89 mmHg | ±20.8 mg/dl 1 Val. Efficiency - 92.19% |

Derived Markers
Improve Detection - New Correlations
HR Variability · Vascular Aging
Respiratory Rate · Perfusion Index
Arterial Compliance

Integrated Methodology
A - Preparatory ML (DSP)
B - Classical ML (GPR, etc)
C - Deep Learning (RNN, etc)

Ex. MAE &lt;3 BPM *
&lt;1% *
&lt;5 mmHg *
±15 mg/dl *
Final Predictive Measurement

* Expected Results cannot be guaranteed
1) Results obtained for normal BG levels (75 - 114 mg/dl) in previous Clinical Studies and validated according to class prediction (75-83, 84-93, 94-104,105-114 mg/dl)

Prediction

![img-26.jpeg](img-26.jpeg)

HRV · Arterial Compliance · Vascular Aging · Perfusion Index · Respiratory Rate

Prediction before damage

i.e.

Hypertension

(consistently high BP)

Coronary Artery Disease (CAD)

(poor VA &amp; PI, high BP, poor AC)

Ventricular Hypertrophy

(high BP &amp; HR, poor VA)

Type 2 Diabetes

(consistently high BG, odd BP &amp; AC)

Asthma

(High HR, low PI &amp; SpO2)

1 +27 conditions

Hypotension

Atrial Fibrillation

Tachycardia

Bradycardia

Heart Failure (CHF)

Arteriosclerosis

Peripheral Artery Disease (PAD)

Ischemic Heart Disease

Orthostatic Hypotension

Hypoglycemia

Metabolic Syndrome

Insulin Resistance

C. Obstructive Pulmonary Disease (COPD)

Pulmonary Hypertension

Anemia

Atherosclerosis

Autonomic Dysfunction

Dehydration

Overtraining Syndrome

Polycystic Ovary Syndrome (PCOS)

Non-Alcoholic Fatty Liver Disease (NAFLD)

Gestational Diabetes (...)

2 +19 complications

Diabetic Retinopathy

Stroke

Transient Ischemic Attacks (TIAs)

Sudden Cardiac Arrest

Heart Attack (Myocardial Infarction)

Aneurysm

Blood Clots

Chronic Kidney Disease (CKD)

Preeclampsia

Pulmonary Embolism

Respiratory Failure

Pulmonary Edema

Deep Vein Thrombosis

Critical Limb Ischemia

Cognitive Decline

Dementia

Multi-Organ Dysfunction Risk (s. inflammation)

Peripheral Neuropathy

Shock (Hypovolemic or Cardiogenic)

Sparse Parametric

Non Parametric

Temporal Embeddings

(Risk Prediction)

Optical novel predictors

92 Wellness Score

NCD Risk Prediction (5 yrs)

T2 Diabetes 4%

Hypertension 10%

Anemia 2%

Ischemic HD 2%

Go-to-Market

Customer Segments

Risk &amp; Organization Structure

# Targeted Personalized Prevention

US · Mexico · Canada · LATAM

![img-27.jpeg](img-27.jpeg)

Public Health, Prevention

&amp; Personalized Medicine Market

$611 B

NCD Economic Burden - 2030

$47 T

WHO · CDC · Global Wellness Institute · WEF

# 1

# Women

213K Org

348M Ind

Maternity Clinics

Fertility Clinics

Comm. Centers

# Children

255K Org

67M Ind

Pediatric Clinics

School Programs

# 2

# Elders

158K Org

118M Ind

Retirement Homes

Insurance

# 3

# Children

255K Org

67M Ind

Pediatric Clinics

School Programs

# 4

Special Attention

# 5

# Underserved Communities

![img-28.jpeg](img-28.jpeg)
5,000 Patients

![img-29.jpeg](img-29.jpeg)

# Sofia Alvarez

Woman · 28

sofia@viit.health

Wellness Score

![img-30.jpeg](img-30.jpeg)

![img-31.jpeg](img-31.jpeg)

# Wellness Score

![img-32.jpeg](img-32.jpeg)

Glucose

HR

SpO2

Blood Pressure

Temperature

# 89

March 25 - 2024

# History

86

99

112

65

36

2

Blood Pressure

Temperature

Sofia, your results indicate that you keep improving. Remember to do your anaerobic exercises to strengthen your circulatory system!

P.7

# Commercial Plan

*Forward Looking Projections cannot be guaranteed*

## $350 Device Cost
## $200-$500 Mo. Org Subscription
## $10-$20 Mo. Individual Subscription

Validation
Growth
Maturity

## Targeted Personalized Prevention (B2B/B2B2C)
## Individual Prevention (B2C)
## Treatment (B2B/B2C)

| Market Activation | Expansion |  |  |
| --- | --- | --- | --- |
| Underserved Population Focus on Women | Women | At Risk/Wellness Conscious | Hospitals / MDs / Patients |
|  | Elders | Use-at-Home | Diagnosis |
|  | Children | Telemedicine | Treatment |
| Units: 200 - 550 Revenue: $3M * 2026-27 (MX) | Units: 15K Revenue: $13M * 2028 (US) | Units: 60K Revenue: $42M * 2029 | Units: 119K Revenue: $80M * 2030 (LATAM) |

180 Units Requested
365 SURGICAL
ACTIVZ
Transform Health
SAGE
PLENNA
Clients &amp; Commercial Partners
GORIERNO DE LA CIUDAD DE MÉXICO
novos nordisk
IMSS

NIH
SBIR·STTR
SAFETY INSTRUCTIONS
Prepared by the

# Company Structure

![img-33.jpeg](img-33.jpeg)

Grant Opportunities
(CONAHCYT / SECTEI)
4 Previous Grants ($3 M)
Clinical Trials - May ($150K)
(Prepared)

![img-34.jpeg](img-34.jpeg)

# viit health

C Corporation
Delaware, US
Incorporated
EIN: 87-1619332
1647 S Saguaro
Mesa, AZ - 85202

![img-35.jpeg](img-35.jpeg)

# viit health

LTD Corporation
Ireland, EU
Pending

![img-36.jpeg](img-36.jpeg)

Principal Company (Headquarters)
Owns all subsidiaries
Holds all IP
Consolidates Global Financials
Global Contracts &amp; Investments
US Team / Optics &amp; Hardware Laboratory
US / Canada Sales
Manufacturing (Optional)
Royalties / Licensing / Transfer payments (Subs)

Grant Opportunities (SBIR / NIH)
$2.4M - $6M (R&amp;D)
1st Submission (40%) - Apr
(Active)
2nd Submission (70%) - Sep
3rd Submission (90%) - Jan

Medical
Cedars Sinai
Endeavor Health
Penn Medicine

Commercial
Walmart
HENRY SCHEIN
COMPUTING FOR HEALTH CARE PROFESSIONALS
novo nordisk

Product
Fresh
JABIL
HAMAMATSU
ASU

Development
PHARMATICS
SOFTEQ
DASSAULT SYSTEMES
MODEX
HEMEX
NXVA
UNIVERSIDADE NOVA DE LISBOA
IED
Institute of Entrepreneurship Development

Research &amp; Development Hub
Machine Learning &amp; AI
Regional Contracts
EU Team
European &amp; UK Sales
Manufacturing (Optional)

Grant Opportunities
(Horizon Europe / NHS)
Previous (7/8 - $12M EU)
Personalized Prevention 2026

P.8

Abbott
Dexcom
J&amp;J
HUAWEI
SAMSUNG
Big Tech &amp; Pharma are limited by flexibility (Business Model, Brand, Form Factor) &amp; Technical Challenges - They support DeepTech Startups

# Competitive Landscape

| Glucose Monitoring | Universality Collective use | Affordability vs Puncture/CGM | Accuracy & Simplicity | Commercial Availability | Diversification Other Markers | Pain Invasive | Seed Round Comparison |
| --- | --- | --- | --- | --- | --- | --- | --- |
| viit health $4.7 M funding | Transmittance NIR Spectroscopy PPG / Quantum Light Rotation Multi-sensor (Optical / Bioimpedance) AI Insights / Desktop / Portable Strong Signal / Multi-metric / Collective | 5 | 5 | 4 | 5 | 5 | $3,300,000 (TBR) 2024 |
| cnoga Digital Core | Reflective NIR Spectroscopy Multi-sensor (Op./Thermal /Bioimpedance) Calibrated with Puncture Measures in Interstitial Fluid Faint Signal / Heavy Noise / Individual | 3 | 4 | 5 | 3 | 5 | $12,500,000 2014 |
| $60 M funding | Reflective mid-IR Spectroscopy Photothermal Process Portable device Measures in Interstitial Fluid Faint Signal / Heavy Noise / Uni-metric | 5 | 3 | 5 | 2 | 5 | $5,000,000 2018 |
| DIAMONTECH $20 M funding | Nanotechnology / Reverse Iontophoresis Ionized Molecule Attraction Graphene base wearable Measures in Interstitial Fluid Faint Signal / Heavy Noise | 2 | 3 | 5 | 3 | 5 | ~$2,000,000 2017 |
| Graphwear $25 M funding | Dielectric Spectroscopy / Radio Frequency Multi-sensor (Optical/Thermal) Semi-wearable Measures in Interstitial Fluid Faint Signal / Significant Confounders | 2 | 3 | 4 | 2 | 5 | $5,900,000 2020 |
| KNOW LABS $12 M funding | Smart ring for biomarker tracking Does not measure Glucose / Blood Pressure | 2 | 2 | 3 | 5 | 5 | $2,300,000 2015 |

P.9

Stage of Development

2017

TRL 5-6

System demonstration

Relevant Environment

2025

3.0

2025

Lipids

Ox. Stress

# 2025 Product Completion

Final Iteration (3.0)
Quantum Light Rotation
Bioimpedance
Signal Reproducibility
Prototype Prod (10 u)

**Fresh**
NIH Grant
($2.4M)

ML Training
Specificity
Sensitivity

**PHARMATICS**

Full Patent
Research Paper

Prevention App
Production
(200 u)
Regulation (Prev)
COFEPRIS
SpO2/HR/BP
Specialized Study
(Women)

# 2026 Commercialization

Placement
(200 u)
Market Activation
(Women/Underserved)
Regulation (Prev)
FDA
SpO2/HR/BP
Commercial Contracts
(10,000 units)

Growth Capital
($10 M)
Production
(10,000 units)
Market Expansion
(US/MX)

**Profitability**

* Forward Looking Projections cannot be guaranteed

| MODERATE GENERAL & MEDICO ON INFORMATION & CONVEYANCE | 1,350 p | 1,350 p | 3,000 p | 14,000 p | 80,000 p | Endeavor Health. | 1,350 p | 500 p |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |

* Forward Looking Projections cannot be guaranteed

P.10

P.11

![img-0.jpeg](img-0.jpeg)
Blood Pressure (Sphygmomanometer)

![img-1.jpeg](img-1.jpeg)
HR &amp; SpO2 (Pulse Oximeter)

![img-2.jpeg](img-2.jpeg)
Blood Glucose (Capillary test)

![img-3.jpeg](img-3.jpeg)
Viit Health measures in 30 seconds what could take +17 minutes

![img-4.jpeg](img-4.jpeg)

![img-5.jpeg](img-5.jpeg)

Financial Position
* Expected for Founders after SAFE conversion &amp; Equity Compensation
* Series A may not be needed (financing options / revenue acceleration)
* Forward Looking Projections cannot be guaranteed
Raised to Date $4.7M

R&amp;D (2017-20) Pre-Seed (2021-22) Seed (2023 - 2025) Series A (Expected Q4 2026)

$3 M (Pre Val) $632 K ($15M CAP) $3.3 M ($20M CAP) $10 M ($70M Exp. Val)
Current ownership (CO): 100% Founders CO: 81.74% Founders * 7% Dilution (if needed) *

Research &amp; Development · Calibration
Grants / Founders SAFE
CONACYT Walton Family
Mexico City's Gov Crowdfunding (407 p)
Predecessor Comp Angel Investors

CONAHCYT
CONACYT
MEXICO CITY'S GOV
GODIERNO DE LA CIUDAD DE MEXICO

WELTON ENTERPRISES
WEFUNDER

Product Validation · Commercial Activation
Raised $1.1M - SAFE
Softeq Venture Fund
Crowdfunding (447 p)
Angel Investors
SOFTEQ
Expected Upcoming (Potential)
Jun - $200K Sabacica Capital
Aug - $500K Total Impact Capital
Sep - $300K WeFunder

Production · Growth
Potential $2.5M
Sabacica Capital
Softeq Venture Fund
Interested Leads
MaC Ventures (lead)
Glicso Partners (co-lead)

MEXICO CITY
SORTEQ
GLISCO PARTNERS

28% 12% 20% 34% 6%
Hardware &amp; Software Dev Machin Learning Clinical Studies &amp; Regulatory Operations &amp; Legal

Open $2.28M - Direct Investment
$20M Pre-Money valuation
Potential 27X ROI 5yrs *

P.12

![img-6.jpeg](img-6.jpeg)
Financial Projections

# Help us reshape the future of healthcare

![img-7.jpeg](img-7.jpeg)

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** Viit Health Inc

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** DE

**Date of Organization:** 06-15-2021

**Physical Address:** 1647 S Saguaro, Mesa, AZ, 85202

**Issuer Website:** https://www.viit.health

**Is there a Co-Issuer?:** Yes

**Intermediary Name:** Wefunder Portal LLC

**Intermediary CIK:** 0001670254

**Intermediary File Number:** 007-00033

**Intermediary CRD Number:** 283503

### Offering Information

**Compensation to Intermediary:** 7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.

**Financial Interest in Issuer:** No

**Type of Security Offered:** Other

**Other Description of Security:** Simple Agreement for Future Equity (SAFE)

**Number of Securities Offered:** 50000

**Price per Security:** $1.00

**Method for Determining Price:** Pro-rated portion of the total principal value of $50,000; interests will be sold in increments of $1; each investment is convertible to one share of stock as described under Item 13.

**Target Offering Amount:** $50,000.00

**Oversubscription Accepted:** Yes

**Oversubscription Allocation Type:** Other

**Description of Oversubscription:** As determined by the issuer

**Maximum Offering Amount:** $111,308.00

**Deadline to Reach Target Amount:** 04-30-2026

### Annual Report Disclosure Requirements

**Current Number of Employees:** 15

**Total Assets (Most Recent Fiscal Year):** $25,065.00

**Total Assets (Prior Fiscal Year):** $13,044.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $25,065.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $13,044.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $0.00

**Short-Term Debt (Prior Fiscal Year):** $0.00

**Long-Term Debt (Most Recent Fiscal Year):** $1,688,898.00

**Long-Term Debt (Prior Fiscal Year):** $1,330,283.00

**Revenues/Sales (Most Recent Fiscal Year):** $0.00

**Revenues/Sales (Prior Fiscal Year):** $0.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $0.00

**Cost of Goods Sold (Prior Fiscal Year):** $0.00

**Taxes Paid (Most Recent Fiscal Year):** $850.00

**Taxes Paid (Prior Fiscal Year):** $450.00

**Net Income (Most Recent Fiscal Year):** $-346,594.00

**Net Income (Prior Fiscal Year):** $-533,768.00

**Jurisdictions Offered:**

ALABAMA, ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VERMONT, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, WYOMING, B5, GU, PR, VI, 1V

### Signatures

**Issuer:** Viit Health Inc

**Signature:** Luis Fernando Gomez

**Title:** CEO

---

**Signature:** Luis Fernando

**Title:** CEO

**Date:** 06-09-2025

---

**Signature:** Gerardo Rioseco Rubio

**Title:** Treasurer

**Date:** 06-09-2025

---

**Signature:** Shaun Rosenthal

**Title:** Director

**Date:** 06-09-2025

---

**Signature:** Luis Gomez Sanchez

**Title:** President

**Date:** 06-09-2025

---

**Signature:** Lorena de la Maza Krzeptowsky

**Title:** Vice President

**Date:** 06-10-2025

---

**Signature:** Luis Fernando Gomez

**Title:** CEO

**Date:** 06-10-2025